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Abstract
Phosphoinositide-specific phospholipase C (PLC) is an intensively studied fam-
ily of enzymes constituting a junction between trans-membrane signal transduc-
tion processes and phosphoinositide lipid signalling. PLCs are activated in re-
sponse to stimulation of cell surface receptors at the plasma membrane, and the
signals are carried downstream by other transducers. PLCs catalyse the hydroly-
sis of phosphatidylinositol 4,5-bisphosphate [PtdIns(4,5)P2] to diacylglycerol and
inositol 1,4,5-trisphosphate, which are both well known intracellular second mes-
sengers. This study mainly focused on the PLC sub-family which is closely linked
to the Ras oncogene and may play a role in tumorigenesis and development. The
functions and regulatory mechanism of PLC are not yet understood in detail. To
address these issues activity and structural studies were performed.
Activity studies were carried out in vivo using cell lines and in vitro using
lipid vesicles in a model system. The latter was designed to study protein-protein
and lipid-protein interactions using PLC purified to homogeneity and guanosine
triphosphatases (GTPases) prenylated in vitro. Evidence was found for a direct
interaction between the GTPases and the PLC that mediated activation of the phos-
pholipase. Furthermore, the correlation between PLC activity and substrate presen-
tation in lipid vesicles of various sizes and lipid compositions was analysed. For the
first time, PLC activity was found to depend upon the electrostatic potential and the
stored elastic curvature stress of the lipid bilayer of the vesicles.
The binding and the activation process between GTPase (using H-Ras) and
PLC was also investigated at a molecular level in vitro. Functional studies were
2carried out using Förster resonance energy transfer (FRET) to determine if PLC
undergoes a conformational change upon H-Ras binding. This would distinguish
whether conformational change or translocation of PLC to the membrane inter-
face (where GTPases are localised) is most likely to be the key event during PLC
activation; no conformational change was observed.
Electron crystallographic structural studies, in which two-dimensional protein
crystals are grown on a lipid monolayer followed by electron microscopy, were at-
tempted. The aim was to retrieve structural information in a functional state that
resembles the natural one. Protein and lipid monolayer compositions (lipid propor-
tions, lipid concentration, protein concentration and incubation time) were screened
to identify conditions where specific protein-lipid interaction would favour two-
dimensional crystal formation. The protein was expressed with a His6-tag that al-
lowed specific binding to nickel chelating lipids included in the lipid monolayer.
In addition, catalytically inactive PLC mutants were generated and their ability
to bind PtdIns(4,5)P2, and thereby to drive the crystallisation process, was inves-
tigated. Conditions that led to protein-lipid binding, but not to two-dimensional
crystallisation, were identified.
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Chapter 1
General introduction
1.1 PLC family of enzymes
Phosphoinositide-specific phospholipase Cs (PLCs) are a family of enzymes that
has been intensively studied over the last twenty years due to the crucial role they
play in signal transduction and regulation of important cellular functions [1–6].
The PLC family includes thirteen isozymes which are divided into six sub-families:
PLCβ, PLCγ, PLCδ, PLC PLCη and PLCζ according to their cellular regulation
and structural organisation (see fig. 1.1).
From a structural point of view, PLCs can be described as modular proteins in
which some structural domains are common to all the PLCs (such as: pleckstrin ho-
mology (PH) domain, EF-hand motif, the X and the Y regions, and the C2 domain),
while others are PLC sub-family specific (see fig. 1.2).
The PH domain is formed by about 130 amino acids [9]. It is typically found in
membrane-associated proteins and it is often involved in membrane binding [10].
The PH domains are characterised by a common core structure, although they share
a limited sequence identity (less than 27% sequence identity [11]), thereby suggest-
ing that the PH domains have different binding specificities [12–14]. This is true
also for the PH domains within the PLC family. Indeed, the PHPLCδ1 domain binds
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Figure 1.1. Dendogram of the PLC family, figure based on [7].
specifically to the head group of PtdIns(4,5)P2 [15–18], while PHPLCβ or PHPLCγ
bind to specific membrane protein in the plasma membrane [19, 20].
The EF-hand domain is a helix-loop-helix structure associated with divalent
metal ion binding proteins such as calmodulin. However, no metal ions were seen
bound to the EF-hand domain in the PLCδ1 crystal structure [21, 22]. At this time
the function of this domain is not clear, but it is thought to be involved in a regula-
tory mechanism [21].
The X (≈ 145 residues) and Y (≈ 245 residues) regions, which together form
the catalytic core of PLCs, are highly conserved among all the isozymes (≈ 60%
sequence identity) [2, 23]. The catalytic domain resembles an incomplete triose-
phosphate isomerase (TIM) α/β barrel which is comprised of alternating α-helices
and β-strands, whilst the linker that separates the X and the Y regions (X-Y linker)
remains highly disordered [24]. The X-Y linker is different in length among the
PLCs and it was recently suggested to play an important regulatory role [25], which
was investigated further in this work (see sec. 6). In addition, the ridge of hydropho-
bic residues that surround the active site, as shown by the PLCδ crystal structure (see
fig. 1.8), is suggested to insert into the membrane, thereby increasing the binding
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Figure 1.2. Schematic representation of the domain organisation of the PLC isoforms
(PLCδ, PLCζ , PLCγ, PLCη, PLCβ and PLC). The EF-hand (in fuchsia), the X and Y re-
gions, which form the catalytic domain (in yellow) and the C2 domain (in blue) are present
in all of the isoforms, and the pleckstrin homology (PH) domain (in green) is present in all
except PLCζ . The isozymes’ (encoded by individual genes) splice variants identified for
each of the PLC subfamily are reported below the name of the PLC subfamily. Adapted
from [8].
affinity and the activity of the enzyme [26]. This possible mechanism of PLC regu-
lation was addressed in the present study by measuring the PLC activity as function
of the lipid presentation (see sec. 6).
The C2 domain is made up of eight anti-parallel β-strands [27]. Usually, this
domain is involved in calcium binding, as a consequence of which it may change
the electrostatic potential and interact with the membrane [28] (for more details see
sec. 1.4.2.5). However, it was shown that the C2PLCβ domain binds to the Gα
sub-units of GTP heterotrimeric proteins [29], therefore the C2 domain might have
different functions within the PLC family.
The PLC sub-families that are relevant to the work presented here, PLC, PLCβ
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and PLCδ, are briefly introduced below.
1.1.1 PLC
PLC is expressed in a wide variety of tissues with relatively high levels in the
lung and heart [23, 23, 30, 31]. PLC is the largest isozyme within the PLC family
with molecular sizes of 230 KDa (1994 residues) and 260 KDa (2303 residues)
corresponding to the two splice variants [32]. Furthermore, PLC is unique among
the other members of the PLC family due to the presence of a N-terminal CDC25
domain and two C-terminal ras-associated (RA) domains (RA1 1688-1792 AA and
RA2 1813-1916 AA).
The CDC25 domain of PLC exhibits its Ras-specific guanine exchange factor
(GEF) activity on Rap1, but not on any other members of the Ras GTPases fam-
ily (see sec. 1.2), as was hypothesised initially [33–35]. In addition, the CDC25
domain may also have a role in the localisation of PLC; it was observed that epi-
dermal growth factor induces PLC translocation to the Golgi apparatus in Cos-7
cells that express Rap1A, whereas PLC without the CDC25 domain was translo-
cated only transiently [33]. Since, PLC can be activated downstream to GTPases
of the Ras and Rap family, based on these data, it is possible to speculate concerning
prolonged activation of Rap1 through a feedback mechanism [23, 33].
The structures of the RA domains were solved separately by NMR (see fig. 1.3,
A-D), and both RA1 and RA2 structures showed ubiquitin-like folds [36] as pre-
dicted by sequence analysis [37]. RA1 and RA2 have a similar structure to other
RA domains (CrafRDB, RalGDSRA or PI3KγRBD) that are known to bind the
Ras GTPase family directly, even though they share only limited sequence homol-
ogy [36, 38, 39]. However, only RA2 was found capable of productive binding to
Ras [36], thereby indicating that RA1 and RA2 have different functions. This in-
ference was reinforced by the comparison between the NMR spectra of RA1, RA2
and RA1RA2 (tandem), which suggested that RA1 and RA2 domains act as distinct
1.1 PLC family of enzymes 11
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Figure 1.3. NMR structures of the RA1 (ID = 2BYE) and of RA2 (ID = 2BYF) domains of
PLC [36]; RA1 light orange and the RA2 orange. The RA1 and RA2 domains are shown
as ribbons in equivalent orientations and with the Ras binding site facing out of the page
(A and C), or rotated 90 ◦ to the right about the Z axis (B and D). The relative electrostatic
potentials of RA1 (A’ and B’) and RA2 (C’ and D’) are shown below in the same two
orientations. The relative electrostatic potential is indicated by the colour (red negatively
charged, blue positively charged). The sequences of RA1 and of RA2 are shown in the
bottom of the figure. The RA2 residues involved in Ras binding are underlined.
domains and not as tandem domains [36]. Further aspects of the different func-
tions of these two domains were determined by analysing the structural data of the
RA2-H-Ras complex (see fig. 1.4). The structure of RA2 in complex with H-Ras,
which was resolved to 1.9 Å resolution by X-ray crystallography [36], identified the
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Figure 1.4. Structure of RA2 (orange) in complex with H-Ras (blue)(ID= 2C5L) obtained
by 3D crystallography [36]. The RA2 domain and the H-Ras are shown as ribbons, the
residues involved in protein-protein binding are shown in stick format.
residues involved in the binding. Based on this finding, the comparison of RA1 and
RA2 structures in isolation showed that RA1 lacks important amino acids that in
RA2 are known to be involved in H-Ras binding. The lack of RA1 binding to Ras
was explained by analysis of the electrostatic potential of the RA1-Ras interface.
Indeed, the negatively charged residues at the RA1 interface would be unlikely to
support an interaction with the negative electrostatic potential of Ras [36], see fig.
1.3, A’-D’. All these observations provide a strong explanation for the absence of
RA1-Ras binding [36].
The presence of the RA2 domain in PLC and the discovery of PLC stimulation
by Ras [36], a well known oncogene, made the regulatory mechanism of PLC the
object of several studies [23, 36].
The presence of the CDC25 and of the RA domains suggests that PLC has a
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Figure 1.5. The residues of the RA2 (orange) and of H-Ras (blue) involved in the PLC-H-
Ras complex formation are highlighted within the structure (semi-transparent) of the RA2-
H-Ras complex (ID= 2C5L) [36].
unique regulatory mechanism compared to the other PLCs, and that, over all, the up-
stream and downstream signalling pathways of PLC are quite complex. The com-
plexity of the PLC regulatory mechanisms suggested a possible interplay of PLC
with the other members of the family; PLC and other PLCs can be activated down-
stream to the same surface receptor (PLCγ and PLC are activated downstream of
receptor tyrosine kinases (RTK or CD44), whilst PLCβ and PLC are downstream
of G-protein coupled receptor) [8] or to the same transducers [8].
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1.1.1.1 PLC signalling pathways
Various cell-signalling pathways converge at and several others arise from PLC.
PLC is activated downstream of transmembrane receptors such as G-protein cou-
pled receptors (GPCRs) and receptor tyrosine kinases (RTK), see figure 1.6. GPCRs
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Figure 1.6. Cartoon of the PLC signalling pathways. Trans-membrane receptors such
as the G-protein coupled receptors (GPCRs), or receptor tyrosine kinases (RTK) or CD44,
are activated by small signalling molecules (in red). The GPCRs can activate Gα12/13
which in turn activates RhoGEFs (such as p115-RhoGEF, PDZ-RhoGEF, Lbc-RhoGEF and
LARG) and then Rho. Alternatively Rho can be activated downstream of the membrane
protein CD44. GTP-Rho interacts with a specific region of the catalytic domain (within
Y) of PLC. The GPCRs (such as β-adrenergic or M3 muscarinic receptors) can activate
Gαs which in turn activate adenylate cyclase (AC), cyclic AMP (cAMP), cyclic AMP-
activated Rap-GEF, EPAC, and ultimately Rap. Rap interacts directly with the RA2 domain
of PLC [40]. Receptor tyrosine kinases (such as EGF) can activate Ras or Rap GTPases
downstream of Sos. The suggested GEFs activity of PLC for Ras and Rap is awaiting
further investigation. PLC activation, mediated by Gα12/13 and by Rho GTPases [19],
may occur downstream of LPA and thrombin receptors. However, this hypothesis needs to
be experimentally verified [41].
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are a large family of receptors (there are about 800 human genes encoding for
GPCRs) characterised by specific tissue distributions and able to bind selectively
to heterotrimeric G-protein families (Gs, Gi, Gq or G12/13) [42, 43]. Heterotrimeric
G-protein consists of α, β and γ subunits. The activation of G12/13-coupled recep-
tors leads to activation of the α12/13 subunits, and dissociation from the βγ dimer
of the heterotrimeric G protein [44–47]. The Gα12/13 subunits are N-terminally
palmitoylated, hence localised at the plasma membrane to favour the receptor in-
teraction [48]. They are characterised by a low guanosine diphosphate (GDP/GTP)
exchange rate thereby enabling a prolonged downstream signalling [49]. Gα12/13
activates RhoGEFs (guanosine nucleotide exchange factor) which in turn acts as
GAP (GTPase activating protein) for Gα12/13 by enhancing the Gα12/13 rate of
GTP hydrolysis to GDP and as GEFs for GTPases of the Rho family. Whether
Gα12 or Gα13 activate PLC directly or through Rho is not clear, but mutagenesis
experiments suggest the latter [50]. RhoGEFs catalyse the exchange of the GDP
for GTP (bound to Rho) via a Rho intermediate, which is not bound to GDP or
Mg2+. This GDP/GTP exchange results in a conformational change in the switch
regions of Rho, thereby enabling GTP bound Rho to interact efficiently with the ef-
fector [40,51,52]. The members of the Rho family: RhoA, RhoB and RhoC activate
PLC, by interaction with a specific region (≈ 70 residues) within the Y region of
the catalytic domain [53]. This region is unique among all the other isozymes, and
conserved in the PLC of all species [23, 50, 53, 54].
In a separate signalling pathway, Gs-coupled receptors activate in turn cyclic
AMP, EPAC1 and then Rap (Rap1A or Rap2B) [40], which ultimately activates
PLC by direct interaction with the RA2 domain [20, 52]. However, it has been
shown that RA2 specifically binds to Ras isoforms and with distinct affinity. RA2
binds to H-Ras (KdH−Ras = 1.4 μM) with higher affinity than to Rap1 (KdRap1A
= 11.5 μM) and Rap2 (KdRap2B = 13.8 μM). The difference of affinity can be ex-
plained at the molecular level by the lack of key residues engaged in the binding,
see figure 1.5. The negative charge of a glutamic acid (E31) in H-Ras is replaced
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by a positively charged lysine (K31) in Rap1 and the ion pair interaction with an-
other glutamic acid (E63) in H-Ras is not supported because it is replaced with a
glutamine in Rap1.
The Gβγ subunits also activate PLC [50, 54], but the mechanism is not known
and an interaction with the PH domain can only be inferred on the basis of the Gβγ
interaction with other proteins [55, 56].
PLC is activated downstream from the RTKs by direct interaction with the
Ras family of small GTPases [32, 34, 57]. The RTK recruits a scaffold complex
SHC/Grb2 at the membrane, which in turn recruits SOS, a guanine nucleotide ex-
change factor (GEF) for Ras. The signal transduction continues with the recruitment
of Ras at the membrane followed by Ras activation. Ultimately, GTP-Ras activates
the effector, PLC, upon direct binding to the RA2 domain [31, 32, 34, 36, 52, 58],
see above.
In Cos-7 cells, co-expression of PLC with H-Ras or Rap-1 causes PLC translo-
cation from the cytosol to the plasma-membrane and the Golgi apparatus respec-
tively [32]. More recently, simultaneous PLC activation by RhoA and K-Ras has
been shown in vitro to occur through direct binding to two distinct regions of
PLC [58]. Whether or not concomitant activation of PLC normally occurs in
vivo remains unknown.
Although the interaction of PLC with Rho or Ras was suggested to be direct
[23, 36], the details of the mechanism of activation are not yet well understood. In
this respect, two activation mechanisms have been hypothesised. One hypothesis is
that PLC translocation (as a result of transducer-PLC interaction) from the cytosol
to the membrane (where the PtdIns(4,5)P2 substrate is localised), is necessary and
sufficient to fully activate PLC [32, 58]. The alternative hypothesis is that the
PLC translocation is not sufficient to induce full PLC activation, but that it is also
necessary for a conformational change to remove an auto-inhibitory constraint in
PLC [36, 59–61]. To clarify the roles that translocation or conformational changes
play in the PLC activation mechanism, further investigation was carried out by the
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Katan group [36]. It was shown that PLC supplied with a C-terminal -CAAX box,
and therefore localised at the plasma membrane, has higher activity that the wild-
type PLC, but also that it could be further activated upon Ras or EGF stimulation
[36]. This indicates that translocation alone is not enough to fully activate PLC [36]
and that PLC translocation and conformational changes are both necessary to fully
activate the enzyme [36]. Moreover, it suggests that the conformational change
involved the RA2 domain [36]
The necessity of a conformational change to fully activate PLC was also claimed
by a more recent study of Sondek and Harden’s group [25]. However, in this study
the conformational change was suggested to involve the X-Y linker which was pro-
posed to auto-inhibit the PLCs [25]. Upon translocation of PLC to the plasma
membrane, the X-Y loop, which is negatively charged like the membrane surface,
was proposed to relocate to reduce the electrostatic repulsion. The X-Y loop re-
location would make the catalytic pocket accessible to the PtdIns(4,5)P2 substrate.
The auto-inhibitory function of the X-Y linker, initially suggested for PLCβ 2 (see
sec. 1.1.2 and 6.1) was extended to PLC and the others isozymes based on se-
quence similarities and on activity measurements [25]. In this respect, the deletion
of the PLC X-Y linker (110 residues), was shown to generate a mutant with higher
basal activity than the wild-type and that could be further activated by RhoA or
Ras [25, 58]. Although these two works point out two different regions of PLC
as the regions responsible for the auto-inhibition, they both agree on the same gen-
eral mechanism and claim that both translocation and conformational change are
required to fully activate PLC.
Further investigations in this direction were carried out in the work presented
here (see sec. 4).
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1.1.2 PLCβ
PLCβ exists in four different isoforms (PLCβ1−4), and they are characterised among
the other PLC sub-families by the C-terminal region (≈ 400 AA) enriched in charged
residues [5, 62]. PLCβ isozymes have a complex mechanism of regulation. All
PLCβ isoforms are activated by Gαq subunits of heterotrimeric G protein [63], but
only PLCβ2 and PLCβ3 are also activated by Gβγ [2,5,64] and by small GTPases of
the Rho subfamily: Rac1, Rac2 and Rac3, but not of the other Rho isozymes [65–68].
The PHPLCβ domain does not bind to lipids strongly enough to translocate
PLCβ to the membrane interface, therefore it cannot not have a direct membrane
targeting function as in PHPLCδ [17, 29]. However, it has an important regula-
tory role, together with the C-terminal region. Indeed, a specific region (71-88
AA) of the PHPLCβ domain was identified to mediate PLCβ activation by βγ sub-
units [16, 17, 69, 70] and by Rho GTPases [66, 67], while the two basic clusters
within the (PLCβ sub-family specific) C-terminal region were reported to bind to
activated Gαq subunits in a GDP/GTP dependent fashion [29, 71–75].
The importance of PLC-membrane association for the regulation of the enzy-
matic activity is almost established, but the details of the mechanism remain unclear.
In this respect, a mechanism of PLCβ activation has been recently proposed by Son-
dek and Harden based on the structural data of PLCβ (see fig. 1.7 and 6.2) [25].
According to this mechanism (see sec. 6), PLCβ would translocate at the membrane
upon interaction with the transducer. Since the PLC would be held in close proxim-
ity to the membrane, the charge repulsion between the membrane and the negatively
charged X-Y linker would increase thereby inducing the displacement of the X-Y
linker (see fig. 6.3). The X-Y linker would relocate in a conformation that allows
accessibility of the catalytic pocket to the substrate [25] (see fig. 6.1). This mech-
anism, known as an auto-inhibitory mechanism, was based on the PLCβ structure
and supported by in vivo activity measurements which showed that PLC-β2 mu-
tants lacking the X-Y linker had higher basal activity [25]. Furthermore, neither
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Figure 1.7. Structure of PLCβ2 (PDB ID = 2ZKM) [25] represented as a cartoon. The
domains are represented in different colors the PH domain is in green, the array of EF
hands is in fuchsia, the X and the Y regions forming the catalytic domain are in yellow and
the structured part of the X-Y linker (516-537 AA) is in red; the X-Y linker is stabilised by
hydrogen bonds (in dark blue) to the X and Y region of the catalytic domain. The residues
531-536 AA of the X-Y linker interact with the X region (408-410 AA), and the residues
S527 and D528 of the X-Y linker interact with the Y region (G603).
Gαβ nor Gαq activate PLCβ2 via this linker [76, 77]. The auto-inhibitory mecha-
nism was proposed to be common to all the PLC isozymes due to the similarities of
the catalytic domains and of the X-Y linker characteristics among the subfamilies
of PLCs [25].
In line with the auto-inhibitory mechanism, the role played by the PLC-β 2-
membrane interaction and the substrate presentation was investigated in vitro in
the present study (see sec. 6).
1.1.3 PLCδ
PLCδ are multi-domain enzymes of ≈ 85 KDa [78] that contain a PH domain,
EF-hand motif, catalytic domain and C2 domain (see fig. 1.2). The PLCδ sub-
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family comprises three isozymes PLCδ1, 3 and 4. Each isozyme is expressed within
a specific tissue or temporal distribution (e.g. PLCδ4 is expressed in the nucleus
and mainly during the transition from G1 to S-phase, while the expression level of
PLCδ1 remains constant during the cell cycle) [79].
Structural studies of PLCδ1 [21] suggested that this enzyme could make multiple
interactions with cellular membranes using the PH domain, the hydrophobic ridge
of the catalytic domain and the C2 domain (see fig. 1.8).
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Figure 1.8. Structure of PLCδ1 (ID = 1 DJX), and of the PHPLCδ domain (ID = 1MAI), in
green, the EF-hand (in fuchsia), the X and Y domains (in yellow), and the C2 domain (in
blue). The residues of the hydrophobic ridge (leu320, tyr358, phe360 and trp555) around
the catalytic domain, that were suggested to undergo partial insertion into the membrane
bilayer [26], are represented in stick format.
The regulatory function of the PHPLCδ1 domain was clarified upon identification
of the PHδ1 domain ligands: PtdIns(4,5)P2 and Ins(1,4,5)P3 [80]. The PH domain
in PLCδ1 binds to PtdIns(4,5)P2 thereby tethering the host protein to the membrane.
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Once at the membrane, the enzyme can hydrolyse several molecules of the substrate
without dissociating from the membrane [21,81]. However, the PH domain binds to
the soluble product of the enzymatic reaction, Ins(1,4,5)P3 (Kd = 210 nM [15]) as
well as to the PLC PtdIns(4,5)P2 substrate (Kd = 2μM [5,9]), suggesting a feedback
regulatory function of the PHPLCδ domain [81–84]. Furthermore, due to the speci-
ficity and the high affinity binding of PHPLCδ1 to PtdIns(4,5)P2 and to Ins(1,4,5)P3,
PHPLCδ1 was successfully used as a cellular probe for these compounds [85–87].
For these reasons, the design of a PtdIns(4,5)P2 probe using the PHPLCδ1 is also
described in the present work (see sec. 7.2.6).
Activity studies indicated the unique regulation of PLCδ1 and its strong de-
pendency upon the Ca2+ ion concentration [84]. It was shown that an increase
of Ca2+ ion concentration within the physiological range (0.1-10 μM) was suffi-
cient to stimulate PLCδ1 [84]. This observation correlates well with the structure of
PLCδ1, which showed the presence of up to four Ca2+ binding sites in the catalytic
pocket, the existence of up to three Ca2+ binding sites, which favour the binding to
PtdIns(4,5)P2 [21], in the C2 domain [21, 22, 88] and possibly other Ca2+ binding
sites are also in the EF-hand [21]. In particular, the Ca2+ binding sites within the
C2 domain are conserved in the C2 domain of synaptotagmin I, which is well char-
acterised and is reported to bind to the phospholipids in a Ca2+ dependent fashion,
with an optimum binding between 1-10 μM Ca2+ ion concentration [89, 90] (see
sec. 1.4.2.5).
1.2 Ras super-family
The Ras super-family consists of small monomeric guanosine triphosphate-binding
proteins, GTPases, of 20-30 KDa, which function as transducers in specific sig-
nalling pathways. They regulate myriads of crucial cellular processes such as gene
transcription, proliferation, differentiation, migration and apoptosis [91–93]. Ras
proteins were discovered about 30 years ago as proteins encoded by retroviral onco-
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genes [57, 94, 95], and since then the important role that Ras plays in cancer has
become increasingly evident. Cancer occurs when normal growth regulation is not
controlled due to anomalous signaling mechanisms, and misregulation of Ras sig-
naling occurs in ≈ 20% of the human tumours, with one of the Ras genes containing
activating mutations (most frequently in K-Ras ≈ 85%, then in N-Ras ≈ 15%, and
in H-Ras ≈ 1%) [96]. Based on the sequence homology, five groups may be dis-
tinguished within the Ras super-family: Ras, Rho, Rab, Arf and Ran [97], see table
1.1. All the GTPases of the Ras super-family are membrane anchored transducers
which cycle between a GDP and a GTP bound form [95]. Only when they are in
the GTP bound form, the GTPases are capable of high binding affinity and effector
activation.
Table 1.1. Ras sub-family classification and their main biological functions: cell signal-
ing/cell growth/differentiation (*), cytoskeletal rearrangement (), and nuclear import or
export (φ).
Rho RhoA RhoB RhoC Rac1 Rac2 Rac3
Rnd1 Rnd2 Rnd3 RhoH RhoD RhoG Cdc42
Rif TC10 TCL RhoBTB1 RhoBBTB2 Wrch-1 Wrch-2
Ras∗ K-Ras H-Ras N-Ras RalA RalB TC21 Rit1 Rit2
Rap1A Rap1B Rap2A Rap2B Rap2C R-Ras M-Ras E-Ras
Noey2 Di-Ras1 Di-Ras2 RasD RRP22 RasL10B Rem Gem
Rad Rerg Ris FLJ22655 RasL11 Rheb NKIRas
Ran φ Ran
Rab∗ Rab1 - Rab19 Rab21 Rab24
Rab26 -Rab28 Rab36-Rab40 Rab42
Arf∗ Sar1a Sar1b Arf1-5 Arf4L
Arl1-Arl9, Arl10C Arl10B Arl10A, Arl11
FLJ22959 LOC339231 Arf2L1 ArfRP
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GTPases undergo a conformational change when cycling between GDP and
GTP bound states. The conformational change affects the switch I and the switch II
regions. These two regions, which are of ten amino acids each, together with the α2
helix, are responsible for the interaction with the specific downstream effectors. In
the GTP-bound conformation, a GTPase is capable of high affinity and therefore of
productive binding to the effector, which in turn propagates the signal cascade [98].
The activity of the Ras super-family GTPases is tightly regulated by three groups
of regulatory proteins: guanosine nucleotide exchange factors (GEFs), GTPase-
activating proteins (GAPs), and guanine nucleotide dissociation inhibitors (GDIs).
At least 30 GEFs have been identified. They are characterised by the presence of
a catalytic domain, the diffuse B-cell lymphoma (Dbl) homology domain (DH), and
a PH domain. The DH domain binds the switch I, the switch II, β2/ β3, α2 and α3
causing a conformational change that induces nucleotide ejection and consequent
GTPases activation [99]. The PH domain might have different functions according
to the structural data available for several GEF proteins. It might be responsible
for the membrane interaction or contribute to the GEF activity [100]. In addition,
RasGEFs are characterised by the presence of a CDC25 homology domain (≈ 250
amino acids) [101], and some of them are possibly regulated by Ca2+ and DAG
via the presence of structural elements such as a C1 domain or Ca2+ binding EF
hands [102, 103].
GAPs deactivate the GTPases by increasing the intrinsic GTPase hydrolysis ac-
tivity converting GTP to GDP [104]. There are at least 20 GAPs that have been
identified and some of the GAP enzymes that deactivate Ras are regulated by Ca2+
via the two C2 domains present in the enzyme [105].
GDIs bind to the switch I, the switch II, β3 and α2 of GDP bound GTPase,
thereby preventing GDP dissociation from the GTPase, and thus functioning as in-
hibitors. GDIs sequester the inactive GTPase into the cytoplasm [106, 107], which
otherwise would be localised at the membrane due to isoprenylaion at the C-terminus
[108].
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As much as the functional state, also the spatial localisation of the GTPases is
tightly regulated [109,110]. The members of Arf or Arl are myristoylated (C14:0) at
the N-terminal helix. The Ras isoforms are post-translationally modified at the C-
terminal -CAAX motif by addition of isoprenoids lipids [111, 112], see figure 1.9.
The cystein of the CAAX motif is farnesylated (15 carbons) in Ras isoforms, or
geranylgeranyl (20 carbons) prenylated in Rho isoforms. Farnesylation is catalysed
by farnesyltransferase (FTases) while the geranylgeranyl prenylation is catalysed by
geranylgeranyl transferase type I (GGTase type I) in Rho isoforms, or by geranyl-
geranyl transferase type II (GGTase type II) exclusively in Rab isoforms [113], see
figure 1.9.
Prenylation, which occurs in the cytosol [115], results in protein association
with the ER where it is further modified by AAX proteolysis (catalysed by Ras
converting enzyme, Rce1) and methylation of the prenylated cysteine by isoprenyl-
cysteine carboxy-methyltransferase (Icmt) [114, 116], see figure 1.9. GGTase type
I is a heterodimer consisting of an α (≈ 48 K Da, present also in FTases [117]) and
a β (≈ 42 K Da) subunit [118].
Prenylation, together with the amino acid sequence next to the -CAAX box, or
other post-translated modification such as acylation, are the means by which the
GTPase localisation is tightly regulated [119–122]. In this respect, farnesylated K-
Ras is transfered from the endoplasmic reticulum (ER) to the plasma membrane
thanks to the specificity conferred by the presence of a stretch of six lysines in
proximity of the -CAAX motif [121,123]. On the other hand, N-Ras and H-Ras after
farnesylation (which is not sufficient to localise the protein at the membrane) are S-
acylated (or more commonly palmitate) in one (N-Ras) or two adjacent cysteines
(H-Ras). Only fully post-translationally modified N-Ras and H-Ras isoforms are
transfered from the ER to their subcellular target membrane [124]. Possibly single,
or double, S-acylation is sufficient to regulate the subcellular distribution. Indeed,
mono S-acylated N-Ras appears to be associated with the Golgi [125], while the
doubly S-acylated H-Ras is predominately localised at the plasma membrane [126].
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Figure 1.9. Overview of protein prenylation reactions catalysed by farnesyltransferase
(FTase), or geranylgeranyl transferase type I (GGTase type I), and the chemical struc-
ture of the lipid donor: farnesylpyrophosphate (FPP), and of geranylgeranylpyrophosphate
(GGPP). Proteins that contain a carboxy-terminal CAAX motif (cystein, two aliphatic
residues and any residue) are initially modified by the cytosolic CAAX prenyltranferases,
farnesyltransferase, or geranylgeranyltransfersase-I, which add a 15-carbon farnesyl (F) or
a 20-carbon geranylgeranyl (GG) group to the cysteine residue. Following prenylation,
the CAAX protein travels to the endoplasmic reticulum (ER), where the C-terminal three
amino acids (AAX) are proteolytically removed by RCE1 and then carboxy-methylated on
the α-carboxyl group by isoprenylcysteine carboxy-methyltransferase (ICMT). The fully
processed CAAX proteins are directed to their appropriate cellular location, which is often
the cytoplasmic surface of the cell membrane. Figure based on [114]
Then again, the Rho GTPases are partly localised at the membrane and partly in
the cytosol due to the Rho guanine dissociation inhibitor (RhoGDI), as mentioned
above [123]. This means that only a small portion of the total Rho population in
a cell can be activated at any one time (≈ 5% of the total RhoA [127], Rac1 and
CDC42 [128]).
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Since it was shown 20 years ago that several GTPases are capable of activating
PLC isoforms [2, 31, 32, 50], a few of these interactions have been characterised at
a functional (Rac GTPases or Cdc25 - PLCβ2 activation) and structural level (H-
Ras-RA2PLC domain [36], Rac1-truncated PLCβ2 [67] or Rac2-spPH domain of
PLCγ2).
1.2.1 Rho-family
The Rho sub-family includes ten different transducers of which Rho (A, B, C iso-
forms), Rac (1, 2 and 3 isoforms) and Cdc42 (Cdc42Hs and G25K isoforms) are the
best characterised. In this thesis, RhoA and Rac2 are the enzymes of the Rho sub-
family that will be discussed more extensively. RhoGEFs all have a Dbl-homology
domain (DH) which is responsible for their catalytic activity, and a PH domain
which might mediate translocation to the membrane by lipid binding. The Rho GT-
Pase’s localisation at the membrane is regulated by post translation modification
which introduces a lipid modification. The -CAAL motif at the C-terminus of the
Rho GTPases is recognised by a prenyltransferase enzyme, such as a GGTase type I,
and it is sufficient and necessary for geranylgeranyl or farnesyl prenylation (RhoD,
RhoE) [129] or both (RhoB) [130], (see fig. 1.10).
Constitutively active Rho-GTPases can be generated by single point mutations
(gly12val or leu61gln in Rac or gly14val on RhoA) which prevent intrinsic, or GAP
induced, GTP hydrolysis activity. The conformational change of Rho-GTPase upon
GTP binding is limited to the switch I and switch II regions, although the activated
Rho-GTPase can also recognise the effector using other areas of the protein.
1.2.2 Ras-family
Within the Ras-family, three highly conserved members (85% sequence identity)
have been identified: Harvey (H-), Kirsten (K-) and neuroblastoma (N-) Ras.
Mutational studies indicated that the switch I region of the Ras sub-family GT-
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GG-
protein
Figure 1.10. Structure of GGTase type I (PDB ID = 1N4P) in complex with geranylger-
anylpyrophosphate (in yellow). GGTase type I consists of a β subunit (in green), and of an
α subunit (in fuchsia). GGTase type I requires a zinc ion (in purple) as co-factor which is
engaged in hydrogen bonding between the enzyme and the C-terminus of the protein, thus
stabilising the binding and orienting the protein for substrate binding. In the top rectangle,
the GGTase type I catalytic pocket also with the C-terminus of a GG-protein (in blue). The
binding of a fresh GGPP act to displace of the newly prenylated protein from the active site.
Pase is responsible for binding to most effectors [131, 132]. However, structural
studies of Ras binding to PLC showed interaction of both switch I and of switch II
of Ras with the RA2 domain of PLC (see fig. 1.4 and 1.5). Only one other effector,
PI3Kγ, together with Ras was reported to interact with both Ras switch I and switch
II region [131,133]. The details of effector activation are not clear. Activation seems
to be dependent not only on Ras binding, but also on the effector translocation to
the membrane interface where Ras is localised, due to its post-translational modifi-
cations at the C-terminal CAAX motif (see sec. 1.2).
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1.3 Catalytic activity of PLC
The mammalian phosphoinositide-specific PLC isozymes (classified EC 3.1.4.11)
engage Ca2+ as cofactor and catalyse the hydrolysis of phosphatidylinositol-4,5-
bisphosphate [PtdIns(4,5)P2] to D-myo-inositol 1,4,5-trisphosphate (InsP3) and di-
acylglycerol (DAG), see figure 1.11 [134–138]. Water soluble, InsP3, is released
in the cytosol while DAG remains at the membrane. The two products function as
second messengers: InsP3 causes release of intracellular calcium stores, and DAG
activates proteins kinase C (PKC) [139, 140].
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Figure 1.11. PLC catalytic reaction. Chemical structures of the substrate and products:
phosphatidylinositol- 4,5-bisphosphate and of the reaction products: myo-inositol 1,4,5-
trisphosphate (InsP3) and diacylglycerol(DAG). The substrate, PtdIns(4,5)P2, is stereo-
specifically recognised by the interaction between the phosphate groups and the side chains
of the amino acids in the catalytic pocket [21, 22].
The substrate specificity toward PtdIns(4,5)P2, compared to PtdIns(4)P, PtdIns(5)P
or PtdIns, arises from the higher binding stability of the PLC catalytic pocket for
PtdIns(4,5)P2 that is achieved by the interactions between the 4- and 5-phosphates
of the substrate and the residues (ser522, lys438, lys440 and arg549) or regions of
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the Y domain of PLC [21, 22], (see fig. 1.12). Together with these four residues
involved in substrate recognition, there are four other residues involved in the catal-
ysis that are highly conserved between all the PLCs, suggesting a common mecha-
nism of substrate recognition and of catalysis. These additional residues are: three
negatively charged residues (glu341, asp343, glu390) plus asn312 [21, 22], see fig-
ure 1.12. These residues interact with the Ca2+ metal ion, cofactor, and the 2-
hydroxyl of PtdIns(4,5)P2, and it was shown that mutations of these residues affect
PLC’s dependency upon calcium concentration [141, 142]. Furthermore, the bind-
ing of the substrate is stabilised by an apolar interaction between the inositol ring
and the side-chain ring of tyrosine (tyr 551).
On the basis of the PLCδ1 crystal structure, the mechanism of hydrolysis was
proposed to follow general acid-basic catalysis, although the roles of the individual
amino acids in the catalytic pocket is not yet fully understood [21, 22]. A role in
catalysis was recognised for a phosphate-activating residue: an aspartate residue
(asp343), Ca2+ ion, and two histidines (his311 and his356) acting as a general base-
general acid pair [143].
According to the mechanism of reaction the phosphate-activating residue inter-
acts with the 2-hydroxyl group of inositol, thereby lowering the pKa of the incoming
nucleophile and facilitating proton stripping. Mutagenesis experiments suggested
that his311 acts as the general base in this first step (see fig. 1.13) [141,144,145], al-
though other studies instead suggested that glutamic acid (glu390 or glu341), which
forms hydrogen bonds with both the cofactor and with the 2-OH group (see fig.
1.12), might act as the general base [21, 22]. This would bring the hydroxyl and
the I-phosphate into proximity, and in a proper orientation, for the catalytic reac-
tion to proceed [22, 143]. At this stage, his311 interacts with a non-bridging oxy-
gen of the I-phosphate, thereby stabilising the negative charge. Also the cofactor,
Ca2+ ion, that coordinates the 2-hydroxyl group and a non-bridging oxygen of the
1-phosphate, thereby lowering the pKa and stabilising the transitional state by elec-
trostatic interaction [22].
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Ca2+
Figure 1.12. Representation of the catalytic pocket of PLCδ1 crystallised with the substrate
head group, Ins(1,4,5)P3, and the cofactor, Ca2+, in orange, (ID = 1DJX). The residues
involved in the interaction with Ca2+ or Ins(1,4,5)P3 are labelled and represented in lines
format. These residues and Ins(1,4,5)P3 are color-coded by element(C in yellow, N in blue,
O in red and P in light green). The interactions between the side chains of the protein, the
ligand and the cofactor are shown as dotted lines (dark green). Figure adapted from [2].
The mechanism of the PtdIns(4,5)P2 hydrolysis by mammalian PLCs follow a
two step sequential mechanism [136] (see fig. 1.13). In the first, slow, step, the
intramolecular phosphotransferase reaction results in the formation of DAG and
1,2-cyclic-phosphate, Ins(1:2-cyclic 4,5)P3 [142]. In the second step, attack of
a water molecule, converts 1,2-cyclic-phosphate into inositol 1,4,5-trisphosphate,
InsP3, a cyclic phosphodiesterase reaction. [136]. This caused mammalian PLC to
produce cyclic and acyclic inositol phosphatases simultaneously with a fixed ratio
that depending on the PLC subfamily, the pH and the free Ca2+ concentration, the
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Figure 1.13. Sequential PLC reaction mechanism. The first step, the intramolecular phos-
photransferase reaction is initiated upon intramolecular attack of the 2-hydroxyl group on
the phosphodiester phosphate of PtdIns(4,5)P2 and it results in the formation of 1,2-cyclic-
phosphate [142]. In mammalian PLC the cyclic product is held in the active site, but in
bacterial PLC the cyclic product is quickly released. Since the release of the cyclic prod-
uct proceeds slowly with a rate comparable to the attack of a water molecule, mammalian
PLC simultaneously produces cyclic and acyclic inositol phosphatases in a fixed ratio that
depends on the PLC subfamily, the pH and the free Ca2+ concentration, temperature and
water activity [136]. This second reaction step is the phosphodiesterase step [146].
temperature and water activity [146].
The PLC phosphodiesterase reaction is known to be characterised by interfa-
cial activation [147]. Indeed, the Vmax of PLC catalysis was shown to increase by
5-6-fold when the substrate was presented in a micellar rather than a monomeric
state [148–152]. However, it is still to be ascertained if the catalytic activity in-
creases when the enzyme binds to an interface due to substrate-based effects (be-
cause of the increased substrate concentration), or due to enzyme-based effects
(conformational changes, enzyme dimerisation or allosteric effects) [153]. Stud-
ies on PLCδ1 suggested the existence of more active and less active forms of the
enzyme [136], and that the X-Y linker (443-488 AA), which in the crystal struc-
ture, is disordered, could be responsible for this activity modulation [21]. The X-Y
linker could affect the product release or the substrate accessibility in line with the
general auto-inhibition mechanism described in section 1.1 and 6 [25] and indepen-
dent studies on PLCγ [154].
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1.3.1 DAG and InsP3
The products of the PLC catalytic activity are: DAG which localises at the mem-
brane with the substrate, and InsP3 which is released into the cytosol. They are
important second messengers in cell signaling, carrying downstream the cell sig-
nal initiated at the membrane surface that induced PLC activation. InsP3 func-
tions as ligand of specific receptors which are mainly located in the endoplasmic
reticulum (ER) [155], inducing the release of Ca2+ from intracellular Ca2+ stores.
This increase of the Ca2+ concentration in the cytosol results in a parallel increase
of the Ca2+ concentration in the mitochondria, where it stimulates metabolic en-
zymes [156], or it might induce apoptosis [157].
DAG activates several members of the protein kinase C family [158, 159] and
some ion channels [160] by direct binding or by perturbing the membrane properties
[161,162]. Indeed the presence of DAGis correlated to stored elastic curvature stress
and elastic frustration [163].
Having a small head group (type II), DAG is found to increase the spacing be-
tween the head groups of the phospholipids (this effect is even more pronounced if
the DAG is unsaturated) in the membrane [163] and to facilitate the insertion of pro-
tein into the membrane [162]. It induces also the formation of non-bilayer phases
such as hexagonal phases HII [162].
1.4 Inositol phospholipids
The inositol phospholipids (PIs) comprise a family of eight lipid species, which
act as essential signalling molecules in mammalian cells [164, 165]. Inositol phos-
pholipids are characterised by the myo-inositol moiety attached to diacylglycerol
(DAG) via a phosphate di-ester at the 1 position (see fig. 1.11). The eight dif-
ferent inositol phospholipids are generated by the phosphorylation of three of the
five free hydroxyls (at positions 3, 4 or 5) of the inositol ring of the precursor (Pt-
1.4 Inositol phospholipids 33
dIns) [166, 167].
The PIs regulate essential receptor-mediated signal transduction processes by
functioning as versatile signalling molecules [164–166]. The PIs versatility arises
from, first, the fact that PIs are generated by combinatorial actions of lipid kinases
and phosphatases, and some of them are both substrate for and products of these
enzymes (see fig.1.14). Second, the concentration of each inositol phospholipid
is temporally regulated by transient synthesis and rapid metabolism, e.g. the con-
centration of PtdIns(3,4,5)P3 can increase by factors ranging from 2- to 100-fold
upon stimulation of tyrosine kinase and some G-protein-coupled receptors [168].
Third, the specific spatial intracellular distribution of each phosphoinositide: this is
achieved by localised synthesis and by maintaining the phosphoinositides in distinct
cellular locations or organelles [169]. Fourth, each phosphoinositide interacts with
effectors through a PI-binding domain with an appropriate degree of specificity.
PI-protein binding is based on an electrostatic interaction between the lipid head
group, which is negatively charged, and the specific PI-binding domain [such as a
pleckstrin homology (PH), phagocyte oxidase (PX) or epsin N-terminal homology
(ENTH)] hosted by the target protein. This PI-protein binding can result in partial
protein insertion into the membrane [170,171]. In this scenario, hydrophobic inter-
actions between the protein and the internal hydrophobic region of the membrane
occur, further stabilising the binding. This could be the case for PLCδ which has a
hydrophobic ridge that is suggested to partially insert into the lipid bilayer, see sec-
tion 1.1.3. In general, PI-protein binding is of low affinity, but there are exceptions
with high affinity, such as the binding between the PHPLCδ1 and PtdIns(4,5)P2, see
section 1.1.3 [10, 24].
The PIs typically represent 10% of the total membrane lipid content in eukary-
otic cells [172] and they are present mainly in the cytosolic surface of membranes.
PIs are multivalent anionic lipid molecules, the charge of which can vary between -
2 and - 5 depending on the concentration of cations and the presence of associated
proteins.
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Figure 1.14. Schematic biosynthesis of the phosphoinositides, the reactions shown as a
dotted line are documented in vitro, but their relevance in vivo have yet to be verified.
The precursor of phosphoinositides, PtdIns, is synthesised mainly in the endoplasmic retic-
ulum (ER) and then transported by PtdIns transfer proteins to the target cellular membrane.
PtdIns(4,5)P2 is synthesised by phosphorylation at position 5 of the inositol ring by type I
PtdInsP-5-OH kinases and by phosphorylation at position 4 of the inositol ring by type II
PtdInsP-5-OH kinases [173].
1.4.1 PtdIns(4,5)P2
PtdIns(4,5)P2 is localised mainly in the inner leaflet of the plasma membrane where
its concentration is estimated to be 0.5-1% of the total phospholipids [170, 174].
However, other pools of PtdIns(4,5)P2, the maintainance of which is regulated
by PI transfer proteins (PITP), are also present in the Golgi, the ER and the nu-
clear membranes [175–177]. Within a membrane bilayer localised areas enriched
in PtdIns(4,5)P2, called lipid domain, have been reported, but the mechanism of
PtdIns(4,5)P2 domain formation is not clear yet, even though several mechanisms
to drive domain formation have been suggested: hydrogen bond formation between
the PtdIns(4,5)P2 head groups [178], partition of PtdIns(4,5)P2 into cholesterol-rich
membrane rafts [179,180], localised synthesis of PtdIns(4,5)P2 [181], sequestration
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by local membrane curvature, or sequestration due to a local electrostatic potential
generated by specific enzymes (e.g. MARCKS) [174].
PtdIns(4,5)P2 can be synthesised via a sequential mechanisms in which PtdIns is
first phosphorylated at the 4-position by PI 4-kinases [182], and then the PtdIns(4)P
produced is phosphorylated at the 5-position by the type I PIP kinases (or PIP5Ks)
[183]. Alternatively, PtdIns(4,5)P2 can be synthesised via PtdIns(5)P which can
then be phosphorylated at the 4-position by type-II PIP kinases (or PIP4Ks) [184].
PtdIns(4,5)P2 accomplishes its role as a signalling molecule directly through
variation of its own concentration, or indirectly via its metabolites [4,185]. PtdIns(4,5)P2
can interact directly with a number of effectors by binding to specific PtdIns(4,5)P2
binding domains (e.g. PHPLCδ domain), or to clusters of basic/hydrophobic residues.
In the latter case, binding is driven by the electrostatic potential, since the basic
residues (e.g the cluster of 13 basic residues on MARCKS [186]) generate a pos-
itive electrostatic potential that attracts the negatively charged PtdIns(4,5)P2 (-4 at
pH 7.0 according to NMR experiments [187], or -3 according to electrophoretic
mobility experiments of PtdIns(4,5)P2 [188, 189]) [174, 190, 191]. As a result of
these direct interactions, PtdIns(4,5)P2 appears to be a crucial regulator of: actin
cytoskeleton regulation [192–195], assembly/disassembly of vesicular coats, exo-
cytosis [196–198], endocytosis [199, 200], regulated secretion, ion channel activa-
tion [201–206]. These specific interactions are affected by the PtdIns(4,5)P2 con-
centration which is regulated by kinases [173, 203, 207] [which enriched the mem-
branes in PtdIns(4,5)P2 by synthesising fresh PtdIns(4,5)P2, as described above, or
deplete the membranes upon phosphorylation of PtdIns(4,5)P2 to PtdIns(3,4,5)P3]
and by phosphatases [208] [which decrease the level of PtdIns(4,5)P2 upon dephos-
phorylation to PtdIns(4)P or to PtdIns(5)P], see figure 1.14.
In addition, PtdIns(4,5)P2 is the substrate for three important receptor-regulated
signal-generating enzymes: PI-phospholipase C (PI-PLC), phospholipase A2 and
Type I PI 3-kinases [209]. Therefore, the multiplicity of PtdIns(4,5)P2 functions
is amplified further by considering that PtdIns(4,5)P2 is the source of three second
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messengers: inositol 1,4,5-trisphosphate Ins(1,4,5)P3, diacylglycerol (DAG) (see
sec. 1.3) and phosphatidyl inositol 3,4,5-trisphosphate PtdIns(3,4,5)P3.
1.4.2 Membrane properties
Eukaryotic cells rely on thousands of different types of lipids to function [210]. The
importance of these many types of lipids is highlighted by the fact that a significant
proportion of all genes (≈ 5%) encode for enzymes related to lipid synthesis [211].
Lipids accomplish functions related to energy storage, signalling or compartmental-
isation. This section will focus on the signalling and compatmentalisation functions
of lipids.
1.4.2.1 Membrane formation
Lipids are amphipathic molecules, having both hydrophilic (the head group) and
hydrophobic (hydrocarbon chains) regions. The co-existence of these two regions
gives lipids unique properties, such as the ability to self-associate in aqueous solu-
tion into a lipid bilayer or membrane. This self-association and membrane forma-
tion is driven by the hydrophobic effect. A membrane consists of two back-to-back
lipid layers in which the hydrocarbon chains face each other and the head groups
form an interface with the aqueous phase (see fig. 1.15, A). Within each lipid layer
the lipid molecules are free to diffuse and specific lipids can concentrate in localised
areas, forming membrane microdomains which have particular functions and prop-
erties. In this respect, the fluid mosaic model is a good description of a biological
membrane bilayer.
1.4.2.2 Biological membrane properties
Biological membranes consists of a lipid bilayer with embedded integral or periph-
eral proteins associated with the lipids. These proteins regulate key biological pro-
cesses such as selective transport of molecules across the membrane, signaling pro-
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Figure 1.15. (A) Structure of a lipid bilayer: the two lipid layers are back-to-back, thereby
defining two polar interfacial regions, each of which contains the lipid head groups (≈ 15
Å), and a hydrophobic core (≈ 30 Å); (B) components of a lipid bilayer as a function of the
bilayer depth: carbon atoms (black line), oxygen atoms from water molecules (blue line) or
phosphorus and oxygen atoms from polar moieties (red line), figure adapted from [212].
cesses or membrane remodeling, to mention only a few. In the past few years, there
has been growing evidence that the lipids can regulate protein function [213–216]
and this has led to a more balanced assessment of the relative contributions of pro-
teins and lipids. Lipids can influence protein function indirectly [217], altering the
biophysical properties of the membrane, or directly, binding to specific intrinsic
(or peripheral) proteins [85, 218, 219]. This explains the great spatial and temporal
variability of the lipid composition in a cell.
Specific properties of the membrane derive from the properties of the lipid
molecules within the membrane. An example is the membrane curvature, which is
dependent on the lipid molecule’s occupancy of space. The lipid molecule’s pack-
ing parameter (S) is determined by the chemical properties of the acyl chains and of
the head groups of the lipid molecules. The packing parameter (S) determines the
favoured curvature of the membrane:
S =
υ
a0 lc
(1.1)
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where: υ is the the volume of the hydrophobic chains, a0 is the surface area at the
head group and lc is the maximum length of the hydrophobic chains [220]. Based
on the packing parameter, lipids are classified as type 0 (S = 1), type I (S < 1) and
type II (S > 1), see figure 1.16, A. Type 0 lipids are characterised by a cylindrical
shape and form flat membranes, while type I lipids have a cone shape with the point
directed toward the hydrophobic core and type II lipids have an inverted cone shape
with the point directed at the aqueous phase. Both type I and type II lipids form
curved membranes with the former bending toward the water and the latter away.
The shape of the membrane at any point is defined by the mean curvature (H) and
the Gaussian curvature (K), which are functions of the principal curvatures of the
membrane: c1 and c2 (see fig. 1.16, B).
H =
1
2
(c1 + c2) (1.2)
K = c1 · c2 (1.3)
The lateral pressure profile (t) across the thickness of the membrane (z) also derives
from the type of lipids within the membrane.
The lateral pressure in the head group region is dominated by electrostatic ef-
fects which are responsible for repulsive forces (see fig. 1.16, C). The lateral pres-
sure profile at the polar-apolar interfacial region is dominated by attractive forces,
which minimises the contact area between the water and the hydrophobic region
(hydration interactions). The hydrophobic chain region is characterised by steric in-
teractions and repulsive forces derived from trans-gauche conformational changes.
When a membrane is at equilibrium the integral of the lateral pressure, t (z), is zero:
∫
t(z) dz = 0 (1.4)
The spontaneous curvature of a symmetrical lipid bilayer may be flat even when
the bilayer is formed by curved single monolayers because the single monolayer
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Figure 1.16. (A) Lipid classification based on the packing parameter S: type 0 lipids (e.g.
PtdChl), type I lipids (e.g. lysophosphatidylcholine) and type II (e.g. PtdEtn or DAG)
lipids; (B) schematic representation of the principal curvatures. The mean curvature is pos-
itive when the monolayer bends toward the hydrophobic chains and negative when it bends
toward the head group; (C) lateral pressure profile across the membrane. The head groups
contribute a positive lateral pressure due to the charge repulsion, the polar-apolar interface
contributes a negative pressure while the acyl chains are characterised by a positive pressure
generated by repulsion of the hydrocarbon chains. These contributions must balance each
other and sum to a total lateral pressure of zero or the membrane would change shape; (D)
principal curvature of a membrane: c1 (where c1 = 1/R1) and c2 (where: c2 = 1/R2).
curvatures would have to be opposite and equal to each other. However, biological
membranes are more often asymmetrical and tend to curve, but this is not always
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energetically favourable. Under specific conditions, membranes remain flat and
store elastic curvature stress until a threshold above which a curvature is generated,
which releases some of that stored elastic curvature stress. It has been observed
that protein insertion into a biological lipid bilayer can induce the release of stored
elastic curvature stress by bringing the head groups together and allowing the chains
to splay more in predominantly type II lipids [212].
The lipids within a membrane can adopt different phase behaviour in vivo which
corresponds to a specific spatial arrangement and motional freedom of each molecule
with respect to the neighbouring lipids. The phase and the unit cell spacing (d) of
lipid mixtures (prepared to mimic biological membrane compositions) can be char-
acterised in vitro by analysis of X-ray diffraction (see fig. 1.17). The possible
lipid phases range from the simple fluid lamellar phase (Lα) to the more complex
inverse micellar phase (L2) or inverse hexagonal phase (HII). The phase behaviour
of a membrane is determined by the total free energy of the system which results
from the combination of four factors: the membrane curvature elasticity (gc), the
packing of the hydrocarbon chains (gp), the hydration forces and the electrostatic
contribution [222]. The membrane curvature elasticity (gc) has been defined by Hel-
frich [223] as the energy required to deform the surface area of an infinitely thin (by
approximation) membrane. The membrane curvature elasticity (gc) is a function of
the bending modulus (k), the Gaussian modulus (kG) and the deformation which is
described by the mean curvature (H) and the Gaussian curvature (K).
gc = 2 k (H −H0)2 + kG K (1.5)
where: H0 is the mean curvature when the membrane is relaxed; it is also called
spontaneous mean curvature.
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Figure 1.17. Representation of a lipid bilayer in fluid lamellar phase, Lα, where the lipid
molecules are able to diffuse within the lipid leaflet of the membrane [221]. The fluid
lamellar phase consists of a series of flat bilayer sheets each separated by a water layer
stacked on top of each other, and the lipid bilayers are thought to resemble the biological
membranes. A is the cross sectional area per lipid, d is the unit cell spacing and dl is the
lipid bilayer thickness. Structural parameters of the fluid bilayer such as dl are crucial to
measure the hydrophobic mismatch between membrane proteins and the membrane, while
A allows the calculation of the free energy required for protein insertion into a bilayer.
1.4.2.3 Membrane curvature and membrane deformation
The curvature of biological membranes is an important property and it is closely
related to the membrane function. Membrane curvature results from the lipid com-
position as well as the membrane associated proteins or intrinsic proteins. Lipid
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asymmetry, which is controlled tightly by enzymes such as phospholipase A2 [224]
CTP:phosphocholine cytidylyltransferase [217], phosphatidylinositoltransfer pro-
tein (PITP) [225] generates a defined curvature in the membrane. Alternatively,
proteins can directly induce membrane curvature by means of one or a combina-
tion of these other mechanisms. In the first instance, proteins with an intrinsic
curvature can impose their curvature on the membrane by a scaffolding mecha-
nism (e.g. the BAR domain [226]). In the second instance, proteins can impose
curvature by using a local spontaneous mechanism upon partial insertion (up to
about 40% of the bilayer thickness) of amphipathic moieties, which are often am-
phipathic α-helices [218]. Epsin is an example of a protein generating membrane
curvature by using the local spontaneous mechanism. Epsin binds with high affin-
ity to PtdIns(4,5)P2 within the membrane and then inserts its amphipathic helices
into the membrane, thereby inducing membrane curvature. In the third instance,
proteins that penetrate only one leaflet of the membrane create an area difference
between the two leaflets of the membrane. This area difference between the two
leaflets results in a membrane curvature [218, 219].
The membrane deformation caused by insertion of protein moieties into the
whole thickness of the lipid bilayer, or by insertion of protein into one leaflet, cannot
be described by the Helfrich model because this is based on the assumption that the
membrane thickness is negligible [227]. However, these particular types of mem-
brane deformation can be described by two approaches: the macroscopic approach
and the microscopic approach. The macroscopic approach uses the trans-membrane
stress profile which describes the stress of any point of the membrane including the
thickness of the membrane and the trans-membrane elastic moduli profile, which
describes the membrane response to any external stimuli [228]. The microscopic
approach describes the behaviour of the membrane based on the interactions be-
tween the lipid molecules, or interactions internal to the monolayer [229, 230].
The function of biological membranes and their curvature are often related. In
recent years there has been growing evidence that membrane curvature is tightly
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regulated, that several (peripheral or integral) proteins can sense membrane curva-
ture, and that their catalytic activity is curvature dependent [226, 231, 232]. How-
ever, the mechanism of activity modulation is not yet understood in detail. In gen-
eral, the mechanism through which a few proteins sense membrane curvature can
be explained by thermodynamics. Indeed, the process of protein-membrane binding
or protein insertion is regulated by the effective energy required which consists of
two contributions: the energy required for membrane deformation and the energy
required for protein interaction (insertion or binding). When the curvature of the
membrane matches the protein’s intrinsic curvature no deformation (of protein or
membrane) is required and the protein-membrane binding is energetically favoured
and therefore likely to take place. Alternatively, proteins characterised by intrinsic
flexibility are capable of sensing the membrane curvature and thereby to adapt to
the membrane curvature. In this case, the elastic energy of the protein has a ma-
jor contribution to the total effective energy that describes the protein-membrane
binding process.
In addition, membrane curvature regulates protein-membrane insertion by mis-
match formation and hydrophobic interactions. Highly curved membranes are char-
acterised by a mismatch in the packing of the lipids in the outer layer. This mis-
match cause defects withing the membrane where hydrophobic areas are exposed
to the aqueous phase [216, 233, 234]. The insertion of hydrophobic or amphiphilic
molecules at defect sites is extremely favourable. The density of defects (Dd) on a
membrane can be calculated on the basis of the membrane curvature [235], assum-
ing that the lipid density in either leaflet is constant using the following equation:
Dd ≈ ΔA
Aves
≈ 8πrl
4πr2
∝ 1
r
(1.6)
where: ΔA is the area increase of the outer leaflet, Aves is the total area of the
vesicle, l is the membrane thickness and r is radius of the vesicle. It is clear from
this model that more protein binds to the membrane (by insertion of amphipatic
motifs) as the membrane curvature increases. However, in many other cases there
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are other components that control the membrane binding such as electrostatic at-
traction [120], partitioning into membrane domains [174] or specific recognition
motifs [236]. Since this might be the case also for PLC [237], partial membrane
insertion cannot be excluded. The protein-membrane binding process can be decou-
pled into an initial transfer of the protein from the aqueous phase to the hydrophobic
phase. The adsorption step is often followed by a conformational change of part of
the protein from random coil to α-helix. Thermodynamically the adsorption process
is described by the standard free energy (ΔGo):
ΔGo = − R T ln 55.5 K (1.7)
where: R is the universal gas constant, T is the temperature, 55.5 is the molar
concentration of water, and K is the equilibrium absorption constant. The entropy
of the binding can be calculated from:
ΔGo = ΔHo − TΔSo (1.8)
The thermodynamic factors that describe the transition from random coil to α-
helix at the membrane have been investigated by Wieprecht and co-workers in SUVs
and LUVs [238]. The helix formation is an enthalpically driven process and is
disfavoured by the reduction of entropy. Even so, when helix formation occurs, the
contribution of the conformational change to the free energy is about 50-70% of the
total over the entire process of absorption [238]. The parameters do not change with
the size of the vesicles on which the protein is absorbed [238].
The α-helix inserted into the membrane is often an amphipathic helix. In more
detail, it has a hydrophilic side and an hydrophobic side along the axis of the helix.
These types of helices are unstructured until they insert into the membrane. The
hydrophobic side of the helix will dip into the hydrophobic core of the lipid bilayer
while the hydrophilic side will remain at the head group interface. This insertion
causes the lipids to rearrange to make space for the helix, and this may result in
membrane curvature
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Various biological processes that take place at the membrane are successfully
predicted and described by the continuum theory of membrane energetics. This
theory interprets the dependency of protein insertion and protein function on the
membrane lipid composition. The continuum theory is based on the forces that
drive lipid bilayer formation, the elasticity and geometry, and predicts the inter-
membrane interactions. An example is provided by rhodopsin, which binds to
lipid vesicles as a function of their lipid composition [213, 239]. Vesicles en-
riched with phoshatidylserine (PtdSer) or phoshatidylethanolamine (PtdEtn) show
increased rhodopsin-membrane binding. The negatively charged PtdSer favours
protein-membrane binding by altering the membrane’s electric surface potential,
while the PtdEtn alters the elastic curvature stress [213, 239].
An elastic membrane deformation is well described in mathematical terms by
Helfrich [240]; this model accounts for bending elasticity, hydrophobic chain splay
and tilt, and lateral compression or stretching of the lipids. Although these the-
ories are powerful in predicting protein-membrane binding, or protein membrane
function dependency, they simplify a system that is much more complex in reality.
Membrane deformation and hydrophobic mismatch cannot regulate the behaviour
of so many different proteins in a cell. There are proteins that interact specifically
with certain types of lipid. These lipids can be considered as co-factors and their
distribution within the membrane can be altered. The protein-lipid interaction can
be described in mathematical terms by quantum chemistry that accounts for protein-
lipid interaction, lipid-water and lipid-lipid interaction.
1.4.2.4 Biological membrane compositions
Biological membranes contain the so-called non bilayer lipids (e.g. PtdEtn), some-
times in high percentages (e.g. the inner leaflet of E.coli contains 75% of non
bilayer lipids). Therefore, non bilayer lipids must have a biological function and
it has been suggested that non bilayer structures might accomplish certain specific
functions (e.g. junctions between mammalian cells).
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Protein-lipid binding can be quantified by the membrane-water partition coef-
ficient (Kpmw). The partition coefficient is related to the free energy of transfer
(ΔGmw) from the aqueous phase to the membrane by the following relationship:
Kmwp = exp
−ΔGmw
RT (1.9)
The electrostatic interactions, the hydrophobic effects, the protein conforma-
tional changes and lipid deformation all contribute to the free energy of trans-
fer [241, 242]. The electrostatic contribution of a membrane can be described by
the Gouy-Chapman theory which assumes that the charges are distributed uniformly
over the membrane and that the dielectric constant is the same as for the bulk aque-
ous phase. Hence, increasing the charge of the protein, or of the membrane (when
they are of opposite signs), causes an increase in binding. An increase of the dielec-
tric constant causes a reduction of binding. However, the Gouy-Chapman theory
does not describe well the electrostatic effect of a system characterised by localised
multivalent lipids such as PtdIns(4,5)P2, or of proteins containing a cluster of pos-
itively (negatively) charged residues. In this case the finite-difference solutions to
the non-linear Poisson-Boltzmann (FDPB) method can be used. This method calcu-
lates the electrostatic contribution based on the difference between the free energy
of the system (ΔGmw) when the protein and the membrane are bound and when
they are not bound.
The distribution of the lipids between the inner and outer leaflets of the plasma
membrane of mammalian cells is asymmetric: the outer leaflet contains mainly
phosphatidylcholines (PtdChl) and sphingomyelin (SpM), while the inner leaflet
contains predominately PtdEtn, PtdSer and phosphatidylinositol (PdtIns) [237], see
figure 1.4.2.4.
The monovalent acidic phospholipids, PtdEtn and PtdSer, have charge -1 while
PtdIns(4,5)P2 has -3 charge at pH 7.4. The cytoplasmic leaflet of the plasma mem-
brane in many cases contains about 25% PtdSer [243]. The asymmetric distribution
of neutral or anionic lipids across the bilayer results in enrichment of the cytosolic
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Figure 1.18. Chemical structures of the major structural lipids: glycerophospho-
lipids [phophatidylcholine (PtdChl), phosphatidylethanolamine (PtdEtn), phosphatidylser-
ine (PtdSer), phosphatidylinositol(PtdIns), phosphatidic acid (PtdOH)] and sphingolipids:
sphingomyelin (SpM). The acyl chains are represented by R or R’.
side of the plasma membrane of mammalian cells with acidic phospholipids [244].
Such asymmetry characterises the plasma membrane and not the other intracellular
membranes [245,246]. This characteristic might allow selective targeting of periph-
eral membrane proteins. For example cytosolic phospholipase A2 is targeted prefer-
entially to ER or Golgi membrane [247] and in vitro binds preferentially to PtdChl
rich vesicles than to PtdSer vesicles through the C2 domain [248–250], or K-Ras4B
that binds preferentially to PtdSer rich vesicles in vitro and is targeted to the plasma
membrane [251]. The proposed model to describe the K-Ras4B-membrane inter-
action, based on in vivo and in vitro data, indicates that the polybasic C-terminal
sequence (GKKKKKKSKTKC) is driving membrane targeting by engaging acidic
lipids on the plasma membrane by electrostatic interaction [121, 252].
1.4.2.5 Membrane binding domains in PLCs
PH domain The pleckstrin homology (or PH) domain as was first identified in
1993 as a 100-120 amino acids sequence that occurs twice in pleckstrin [253]. The
PH domain is often found in protein involved in signal transduction such as GTPase-
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regulated proteins, protein kinases or phospholipases [254]. The PH domains share
a conserved scaffold referred to as the PH superfold [255], but have distinct and
variable loops that control the specificity of the PH domain in terms of function and
ligand binding [256–258], see figure 1.19. A striking characteristic of the PH do-
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Figure 1.19. Structure and surface charge of the PH domain of PLCδ1 and Ark. The
PH domains show a common β sandwich structure (in green) formed by seven-β-strands.
Four strands (β1-β4) form the first twisted sheet with β1 and β2 almost orthogonal to β3
and β4, the other three strands (β5-β7) form the second sheet with β5 almost orthogonal
to β6 and β7 and β4; (A) the PH domain of PLCδ1 in complex with Ins(1,4,5)P3 (PDB
ID= 1MAI) Residues K30 and K57 are engaged in hydrogen bonds with the 4- and 5-
phosphates of Ins(1,4,5)P3, R40 is engaged in hydrogen bonds with just the 5-phosphate
and W36 is engaged in hydrogen bonds with the 1-phosphates; (B) Ark in complex with
Ins(1,3,4,5)P4 (PDB ID= 2UZS). The surface charge of PH domains of PLCδ1 (C) and
Ark (D) shows electrostatic polarisation, the electrostatic potential is mainly positive (in
blue), corresponding to the binding side and negative (in red) on the opposite side of the
molecules.
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main is the strong polarisation of charge which is generally well conserved among
the PH domain family. This polarisation confers electrostatic properties that pro-
mote interaction of the PH domain with the membrane. In addition, the long-range
electrostatic effects might regulate the orientation of the PH domain with respect
to the membrane. Many PH domains are capable of binding phosphoinositides,
and they do so with different degrees of specificity [184]. For example, the PH
domain in PLCδ1 is capable of binding with high specificity and with high affin-
ity to PtdIns(4,5)P2 [24] or to its soluble Ins(1,4,5)P3 head group [15, 259], while
the N-terminal PH domain of plekstrin1 binds to phosphoinositides as well as to
PtdEtn due to the charge interaction. The physiological relevance of different lig-
ands’ affinity for the PH domain might contribute to further regulation of the signal
transduction process. Some proteins might be targeted to the membrane only in the
presence of specific lipids, this could be achieved by high affinity ligand binding
PH domains such as PLCδ1-PtdIns(4,5)P2. Other proteins change the affinity for
the membrane (normally quite low) upon phosphorylation and oligomerisation in
response to cell stimulation.
C2 domain The C2 domain is a ≈ 130 KDa domain that is very common in
eukaryotic proteins involved in signal-transduction, but so far no catalytic function
has been reported for this domain [27]. The known C2 domains have a highly
conserved structure. The structure of the C2 domain shows eight antiparallel β-
strands [260]. Based on the interconnectivity of the β-strands, two topologies of C2
domains may be distinguished. The C2 domains of PLCδ1 [21], PLCβ [29] and of
PLCγ [261] belong to the second topology (see fig. 1.20, A) [262].
The C2 domain is involved in the binding of calcium ions (see fig. 1.20, B).
However, different affinities for the binding of Ca2+ ions have been reported. This
difference suggested that in some cases the principal function of the C2 domain was
not Ca2+ binding, but membrane binding, either in a Ca2+ dependent or independent
manner. In this respect, the C2 domain is the most abundant lipid binding domain
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Figure 1.20. (A) Schematic representation of the topology I and topology II C2 domain; the
first β strand in topology I is in the equivalent position to the eighth β strands in topology II;
the N-terminus and the C-terminus are indicated by the letters N and C; the loops involved
in Ca2+ bindings are in red, (figure adapted from [262]); (B) the structure of the C2 domain
of PLCδ1 (ID = 1DJZ) shows the residues involved in Ca2+ ion coordination (Asp, Asn,
Ile).The C2 domain can bind up to two Ca2+ ions which are coordinated by Asp residues in
the β1-β2 and in the β5-β6 loops.
after the PH domain [27].
The C2 domain-membrane binding can be achieved by three different mecha-
nisms. In the first mechanism, the C2 domain varies its electrostatic potential as a
consequence of Ca2+ binding thereby enabling the interaction with the membrane
and in particular with anionic or zwitterionic lipids [28,90]. Within this first mecha-
nism, the Ca2+-dependent membrane binding of the C2 domain is interpreted using
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two models. According to one model, the Ca2+ ions are concomitantly coordinated
by the C2 domain and to the phospholipids forming a ternary complex. According
to the other model, Ca2+ binding promotes a conformational rearrangement in the
C2 domain. This conformational rearrangement leads to exposure of the membrane
binding sites of the C2 domain to the membrane [262]. In support of this model,
it was shown that the C2 domain in the presence of lipids has different protease
sensitivity when Ca2+ ions are included or are absent [263]. There are also studies
of the C2 domain showing membrane domain formation, such as regions enriched
in anionic lipids in lipid vesicles [264].
In the other two mechanisms, the C2 domain was suggested to interact with the
membrane using two binding sites. The relative contribution of these two bind-
ing sites regulates the lipid selectivity depending on the Ca2+ concentration. One
C2 binding site, which is at the edges of the β sandwich, often contains a string
of cationic residues, which is responsible for the non-selective binding to anionic
phospholipids such as PtdIns(4,5)P2 or PtdSer in absence of Ca2+, and for the se-
lective binding to anionic phospholipids in presence of Ca2+ [265]. The other C2
domain site has a role in direct membrane binding. It contains mainly hydropho-
bic and cationic residues. Therefore it interacts preferentially with zwitterionic-
lipids [249, 266] and it is suggested to partially insert into the membrane. The C2
domain of synaptotagmin I is an example of this dual binding site mechanism. It
binds non-selectively to PtdSer or PtdIns in absence of Ca2+ ions or selectively to
PtdIns in presence of Ca2+ ions [90].
1.5 Structural studies
Determining the structure of a protein can result in a better understanding of its
function and mechanism of regulation. Structural changes associated with the pro-
tein function upon interaction with the effectors or with the substrate, can provide
important information. However, determining structures can be very challenging.
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An important aspect to consider is the correlation of the protein structure with the
functional properties of the protein in the in vivo environment. For this reason, the
conditions adopted for the structural determination that closely mimic the natural
environment, including the ionic strength and the pH, are preferred.
1.5.1 Electron crystallography
Electron crystallography is a complementary method to the more established NMR
or X-ray methods for protein structural determination. Electron crystallography rep-
resents a valuable alternative and it is gaining recognition, especially for proteins
that are unstable, large (< 500 KDa) or that can be produced only in low yield [267].
Furthermore, electron crystallography has the potential to solve the structure of
membrane and soluble proteins [268] with high resolution [269–271]. Electron
crystallography applied to two-dimensional crystals has been demonstrated to be ca-
pable of resolving the 3D structure with a resolution of 8 Å or below [270,272–275].
This technique was first used for purple membrane protein in 1975 [276], and was
then adapted for soluble proteins. Two-dimensional crystals (2D) of biological
macromolecules consist of a regular ordered repeating pattern of molecules formed
at the lipid-water interface. The repeating unit within the crystal is referred to as the
unit cell and it may contain more than one copy of the molecule. A two-dimensional
crystal contains a large number of unit cells; imaging of two-dimensional crystals
by electron microscopy (EM) and the analysis of these data lead to structural infor-
mation.
The mechanism of crystal growth is not very clear yet, but the crystallisation
process is driven by a high local concentration (which can be in the order of 500-
1000 mg/ml) at the lipid surface. The role of the lipid is to increase the protein
concentration upon absorption of the protein thereafter promoting nucleation events
and then possibly crystal growth [277].
The absorption can be specific or nonspecific. Specific absorption is based on
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a distinct property of the protein, such as protein-ligand binding. Nonspecific ab-
sorption is based on electrostatic interaction between the protein and a charged lipid
layer [278,279]. For both types of absorption, binding must occur with high affinity
to drive the protein from the aqueous phase (which can be very similar to a physi-
ological buffer) to the water-lipid interface. The absorption process has an entropic
cost. In addition to protein purity, several other factors contribute to the ease of
crystal formation, such as the type of lipid used, ionic strength, the pH, and the
temperature.
All the high-resolution structures using two-dimensional crystals were obtained
with highly purified proteins, which are more likely to result in well-ordered crys-
tals, that are necessary for achieving high resolution. The highest resolution achieved
by EM crystallography is 1.9 Å and is the 3D structure of the membrane protein
aquaporin 0 [272], while the highest resolution obtained with soluble protein on a
lipid monolayer is 3.7 Å [275]. The resolution achievable with biological samples
is limited by a number of factors that are dependent on the specimen, such as the
order of the crystal, radiation damage, and the preservation of the specimen under
vacuum. Indeed, the theoretical resolution limit of EM, which is dependent on the
acceleration voltage used, corresponds to the wavelengths of the electron waves.
This is typically in the range of 0.01-0.05 Å and therefore beyond the resolution
limit imposed by the sample quality or the experimental limitations.
1.5.1.1 Two-dimensional crystallisation
Two-dimensional crystals of protein can be grown on a lipid-water interface [280].
Lipids represent a versatile substrate for crystallisation because they bind the protein
through the lipid head group which can be readily modified. This allows to tune the
specificity and the strength of the lipid head group-protein binding and therefore the
crystallisation process promptly [281].
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1.5.1.2 Types of protein-lipid binding
Various approaches can be used to bind soluble proteins to a lipid monolayer. Non-
specific interaction such as electrostatic forces can be exploited for this purpose,
of which several examples have been reported in literature: yeast RNA polymerase
II [279]: herpes simplex virus type I [282] was crystallised on a positively charged
lipid monolayer [283–285]; crystals of chaperonin TF55 were obtained on a neg-
atively charged lipid monolayer [286]. Alternatively a specific interaction can be
used to immobilise the target protein at the lipid interface in a predictable orienta-
tion with respect to the binding lipid. Due to the selectivity of the binding, which re-
duces the number of possible protein orientations, a specific interaction is preferred
to a non-specific interaction. An example of a specific interaction is the one be-
tween a sequence of consecutive histidines (His-tag) and metal-chelate complexes,
such as nickel nitrilotriacetic acid (Ni2+-NTA). Also sufficient fluidity and diffusion
within the monolayer plane need to be maintained, the diffusion allows the proteins
to find interactions with each other appropriate to form ordered arrays. The high
concentration of the protein at the lipid interface drives the crystallisation process
without the need of precipitants. However, the efficient recovery of the sample on
the EM grid can be an issue, and can cause sample damage or disruption.
Two-dimensional crystals suitable for electron crystallography can be grown on
lipid tubules, bilayers (vesicles) or monolayers (planar) [287].
1.5.1.3 Tubular
Tubular crystals, due to their geometry, show the protein in a number of different
orientations; therefore, it is unnecessary to tilt these specimens, and the 3D recon-
struction is not anisotropic as it is in other types of crystal [287,288]. These types of
crystals have led to high-resolution structures (4.6 Å) [289,290], and the 3D recon-
struction of proteins crystallised as tubular crystals do not have reduced resolution
in the plane perpendicular to the interface [287].
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1.5.1.4 Vesicular
Vesicular crystals are the easiest to be obtain, probably because of the higher rate of
diffusion of the lipid molecules within a bilayer compared to a monolayer or tubule.
The lipid vesicles usually collapse during sample preparation for EM studies, and
large vesicles (up to 3 μm) are preferred to the small vesicles because they can host
large coherent crystalline areas. A collapsed vesicle has opposite sides of the vesicle
lying one on top of the other. Therefore, the image obtained and the projection
contain contributions from both of the two crystalline areas. The contribution of
each crystal needs to be separated during imaging processing.
1.5.1.5 Planar
Planar crystals consist of a single layer which is usually grown on a lipid mono-
layer. With the lipid monolayer approach, the lipid monolayer is self-assembled on
the top of an aqueous-phase with the head groups pointing toward the water and
the hydrophobic tails pointing toward the air (see fig. 1.21, B). The monolayer
technique is a flexible method because specific or nonspecific types of lipid-protein
interactions can be explored by changing the lipid composition. Non specific in-
teractions of lipids with net (positive or negative) charge are used to form the lipid
monolayer. In a specific interaction, the lipid monolayer is formed of two different
types of lipid, one is the ligand and the other the diluting lipid. The ligand can
be a natural lipid, or more often have a functionalised head group capable of spe-
cific binding to the molecule. In this regard, nickel chelating lipids [291] within a
monolayer represent a successful and versatile approach for 2D crystallisation of
histidine tagged proteins [292, 293]. Furthermore, the lipid monolayer approach
has been used as a model system for the association of proteins, such as p38, with
biological membranes [294]. Planar crystals have led to high-resolution structures
(1.9 Å) [272].
Successful two-dimensional crystal formation results from the combination of a
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number of variables; temperature, protein concentration, lipid concentration, lipid
composition and buffer composition. Therefore combinations of these many vari-
ables need to be tested for any protein, which is a time consuming process. The
crystallisation is assessed by harvesting the crystals and imaging the sample by EM
(often in negative stain). When a set of conditions that lead to crystal formation
have been determined, small variations around this set of parameters are then used
to optimise the crystallisation process to obtain highly ordered crystals [295]. The
resolution of the structure determination is dependent on the quality of the crystals,
highly ordered crystals can lead to high resolution data [270, 296, 297]. The un-
bent crystal is treated as a perfect crystal and the average of all its unit cells is used
determine the 2D projection and 3D reconstruction.
1.5.1.6 Advantages and disadvantages
The electron crystallography approach is particularly suitable for proteins that in-
teract with membranes because the structures so determined will be closely com-
parable to their functional state; cholera toxin and SecA are perfect examples. The
structure of cholera toxin was determined whilst the molecule was penetrating the
membrane by using 2D crystallisation on a lipid monolayer, followed by EM stud-
ies [298, 299]. Conformational changes of SecA, a protein involved in protein
translocation in bacteria, were observed at low-resolution (2 nm) using 2D crys-
tals on a lipid monolayer [300]. In contrast, these conformational changes were not
detectable in the high resolution 3D X-ray crystal structure of SecA. 2D crystalli-
sation of membrane associated proteins such as PLC has the advantages that the
crystallisation conditions are similar to the natural environment, possible detection
of functionally significant conformational changes maybe detected, and near atomic
resolution is also theoretically achievable. Furthermore, this method is particularly
suitable because small quantities of protein are required and PLC is not expressed
in high amounts (0.5 mg per litre of bacterial culture). As a result of the many ad-
vantages offered, 2D crystallisation was chosen as the approach for this project. The
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2D crystals form in near physiological conditions, without the need of precipitant
and they can form in within hours. The short time required for 2D crystal formation,
prevent denaturation and loss of protein function. Crystals contain a large number
of unit cells which can be promptly averaged to increase the signal-to-noise ratio,
thus improving the resolution of the data sets.
1.5.1.7 Crystal formation
Three steps can be defined in the crystal formation process [277]. The first step in-
volves recognition and binding of the protein to the monolayer, the second includes
lateral diffusion within the monolayer and concentration of the protein at the inter-
face. The third step comprises reorganisation of the protein into an ordered array
and eventual crystal formation. Systematic studies of 2D crystallisation systems
highlighted the importance of the lipid layer composition, the lipid phase, and the
lipid concentrations [301].
The design of lipids suitable for specific protein binding, such as nickel chelat-
ing lipids which can be of general use for any His-tagged protein [302], improve-
ment of electron microscopy techniques, improvement of specimen preparation
[303] and implementation of imaging processing [304] contributed to the expan-
sion of this technique. Flat crystals often have lower resolution in the direction
perpendicular to the plane because the data relative to the that dimension are col-
lected by imaging the tilted sample. The samples can be tilted up to 25,◦. In the
first instance, it is necessary to purify the protein to increase the chances of crys-
tal formation. Indeed, if impurities or degradation products (rather than misfolding
products) are present they can prevent growth of the ordered lattice (see sec. 1.5.1.
In the second instance, it is necessary to think of a means to bind the protein to the
lipid monolayer. Lipid monolayers are versatile since their lipid composition can
be varied and lipid molecules can be specifically designed. The 3D reconstruction
is obtained by tilting the specimen at a number of angles and using the images and
their corresponding diffraction pattern.
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Figure 1.21. Schematic representation of the 2D crystal formation process. A crystalli-
sation well is fill with purified protein in buffer (A), the lipid mixture in solvent is spread
over the top of the well when the lipids will self-assemble in a lipid monolayer (B). Over
time the lipids coordinate the protein, and lipid-protein complexes diffuse within the lipid
interface, as well as rotating about the normal axis to the lipid-water interface. Due to dif-
fusion and rotational rearrangement, lipid-protein complexes can bind each other to form
protein-protein contacts which might lead to initial nucleation (C). The crystal grows under
appropriate conditions (D).
The protein concentration at the interface can reach 500-1000 mg/ml where the
concentration of the aqueous solution is only 10-100 μg/ml [305]. This approach,
which only requires micrograms of protein (1-2 μg), is a valid option for proteins
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that are expressed in low amounts and cannot meet the quantities required for 3D
X-ray crystallography (10-20 μg) [306].
1.5.1.8 Sample harvesting
Sample harvesting for electron crystallography is a critical step [307]. It involves
crystal transfer from the air-water interface to an EM grid without compromising
the ordering of the protein array. The degree of sample perturbation is difficult
to control and may result in poor reproducibility, or destruction of the crystals.
Recently a wire-loop has been introduced to harvest 2D crystals prepared on a lipid
monolayer. This method relies on the hydrophilic interactions between the protein
crystal and the carbon layer of a glow discharged grid [308]. The wire loop is
lowered onto the surface of the sample and lifted to harvest the lipid layer plus any
2D crystals that may have formed. The lipid layer and the crystals span the loop;
the crystal’s side is deposited on a glow discharged EM grid, see figure 1.22, A.
Alternatively, a commonly used transfer method involves direct contact between
the EM grid and the sample. The hydrophobic grid is gently placed on the top of
the sample to allow hydrophobic interactions with the lipids’ tails to occur, and
then the grid is gently lifted [309], see figure 1.22, B. Various methods have been
reported to make an EM grid hydrophobic such as baking a freshly carbon coated
grid at 80 ◦C for 1 hour [278], by silanisation of the carbon film [307], or coating
the EM grid with a polymerised layer of amphiphile on the top of the carbon [278].
Damage induced by the transfer is extensively discussed in the literature [309],
and as an alternative holey carbon grids can be used to reduce sample perturbation
and to increase the crystal recovery. The samples are embedded in a vitreous ice
obtained by plunging the EM grid into liquid ethane, or stained with a heavy metal
salt solution such as uranyl acetate.
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Figure 1.22. Schematic representation of the two-dimensional crystal harvesting process
by direct contact with a EM grid (A) or with a wire-loop (B).
1.5.1.9 EM image formation
The electrons of the beam are affected by passing through the specimen. Two types
of interaction can be distinguished: elastic or inelastic. In an elastic collision, the
beam electrons are scattered mainly by interaction with the potential field of the
atomic nuclei, maintaining the same wavelength, but changing direction and phase.
In an inelastic collision, the electrons are scattered mainly by the valence or bond-
ing electrons of the specimen, imparting a different wavelength and some of the
electron’s energy is transferred to the specimen. Only elastically scattered electrons
contribute to image and diffraction pattern formation. The inelastically scattered
electrons contribute to the noise and radiation damage of the sample. The relation-
ship linking elastic (σe) and inelastic scattering (σi) can be approximated by the
following equation [271]:
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σe/σi = Z/19 (1.10)
Biological samples are formed mainly of carbon (ZC=12), nitrogen (ZN=14),
hydrogen (ZH=1) and oxygen (ZO=16). Due to their low atomic number, these
atoms make biological samples weak scattering objects, therefore inelastic scatter-
ing predominates. The specimen needs to be preserved from the vacuum of the EM
in order to collect information from it. There are two approaches: heavy metal stain-
ing (known as negative staining) to preserve the shape of the specimen, or freezing
the specimen at very low temperatures. Both these approaches protect the specimen
from the vacuum and also from the radiation damage caused primarily by inelastic
scattering [310]. Information about the specimen’s structure up to an intermediate
resolution (≈ 20 Å) can be obtained using a negative staining. In negative staining
the information comes from the stain shell surrounding the specimen, with the ad-
vantage that the stain is more stable under the radiation beam than the specimen is
alone. In addition, the heavy metals of the stain increase the scattering, resulting in
a high contrast image. Irradiation of the sample can be limited to 10-20 electrons/Å2
by working in “low dose” mode
1.5.1.10 Diffraction pattern
The diffraction pattern of a 2D crystal is an array of spots that results from the
interference of the scattered waves. The waves add up in phase, this corresponds to
a diffraction spot and they cancel each other out elsewhere. The waves are in phase
when their path lengths (from the emitter to the detector) is the same, or their path
lengths differ by an integer multiple of the wavelength (λ), as described by Bragg’s
law (see fig. 1.23):
nλ = 2dsinθ (1.11)
where:
1.5 Structural studies 62
λ = wavelength of the incident electrons
d = distance between the electrons’ paths
θ = scattering angle
n = integer number
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Figure 1.23. Illustration of Bragg’s law. Two electrons (e1, e2) are scattered at an angle θ
upon interaction with two atoms (C1 and C2) which are at a distance d from each other. The
paths of the two scattered electrons are represented by the black arrows. Their path length
difference corresponds to the sum of length segments X + Y. The length of each segment is
given by: X=Y= d sin θ, therefore the path length difference of the two electrons is equal
to 2d sinθ. When the difference of the electrons’ path length is equal to an integer multiple
(n) of the wavelength (λ), nλ = 2d sin θ, their interference is constructive.
The diffraction pattern enhances intensity in certain directions whilst nullifying
intensity in others directions. The diffraction pattern is said to be in reciprocal
space, since the diffraction spots from high angle scattering contain information
about the fine details of the object, while low angle scattering corresponds to large-
scale features. The unit cells diffract in phase if a Bragg plane passes through
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the same points within each unit cell of the crystal, and if the Bragg plane passes
through the unit cell an integer number of times. The number of Bragg planes along
each dimension of a 2D unit cell is referenced as (h, k). The corresponding spots
in the diffraction pattern are indexed using the same indices (h, k). The phase of a
diffraction wave is given by the ratio between the distance of the scattering object
from the Bragg plane and the distance between two Bragg planes. The intensity of
the diffraction spot is linked to the amplitude of the electron density by a square root
relationship. A diffraction pattern can be obtained from an image by calculation of
the Fourier transform of the image, or by using the microscope in diffraction mode.
In the first case, both amplitudes and phase information are available, whilst in the
second case only the amplitude is available.
1.5.1.11 Image formation
An image results from the interference of the scattered and the unscattered waves (or
electrons), and it represents the projection of the electron density along the optical
axis. The phase contrast resulting from the scattered waves, which have a phase
shift of π/2, and the unscattered is expected to be zero. However, this is true only in
an ideal situation. In reality, images are out of focus and the spherical aberration is
present; these lead to a phase shift (X) [311]:
X(θ) = 2πλ−1(Δf θ2/2− Cs θ4/4) (1.12)
where:
Δf is the defocus
θ is the scattering angle
Cs is the spherical aberration
λ is the wavelength.
The phase shift of the scattered waves generates phase contrast, which is maxi-
mum for X (θ) = ± π/2 since the scattered and unscattered waves are in phase. The
effect of the phase shift as a function of the reciprocal object spacing θ/λ is called
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phase-contrast transfer function (pCTF):
pCTF = −sinX(θ) (1.13)
The pCTF is a sinusoidal function which is zero for X=0, remains negative
until it first intercept the X-axis. For lower object spacing, the pCTF changes sign
periodically and fades out due to EM limitations (see fig. 1.24).
f = 450 nm
f = 70 nm
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Figure 1.24. The pCTF plotted as a function of θ/λ, in [nm−1]. The graphs are obtained
using a CTF simulation applet written by Wen Jiang [312] and using the following values
voltage = 120 keV, Cs = 1.4 mm, and various values of defocus (Δf). The defocus presented
in the top panel is close to the optimum since the pCTF is close to -1, therefore the phase
contrast is maximum, on a wide range of θ/λ.
The phase contrast of the details of the image varies with the θ/λ. No informa-
tion can be recovered when the pCTF is zero. Information from frequencies beyond
the first intercept of the pCFT with the X-axis (high resolution information), can be
recovered by correcting the pCTF for the contrast reversal due to the sign change
and the fading out. The amplitude contrast function, aCTF, is described by:
aCTF = −cosX(θ) (1.14)
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It originates from inelastic scattering and high angle scattered electrons. The
amplitude effect is significant for stained samples, it is minimal for un-stained sam-
ples.
The phase and the amplitude contrast contribute independently to the image.
The contribution is described by the contrast transfer function:
CTF = [−sinX(θ)− cosX(θ)] (1.15)
The effects of the phase and of the amplitude are additive under focussed con-
ditions, therefore the images are recorded under these conditions. To obtain the
three dimensional structure of a specimen using 2D crystals, a few images of the
crystals need to be recorded and crystal patches need to be recorded at various tilt
angles. A micrograph’s image quality is assessed using an optical diffractometer,
which reveals the ordering level within the crystal and the astigmatism of the lenses
of the EM, or drift. Micrographs of the best ordered crystals, with no astigmatism
or drift, are digitalised and transformed into Fourier space. The result is a series
of diffraction peaks, called a reciprocal lattice, from which amplitudes and phases
can be extracted. The spots of the diffraction pattern are indexed associating each
of them with a position on the plane, an amplitude and a phase. This information
refers to the specimen in real space. The signal to noise ratio is increased by fil-
tering the reciprocal lattice. The values obtained for amplitude and phase are used
to calculate the inverse Fourier transform which results in an improved image of
the crystal in real space [296]. Distortions of the crystal imaged in the micrograph
are measured by calculating a so called cross-correlation function and are corrected
by unbending. The calculation of the Fourier transformation and the indexing are
reiterated using the unbent image data. The data from various crystal patches at
zero tilt are then merged together to generate the projection map. The unit cells
are aligned and averaged increasing the signal to noise ratio. The precision of the
alignment directly affects averaging; the better the averaging, the higher the resolu-
tion achieved. 2D crystals facilitate the alignment step and this advantage is more
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marked in the case of a small specimen (< 500 KDa). Indeed, in a 2D crystal, the
unit cells are aligned by simple translation according to the lattice vectors. This is
true for a perfect crystal, but some of the crystal imperfections could be compen-
sated by the unbending step. The three dimensional structure is obtained by merging
the data from the tilted and un-tilted specimens (about 100 images of 2D crystals
which might contain about 5 million molecules) [297, 313]. Comparison of the 3D
structures obtained by growing 2D crystals under different conditions can reveal
functional conformations of the protein. A conformational change, depending on
its nature, may be detectable by comparing projection maps [314].
The phases are extracted from the image and the amplitudes are extracted from
the diffraction pattern intensities. The diffraction pattern is indexed, the intensities
of the diffraction spots are background corrected and then integrated [315]. These
data are analysed and the amplitudes are extracted. The images are corrected for the
CTF. The projection map is obtained by averaging the Fourier transform amplitude
values and the phases data obtained from the corrected images (the Fourier trans-
form amplitude values can be obtained also from the diffraction pattern directly, but
only if large and well ordered crystals can be obtained) [316].
Negative stain might cause sample distortion due to the stain-drying procedure.
Additionally, due to the stains limited penetration, the highest resolution threshold
that can be achieved is ≈ 20 Å. To increase the resolution further, specimens are
usually vitrified [317].
The signal-to-noise ratio is increased upon averaging, so the better the alignment
of the unit cell, the higher the resolution that can be achieved.
1.6 The aims of the project
The enzymes of the PLC family are crucial in cell signalling and are involved in
many physiological processes that are necessary for cell survival. However, the reg-
ulatory mechanisms and the functions are not well understood. In order to achieve
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a better inside into the mechanism of PLC regulation, activity, functional and struc-
tural studies were performed.
Activity studies were performed in vivo and in vitro. In particular, the in vivo
activity measurements were used to study the PLC regulation upon protein-protein
interaction while the in vitro activity measurements were designed to investigate
both protein-protein and lipid-protein interactions involved into PLC regulation (see
sec. 5 and sec. 6).
The protein-protein interaction between GTPase and PLC was further investi-
gated at a molecular level in vitro (see sec. 4). Functional studies were carried out
using Förster resonance energy transfer (FRET) to determine if PLC undergoes a
conformational change upon GTPase binding. Indeed, a conformational change as
well as the translocation of PLC to the membrane interface (where GTPases are
localised) could be responsible for PLC activation.
Electron crystallographic structural studies, in which two-dimensional protein
crystals are grown on a lipid monolayer followed by electron microscopy, were
attempted aiming to retrieve structural information at intermediate resolution (10
A) or higher, in a functional state that resembles the natural one.
Chapter 2
Materials and methods
2.1 Materials
Chemicals: Pefabloc SC and AEBSF from Roche were dissolved in UF water (100
μg/μl and 200 mM respectively) and stored at -20 ◦C.
Protamine sulfhate from Sigma−Aldrichwas dissolved in UF water (1mg/ml),
filter sterilised and stored at RT.
Ampicillin from Sigma was dissolved in UF (50mg/ml) and stored at 4 ◦C;
chloramphenicol from Calbiochem was dissolved in EtOH (50mg/ml) and stored
at -20 ◦C.
Streptavidin from F luka was dissolved to 0.1 mg/ml in 20 mM trisCl pH 7.6,
150 mM NaCl. Biotinylated lipids from Sigma − Aldrich were mixed to 4:1
mol/mol in chloroform-hexane (1:1 v/v). 3-[4(-N-(5-amido-α-N-diaceticacid ly-
syl)] succinyl-1,2-dioleoyl-sn-glycero (nickel complex) [DOGS-NTA(Ni)] and 1,2-
dioleoyl-sn-phosphatidylcholine (DOPC) were purchased in chloroform fromAvanti
Polar Lipids, these were mixed to 10:1, 5:1 and 1:1 mol/mol in chloroform-hexane
(1:1 v/v). Acetic acid, propan-2-ol, chloroform, and MeOH were all analytical
grade and were purchased from BDH, Ltd.
Buffers for liquid chromatography: washing buffer A: 25 mM TrisCl pH 8.0, 300
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mM NaCl, 20 mM imidazole, 1 mM TCEP and complete protease inhibitor cocktail
(EDTA free, 1 tablet for 500 ml buffer, from Roche);
elution buffer B: 25 mM TrisCl pH 8.0, 300 mM NaCl, 300 mM imidazole, 1 mM
TCEP and complete protease inhibitor cocktail (EDTA free, 1 tablet for 500 ml
buffer);
washing buffer C: 100 mM TrisCl pH 8.0, 150 mM NaCl, 1 mM EDTA, 1 mM
TCEP;
elution buffer D: 100 mM TrisCl pH 8.0, 150 mM NaCl, 1 mM EDTA, 1 mM TCEP,
2.5 mM D-desthiobiotin;
elution buffer E: 100 mM TrisCl pH 8.0, 150 mM NaCl, 1 mM EDTA, 1 mM
HABA;
storage buffer F: 100 mM TrisCl pH 8.0, 150 mM NaCl, 1 mM EDTA;
washing buffer G: 25 mM TrisCl pH 8.0, 300 mM NaCl, 1mM TCEP;
washing buffer H: 25 mM TrisCl pH 8.0, 250 mM NaCl, 1 mM TCEP;
elution buffer I: 25 mM TrisCl pH 8.0, 250 mM NaCl, 10 mM maltose, 1 mM
TCEP;
regeneration buffer J: 0.1% SDS;
elution buffer K: 25 mM TrisCl pH 8.0, 1 M NaCl, 1 mM TCEP;
elution buffer L: 25 mM TrisCl pH 8.0, 300 mM NaCl, 3 mM sodium azide, 1mM
TCEP.
Buffers for SDS-PAGE: loading buffer (4 ×) i: 62.5 mM Tris HCl pH 6.8, 25%
w/v glycerol, 2% w/v SDS, 0.01% bromophenol blue, 10% v/v, β-mercaptoethanol;
resolving gel: 387 mM Tris HCl pH 8.8, 0.2% w/v SDS, 0.16% w/v ammonium per-
sulfate, 0.04% v/v TEMED and a mixture of acrylamide and bis-acrylamide at the
required concentration (5.9 % w/v acrylamide, 0.1 % w/v bis-acrylamide to resolve
proteins of 150 - 250 KDa, or 7.4% w/v acrylamide, 0.2% w/v bis-acrylamide to re-
solve proteins of 50 - 150 KDa, or 14.8% w/v acrylamide, 0.3% w/v bis-acrylamide
to resolve proteins of 10 - 50 KDa);
stacking gel: 3.9% w/v acrylamide, 0.1% w/v bis-acrylamide, 252 mM Tris HCl pH
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6.8, 0.2% w/v SDS, 0.08% w/v ammonium persulfate and 0.001% TEMED;
electrophoresis running buffer i: 25 μM Tris Base pH 8.8, 192 mM glycine and
0.2% w/v SDS.
Buffers for native gel electrophoresis: loading buffer ii: 126 mM Tris HCl pH
8.8, 40% w/v glycerol and 0.01% bromophenol blue;
electrophoresis running buffer ii: 25 μM Tris Base pH 8.8, 20 mM glycine;
resolving native gel: 15% w/v acrylamide, 0.3% w/v bis-acrylamide, 427 mM Tris
HCl pH 8.8, 0.3% w/v ammonium persulfate and 0.001% TEMED;
stacking native gel: 3.2% w/v acrylamide, 0.1% w/v bis-acrylamide, 57 mM Tris
HCl pH 6.8, 0.08% w/v ammonium persulfate and 0.001% TEMED.
Buffer for IEF gel electrophoresis: loading buffer iii: 12 mM urea, 90 mM chaps,
90 mM dithiothreitol, 0.01% w/v bromophenol blue;
IEF gel mixture: 14 M Urea, 7.7% w/v acrylamide.
Buffer for agarose gel electrophoresis: DNA loading sample buffer (10 X): 50%
glycerol, 250 mM EDTA, 0.21% bromophenol blue, 0.21% xylene cyanol;
running buffer: TAE buffer;
DNA loading buffer (10 ×): 50% v/v glycerol, 0.1% w/v bromophenol blue.
Buffers for Western blotting: stripping buffer: 2% SDS, 62.5 mM Tris-HCl pH
6.8, 100 mM β-mercaptoethanol;
amido black solution: 2 mg/ml amido black, 90% v/v MeOH 10% glacial acetic
acid;
protein electrophoresis buffer: 25 μM Tris Base pH 8.8, 192 mM glycine;
transfer buffer: 2.5% v/v MeOH, protein electrophoresis buffer;
destaining solution for transfer membranes: 25% v/v isopropanol, 10% v/v acetic
acid.
Buffers for activity assay: master mixture: 25 mM TrisCl pH 6.8, 0.5 mg/ml BSA,
0.04% v/v β-mercaptoethanol, 5 mM EGTA pH 8.0, 2.5 mM CaCl2, 250 mM NaCl,
1% v/v sodium cholate;
neutralisation buffer: 0.5 M KOH, 9 mM borax;
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AG1-X8 washing buffer: 60 mM ammonium formate, 5 mM borax;
AG1-X8 elution buffer: 1.2 M ammonium formate 0.1 M formic acid;
AG1-X8 regeneration buffer: 2 M ammonium formate, 0.1 M formic acid;
cell homogenisation buffer: 20 mM Tris-Cl (pH 8.0), 100 mM NaCl, 1 mM EDTA,
1 mM DTT, 3.75 mM MgCl2, 3 μM GDP, 1 "Complete" protease inhibitor tablet
per 50 ml of buffer;
1.2 × PLC cell-free reaction buffer: 60 mM HEPES-NaOH, pH 7.2, 3.6 mM EGTA,
84 mM KCI, 2.4 mM DTT;
cell-free reaction buffer (PLCβ): 50 mM Tris maleate pH 7.3, 3 mM KCl, 70 mM
EGTA, 1.6 mM DTT.
Other buffers: alkaline lysis buffer I: 50 mM glucose, 25 mM Tris pH 8.0, 10 mM
EDTA pH 8.0 (sterilized through a 0.22 μM filter);
alkaline lysis buffer II: 3 M potassium acetate, 115 mM glacial acetic acid;
bacmid solution I: 15 mM Tris HCl pH 8.0, 10 mM EDTA, 100 μg/ml RNase;
bacmid solution II: 0.2 N NaOH, 1% SDS;
CaCl2 solution: 60 mM CaCl2, 15% (v/v) glycerol, 10 mM PIPES, pH adjusted to
7.0 with KOH;
TE pH 8.0 buffer: 10 mM Tris pH 8.0, 1 mM EDTA pH 8.0;
TAE buffer: 40 mM Tris acetic acid pH 7.8, 5 mM sodium acetate, 1 mM EDTA;
GDP or GTPγS elution buffer: 25 mM TrisCl pH 8.0, 180 mM NaCl, 2mM MgCl2, 50μM
GDP or GTPγS, 1 mM TCEP;
pull-down loading buffer: 25 mM TrisCl pH 8.0, 300 mM NaCl, 1mM TCEP;
trypsin in Versene buffer: 0.02% w/v trypsin, 137 mM NaCl, 2.6 mM KCl, 8 mM
Na2HPO4, 5.5 mM D-glucose, 1.5 mM KH2PO4, 0.5 mM EDTA, 24.7 mM Tris,
0.0015% v/v phenol red, 0.05% w/v trypsin difco 1:250, 0.01% w/v streptomycin
sulfate, 0.006% w/v benzylpenicillin.
Media: SOB medium: 20 g/l bacto tryptone, 0.5 g/l NaCl, 5 g/l yeast extract and
0.187 g/l KCl;
SOC medium: 10 mM MgCl2 and 20 mM glucose in SOB medium;
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L-broth: 10 g/l bacto tryptone, 5 g/l NaCl and 5 g/l yeast extract;
lysis buffer i: 25 mM TrisCl pH 8.0, 250 mM NaCl, 10 mM imidazole, 1 mM
TCEP 10 mM benzamidine, 10 mM lysozime, 2% w/v Triton, 1 μM DNAse I and
complete protease inhibitor cocktail (EDTA free, 1 tablet for 50 ml buffer);
The following media: DMEM, SF900IISFM, Opti-MEM I were purchased from
GIBCO.
Petri dish plates: L-agar: 10 g/l bacto tryptone, 5 g/l NaCl, 5 g/l yeast extract, 15
g/l Agar;
transposition plates: L-agar, 50 μg/ml kanamycin, 10 μg/ml tetracycline, 7 μg/ml
gentamycin, 100 μg/ml bluo-gal, and 40 μg/ml IPTG (available in house);
amplicillin resistant plates: L-agar, 100 μg/ml amplicillin (available in house);
kanamycin resistant plates: L-agar, kanamycin 50 μg/ml (available in house);
chloranphenicol and amplicillin resistant plates: L-agar, 50 μg/ml amplicillin and
10 μg/ml chloranphenicol.
Electron microscopy materials: Copper (300 square mesh), nickel (300 square
mesh) grids and collodion (Parlodion) 2% w/w in amyl acetate were purchased
from Electron Microscopy Sciences.
Enzymes: Thrombin and TeV were purchased from Quiagen. Prescissor was pu-
rified in house. DNAse I was dilute to 3000 units/ml and stored at -20◦C.
2.2 Construct design and DNA manipulation
2.2.1 Agarose gel electrophoresis for DNA
Agarose gel electrophoresis was used to separate DNA fragments according to the
fragment size. The gel was prepared with the percentage of agarose that best re-
solved the DNA size of interest. The agarose (Sigma) was resuspended in TEA
buffer and boiled in the microwave until a homogeneous solution was obtained.
The agarose solution was mixed with gel red (Biotium) 1500:1 v/v, and poured
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into a cassette with a comb inserted into the mixture to allow loading well forma-
tion. The agarose gel was left to settle at room temperature then it was transferred
into the running blocks (powerpack, Bio−Rad) and run in TEA buffer.
Each DNA sample was mixed with DNA loading buffer (10:1) and then loaded
on the agarose gel. The DNA size markers were run next to the sample (1 Kb plus
or 100 kb ladder, Invitrogen) for reference.
The gel was run at low voltage until the sample entered the gel (30 V) and then
at 80 V. The gel was imaged under a UV lamp (G-Box, Syngene).
2.2.2 Plasmid DNA purification from bacteria
In order to purify plasmid DNA on a small scale (5-50 μg) from bacteria, the QIprep
spin miniprep kit (Qiagen) was used. A bacterial culture in L-Broth media (5 ml)
supplied with antibiotic was incubated at 37 ◦C for 15-18 hours and then harvested
by centrifugation at 3700 g, 4 ◦C for 10 min. The supernatant was removed and
the cell pellet was processed according to the manufacturer’s specification. In brief,
cells were alkaline lysed, neutralised and adjusted to high salt binding conditions.
The lysate was clarified by centrifugation at 22000 g, 4 ◦C for 10 min and then it
was applied to a silica column. The bound DNA was washed and then eluted in
elution buffer (30 μl).
In order to obtain purified plasmid on a large scale, (50 μg - 1 mg), a bacterial
culture in L-broth medium (500 ml), supplied with appropriate antibiotic (depend-
ing on the plasmid resistance gene), was incubated at 37 ◦C for 15-18 h and then
harvested by centrifugation at 3700 g, 4 ◦C for 20 min. The supernatant was re-
moved, the cell pellet was kept on ice and resuspended in alkaline buffer I (37 ml).
Cells were lysed under alkaline conditions by addition of alkaline buffer II (50 ml).
The lysate was neutralised by addition of alkaline buffer III (37 ml) and then clar-
ified by centrifugation at 3700 g, 4 ◦C for 10 min and subsequent filtration of the
supernatant through two cheesecloths. The nucleic acid was precipitated by adding
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propan-2-ol to a 70% v/v final concentration and then separated by centrifugation at
3700 g, 4 ◦C for 15 min. The nucleic acid in the mixture was washed with 70% v/v
ethanol and resuspended in TE buffer pH 8.0 (1.5 ml). The RNA in the mixture was
precipitated adding LiCl to a 2.5 M final concentration and then it was separated by
centrifugation at 3700 g, 4 ◦C for 10 min. The nucleic acid contained in the super-
natant was precipitated by addition of propan-2-ol to a 70% v/v final concentration
and then separated by centrifugation at 3700 g, 4 ◦C for 10 min. The nucleic acid
pellet was resuspended in TE buffer pH 8.0 (0.5 ml) in the presence of RNAse at 1
mg/ml final concentration (Quiagen). The mixture was incubated at 37 ◦C for 15
min in shaking conditions to remove the residual RNA. The nucleic acid mixture
was diluted two-fold in a 13% w/w PEG 8000 and 1.6 M NaCl solution and incu-
bated for 60 min on ice. The DNA was pelleted by centrifugation at 20800 g, 4 ◦C
for 10 min (centrifuge 5417R, Eppendorf ). The DNA was resuspended in 200 μl
of TE buffer pH 8.0 and further purified by extraction into aqueous solution. The
DNA solution was vortexed for 30 sec with an equal volume of phenol-chloroform-
isoamyl alcohol (25:24:1) (Sigma). The emulsion was spun down at 22000 g, 4 ◦C
for 10 min (centrifuge 5417R, Eppendorf ) in order to separate the organic and the
aqueous phases.
To obtain highly purified DNA, the extraction was repeated until the interfase
was clear. The aqueous phase was separated and the DNA contained was precip-
itated by adding sodium acetate (0.3 M final concentration) and ethanol (2.5 vol-
umes). The DNA was pelleted by centrifugation at 20800 g, 4 ◦C for 10 min (cen-
trifuge 5417R, Eppendorf ). The purified DNA was washed with 70% ethanol (0.5
ml), air-dried and then resuspended in TE buffer pH 8.0.
The DNA concentration was determined by measuring the absorbance at 260
nm (spectrophotometer NanoDrop ND-1000, Thermo Scientific). An indication
of the DNA purity is given by the ratio between the absorbances at 260 nm and at
280 nm. The A260nm/A260nm ratio was recorded ensuring this value was between
1.6 and 1.8.
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2.2.3 Construct design and cloning
2.2.3.1 Ligation independent cloning
The construct encoding the PIP2 fluorescent probe, eGFP-PH domain of PLCδ1 (1-
175 AA), was cloned into a pTriEx-6 vector. The resulting expression gene has two
small purification tags: StrepII tag on the N-terminus and His10 on the C-terminus
which can be cleaved by PreScission and Thrombin proteases respectively.
The mutants were obtained from the wild type by site-directed mutagenesis (sec.
2.2.6) in a pC-eGFP vector and then each ORF was cloned in the desired vector.
The gene of interest was amplified (sec. 2.2.5) with primers having overhangs
complementary to the pTriEx-6 destination vector. The amplification product was
gel purified as describe in section 2.2.4 and cloned in the destination vector by
ligation independent cloning using the pTriEx-6 Ex/LIC kit (Novagen).
The amplified insert (0.5 μl) was mixed with: dATP (0.6 μl), DTT (0.3 μl), T4
polymerase (0.2 μl) in T4 polymerase buffer (0.6 μl). The mixture was incubated
at RT for 1 h and then at 75 ◦C for 20 min to allow T4 polymerase directional base
excision (3’ → 5’) and formation of overhangs complementary to the destination
vector. The system is designed such that T4 polymerase exonuclease activity is
compensated by the polymerase activity when deoxyadenine triphosphate (dATP) is
encountered, giving overhangs of exactly the right size. The mixture was collected
on the bottom of the vial by centrifugation at 20800 g for 1 min (EBA 21, Hettich)
before the addition of the pTriEx-6 vector (1 μl). The mixture was incubated for
5 min at RT before addition of 25 mM EDTA (1 μl). The sample was incubated
for an other 5 min at RT and used to transform E.coli XL10gold competent cells as
described in section 2.3.2.
Colonies selected on the plate were screened to identify the clones that contained
the insert in the right orientation. For this purpose, the plasmid region spanning
the insert and the vector needs to be amplified, therefore the forward primer was
designed to be complementary to the insert and the reverse primer complementary to
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the vector (and immediately down-stream of the insert). The amplification reaction
using Taq polymerase was prepared (sec. 2.4.2.2.4), but a bacterial colony was
added to the reaction mixture instead of the purified DNA.
The amplification product was analysed by agarose gel electrophoresis. Only
the clones having the insert in the required orientation gave an amplification product
of the expected size. The colonies corresponding to these candidate clones were
used to inoculate a small culture which was used for DNA purification. The purified
DNA was used for sequencing to verify that the clone of interest had been obtained
(sec. 2.2.7).
2.2.3.2 Ligation dependent cloning
The two sub-units of the GGTases type I were cloned into a pFastBacDual vector
(Invitrogen) leaving the two subunits in their native state. The cloning was per-
formed using restriction enzyme digestion followed by a ligation reaction of the
two subunits: Caax-GGTβ and GGTα. The Caax-GGTβ gene was cloned down-
stream from the polyhedrin promoter and the GGTα gene down-stream from the
p10 promoter.
The Caax-GGTβ subunit was amplified with blunt ends from a pVL1392 vec-
tor (given by Prof. M. C. Seabra from Imperial College London). The amplifica-
tion product was gel purified as described in sec. 2.2.4. The destination vector,
pFastBacDual, was linearised upon enzymatic restriction digestion of SmaI (New
England Biolabs). The digestion reaction was prepared mixing: 5 μg pFastBac-
Dual, 5 U/ml SmaI in NEB buffer 4. The mixture was incubated at 25 ◦C for 3 h.
At the end of the incubation time, an aliquot (2 μl) of the restriction mixture was
analysed by agarose gel electrophoresis to verify that the linearisation of the vector
was complete before heat-inactivating the enzyme at 65 ◦C for 20 min.
The gel purified insert (Caax-GGTβ) and the linearised vector were mixed in
various molar ratio (1:1 or 1:2) and ligated using T4 ligase (New England Biolabs).
The ligation reaction was incubated at 16 ◦C O/N. The ligation mixture (2 μl) was
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used to transform E.coli XL10gold competent cells (sec. 2.3.2). The colonies were
screened and the clones verified as described in section 2.2.3.1.
The GGTα subunit was excised from a pVL1392 vector (given by Prof. M.
C. Seabra from Imperial College London) and the destination vector, pFastBacDual
Caax-GGTβ, was linearised upon enzymatic restriction digestion with EcoRI (New
England Biolabs) leading to restricted products with complementary overhangs.
The digestion reaction containing: 5 μg plasmid, 5 U/ml EcoRI in NEB buffer 4
was incubated at 37 ◦C for 3 h. The restriction mixture of the GGTα was loaded
on an agarose gel and the insert was purified. The restriction mixture of the desti-
nation vector pFastBacDual Caax-GGTβ was incubated at 65 ◦C for 20 min to heat
inactivate EcoRI and used for ligation as described above. The ligation mixture was
used to transform E.coli XL10gold competent cells (sec. 2.3.2). The colonies were
screened and the candidate clone verified as described in section 2.2.3.1.
2.2.4 DNA purification from agarose gel
The DNA fragments of interest were purified from agarose gel using the QIAquick
gel extraction kit according to the manufacturer’s instructions. In brief, the gel slide
containing the DNA of interest was cut out and dissolved in a high-salt buffer by
placing the mixture in a water bath at 50 ◦C for 10 min. The solution was applied
to the QIAquick spin column and spun at 20800 g for 1 min. The DNA bound the
silica membrane was washed and then eluted in 30 μl of elution buffer.
The DNA concentration was quantified by spectroscopic analysis as described
in section 2.2.2.
2.2.5 DNA amplification
The open reading frames (ORF) used for cloning have been PCR amplified using
KOD hot start DNA polymerase (EMDBioscience) to ensure fast and high fidelity
replication.
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The amplification reaction was prepared according to the guidelines of the man-
ufacturer. The PCR amplification primers, forward primer (5’→3’) and reverse
primer (3’→5’), were designed to be complementary to the template at the ex-
act ends of the PCR amplification product desired. For an efficient amplification,
primers were at least 21 bases long, containing at least 50% GC bases and a melting
temperature (Tm) above 50 ◦C and not more than 5 ◦C difference.
The PCR amplification mixture contained: purified plasmid DNA as template
(50 ng/μl), forward primer (0.3 μM), reverse primer (0.3 μM), dNTPs (0.2 mM
each deoxynucleotide triphosphate base), MgSO4 (1 mM), 10 × KOD hot start
DNA polymerase KOD buffer (1 ×), hot start DNA polymerase (0.02 U/μl), and
UF water. The PCR amplification reaction was carried out in a PCR machine (G-
STORM) as described in table 2.1:
Table 2.1. PCR amplification reaction using KoD DNA polymerase.
STEP TEMPERATURE AND TIME
1. polymerase activation 95 ◦C for 2 min
2. denaturation 95 ◦C for 20 sec
3. annealing lowest primer Tm for 10 sec
4. elongation 70 ◦C for 15 s/bp
repetition of steps 2-4 35 times
2.2.6 DNA mutagenesis
A single point mutation was introduced in the construct of interest by site-directed
mutagenesis (SDM). Two mutagenic primers, forward (5’→3’) and reverse (3’→5’),
were designed specific for the desired mutation and the template. The mutagenic
primers were complementary to each other and were 25-45 bases in length. The
mutation was located in the middle of the primer and between regions (10-15 bases
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either side) complementary to the template. The mutagenic primer contained at
least 40% GC bases and had a Tm above 78 ◦C.
The mutagenesis reaction mixture contained: purified plasmid DNA as template
(0.2 ng/μl), forward primer (2.5 ngμl), reverse primer (2.5 ngμl), dNTPs (0.2 mM
each deoxynucleotide triphosphate base), 10 × Pfu turbo DNA polymerase buffer
(1×), Pfu turbo DNA polymerase (0.1 U/μl), and UF water.
The site directed mutagenesis reaction was carried out in a PCR machine as
described in table 2.2.
Table 2.2. Side mutagenesis reaction.
STEP TEMPERATURE AND TIME
1. DNA denaturation 95 ◦C for 30 sec
2. denaturation 95 ◦C for 30 sec
3. annealing 55 ◦C for 1 min
4. elongation 68 ◦C for 1 min/kbp
repetition of steps 2-4 18 times
The mutagenesis reaction mixture was restriction digested with Dpn1 (0.1 U/μl)
of 1 h at 37 ◦C. Dpn1 digests the methylated templates which do not contain the mu-
tation, fostering the newly synthesised plasmids (PCR product) which do contain
the mutation. E.coli XL10gold competent cells were transformed with the mutage-
nesis reaction mixture (2 μl) as described in section 2.3.3, and plated on to L-agar
Petri dishes containing the appropriate antibiotic and incubated at 37 ◦C for 18-20 h.
From the colonies obtained, the DNA was purified (see sec. 2.2.2). The entire
ORF was sequenced (see sec. 2.2.7) to ensure the success of the mutation and that
no extra mutations were introduced.
A glycerol stock of the colony of the successful mutant was prepared (see sec.
2.3.3).
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2.2.7 DNA sequencing
DNA was sequenced in order to know the exact base order in a specific region of
DNA.
Sequencing primers were template specific and designed to bind 50-100 base
pairs up-stream the region of interest. The primers were designed having at least
50% G or C base content, 10-15 basis length, and a melting temperature of at least
60 ◦C. The Big Dye (Applied Biosystems) was used for sequencing as recom-
mended by the manufacurer. In brief, the sequencing reaction was prepared mix-
ing: purified DNA as templete (300 ng per reaction), BigDye Terminator v1.1 (2
μl), Big Dye dilution buffer (2 μl), sequencing primer (20 pmol) and UF water (to
20 μl final reaction volume) per reaction. The sequencing reaction was carried out
in a PCR machine as described in table 2.3.
Table 2.3. Sequencing reaction.
STEP TEMPERATURE AND TIME
1. initial denaturation 60 ◦C for 1 min
2. denaturation 96 ◦C for 30 sec
3. annealing 50 ◦C for 15 sec
4. elongation 60 ◦C for 3 min
repetition of steps 2-4 35 times
The unincorporated dye terminators remaining in the sequencing reactions were
removed by gel filtration using the DyeEx 2.0 spin Kit (Qiagen). The column
included in the kit was vortexed to ensure even resuspension of the resin, and then
spun down at 750 g (EBA 21, Hettich) for 3 min to remove the storage buffer. The
sequencing mixture was gently load on the columns without disturbing the resin.
The column was spun at 750 g (Centrifuge 5417R, Eppendorf ) for 3 min. The
flow through was collected and dried in a heating block at 80 ◦C for 10 min. The
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sample was submitted for sequencing in house.
2.3 Protein expression in bacteria
2.3.1 Competent cells
Different strains of bacterial competent cells were prepared in order to transform
them with the plasmid of interest either for DNA storage or for protein expression.
The glycerol stock of the specific bacterial strain was streaked on an L-agar plate
and incubated at 37 ◦C O/N. A colony visible on the plate was selected to inoculate
a small culture in SOB medium (250 ml). The bacterial culture was incubated at
37 ◦C, 250 rpm until the OD595nm reached 0.08 a.u. and then the temperature was
lowered to 18 ◦C. When the OD595nm reached 0.6 a.u., the bacterial culture was
chilled on ice for 10 min and then harvested by centrifugation at 2680 g at 4 ◦C for
10 min (RC3C plus, Sorvall). The supernatant was discarded and the pellet was
washed twice in TB buffer pre-chilled at 4 ◦C. The first time TB buffer (80 ml) was
added to the pellet, the mixture was placed on a shaking table at 4 ◦C, 100 rpm for
10 min. The mixture was incubated on ice for 10 min and then spun down at 2680
g (RC3C plus, Sorvall) 4 ◦C for 10 min. The supernatant was removed and the
pellet was resuspended in TB buffer (20 ml) on a shaking table at 4 ◦C, 100 rpm
for 10 min. Sterile DMSO (7% v/v final concentration) was added to the cells and
incubated on ice for 10 min.
The competent cells were immediately aliquoted into sterile tubes, snap frozen
in liquid N2 and stored at -80 ◦C until use.
The transfection efficiency of the competent cells was tested transforming the
cells as described in section 2.3.2 with a plasmid of known concentration (pDONR
1.2, Invitrogen). Sequential dilutions (1, 10−1, 10−2) of the transformed mixture
were plated (100 μl) in order to obtain a plate with a colony density that could be
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counted easily. The transfection efficiency is given by:
number of colonies
DNA conc in the transfection mixture
2.3.2 Bacteria cell transformation
Competent cells were transformed with purified plasmid working in sterile condi-
tions. Different types of competent cells were used according to the purpose of the
transformation. E.coli DH5α or XL10gold were used for plasmid storage and E.
coli C41(DE3) for protein expression. The genotype of the E. coli strain used is
reported in table 2.4.
Table 2.4. Genotype of the E. coli strain. F− = no F plasmid, F′ = the F plasmid carries
the genes listed in the parenthesis, ompT = mutation in outer membrane protein protease
VII, reducing proteolysis of expressed proteins.
E.coli strain genotype
E.coli C41 DE3 F− ompT hsdSB (rB− mB−) gal dcm (DE3), see ref. [318]
DH5α F− endA1, glnV44, thi-1, recA1, relA1, gyrA96, deoR, nupG,
Φ80dlacZΔM15, Δ(lacZYA-argF)U169, hsdR17(rK− mK+),
λ, see ref. [319]
XL10gold endA1, glnV44, recA1, thi-1, gyrA96, relA1, lac, Hte,
Δ(mcrA)183, Δ(mcrCB-hsdSMR-mrr)173, tetR
F’[proAB lacIqZΔM15, Tn10(TetR Amy CmR)]
Competent cells were thawed on ice. An aliquot (50 μl) of competent cells was
transferred into a chilled snap top tube and briefly mixed with purified plasmid (20-
50 ng). The mixture was incubated on ice for 30 min to allow DNA binding to the
cells. The cells were heat shocked for 30 sec at 42 ◦C to induce membrane pore
formation and plasmid DNA insertion. The cells were left to recover on ice for 2
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min and incubated in SOC media (500 μl) for 1 h at 250 rpm at 37 ◦C. Transformed
cells were selected from non transformed cells by exploiting the antibiotic resistance
gained upon successful transformation. The bacterial culture was plated (100 μl per
plate) on L-agar Petri dishes containing the antibiotic carried in the transformed
plasmid and incubated at 37 ◦C. The colonies of antibiotic resistant bacteria visible
after 15-18 h of incubation were harvested and used.
2.3.3 Glycerol stock
Bacteria, for protein expression or for plasmid storage, transformed with the plas-
mid of interest were stored as a glycerol stock.
A bacterial culture (5 ml) was grown in L-broth enriched with the appropriate
antibiotic at 37 ◦C for 18-20 hours and then mixed in sterile conditions with glycerol
(20% v/v final concentration).
The sample was stored at -80 ◦C until use.
2.3.4 Time course
The best set of conditions for protein expression were investigated monitoring the
expression levels over time varying temperature of incubation, induction point, and
IPTG concentration.
The glycerol stock was thawed on ice and streaked on a Petri dish that was
prepared with LB agar supplied with antibiotics. The Petri dish was incubated at
37 ◦C for 18-20 h. A colony selected from the Petri dish was used to inoculate a
bacterial culture. Bacteria were grown in 2 x YT media supplied with antibiotics and
pre-warmed to 37 ◦C. The bacterial culture was incubated at 37 ◦C, 250 rpm until
the induction time. The bacterial culture was split in two equivalent cultures; one
was induced with IPTG and the other, the control, was not induced. Both cultures
were incubated under the same conditions.
Aliquots were collected from each bacterial culture to screen the total protein
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expression (150 μl) and the protein solubility (1 ml). Samples were collected at
different times after induction (0 h, 2 h, 4 h, 8 h and O/N). The OD600nm was
measured before each sample collection.
The samples for protein expression analysis were mixed with cold acetone (1.35
ml), incubated at -20 ◦C for 15-20 h and then spun down at 15300 g, for 20 min at 4
◦C. The supernatant was removed and the pellet was re-suspended in buffer H (150
μl). An aliquot was used to measure the total protein concentration according to
the Bradford procedure, the rest (28 μl) was mixed with sample buffer (20 μl). The
samples for protein solubility testing were spun down at 15300 g for 20 minutes at
4 ◦C, the supernatant was removed and the pellet was re-suspended in lysis buffer i
(100 μl). The mixture was incubated under shaking conditions for 1 h at 4 ◦C, and
spun down at 15300 g for 20 min at 4 ◦C. The supernatant was collected into a fresh
vial. An aliquot (2 μl) was used to measure the total soluble protein concentration
according to the Bradford procedure. Another aliquot (60 μl) was mixed with the
loading sample buffer I (20 μl). The pellet was re-suspended in buffer H (30 μl).
An aliquot of this mixture (2 μl) was used to measure the total protein concentration
according to the Bradford procedure, the rest (28 μl) was mixed with sample buffer
(20 μl). The samples of the total protein expression, the soluble fraction and the
insoluble fraction were mixed with 4 × SDS-PAGE sample buffer and boiled for 5
min. 10 μg of total protein were loaded for each sample on to SDS-PAGE.
2.3.5 Protein expression in bacteria
Various constructs were expressed recombinantely in E.coli. The genes of inter-
est were fused to purification tags such as multi-histidine, maltose binding protein
(MBP), or strepII tags. The constructs were designed such that the purification tags
could be removed after the tags had been used for purification purposes.
E.coli C41(DE3) competent cells (50 μl) were transformed with 10 ng of plas-
mid containing the gene of interest (together with with 10 ng of pRARE (Novagen)
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if required) as described in sec. 2.3.2. The transformation mixture was plated on the
appropriate antibiotic loaded L-agar plates. The plates were incubated at 37 ◦C O/N
and then a colony visible on the plate was selected to inoculated a 1 liter culture.
The bacterial culture was grown in 2 × YT medium supplied with the appropriate
antibiotics (50 μg/ml ampicillin, 10 μg/ml chloramphenicol) according to the re-
sistance gene in the plasmid and pre-warmed to 37 ◦C. The culture was incubated
at 37 ◦C in shaking mode (350 rpm) until the OD600nm reached 0.4 a.u. at which
stage the temperature was lowered to 20 ◦C (unless stated otherwise in table 2.5).
The protein expression was induced by addition of IPTG (100 μM final concentra-
tion) and the bacterial culture was incubated O/N (unless stated otherwise in table
2.5). Cells were harvested by centrifugation at 2680 g, 30 min at 4 ◦C (RC3C plus,
Sorvall) and the pellets were stored at -20 ◦C until use.
2.4 Protein expression in insect cells
Eukaryotic cells such as insect cells can be used for protein expression. Insect cells
have the advantage of expressing post-translationally modified protein such as phos-
phorylated, glycosylated, fatty acid acylated or methylated protein. Recombinant
protein expression in insect cells is achieved upon cell infection with baculoviruses.
Baculovirus allows simultaneous expression of multiple proteins making it, in com-
bination with specific vectors, remarkably powerful.
2.4.1 Insect cell culture
Insect cells were incubated at 27 ◦C, 150 rpm in Erlenmeyer flasks without exceed-
ing 1/5th of the flask volume to guarantee a good aeration. Insect cell cultures were
incubated for 72 h and then diluted to 5×105 cells/ml in fresh medium. Different
media were used depending on the type of insect cells. For Sf9, Sf10 SF900IISFM
medium was used, for High5 SF900IISFM medium supplied with 2% FBS was
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Table 2.5. List of constructs recombinantly expressed in bacteria. E.coli C41(DE3) were
transformed with the plasmid encoding for the gene of interest or co-transformed with
pRARE for the construct marked with the star. The temperature of the bacterial culture
before and after induction is reported in the table and the harvesting point.
E.coli C41(DE3) temperature harvesting
pIVEXMBPrPLC (1258− 2225AA) * 30 ◦C → 20◦C OD600nm=1 a.u.
pIVEXMBPrPLCStrepII (1258-2225 AA) * 30 ◦C → 20◦C OD600nm=1 a.u.
pTriEx4-rPLCeGFP (1258-2225 AA) * 30 ◦C → 20◦C OD600nm=1 a.u.
pTriEx4-mRFP-rPLC(1258-2225 AA) * 30 ◦C → 20◦C OD600nm=1 a.u.
pTriEx4-mRFPrPLCeGFP (1258-2225 AA) * 30 ◦C → 20◦C OD600nm=1 a.u.
pTriEx4-eGFP (1258-2225 AA) 37 ◦C → 25◦C O/N
pTriEx6-eGFP-rPHδ1 (1-175 AA) * 30 ◦C → 20◦C O/N
pTriEx4-rRhoA FL 37 ◦C→ 20◦C O/N
pTriEx4-hH-Ras (1-166 AA) 37 ◦C → 25◦C O/N
pTriEx4-hmCherry-Ras (1-189 AA) 37 ◦C → 25◦C O/N
used.
2.4.2 Bacmid preparation
Baculoviruses are generated by co-transfection of Sf9 cells either using a replication
deficient bacmid or a recombinant bacmid.
To express a single gene in insect cells, baculoviruses were prepared using the
replication deficient bacmid and the pTriEx vector containing the gene of interest.
To express a complex of two subunits in insect cells, baculoviruses were pre-
pared using the recombinant bacmid containing the genes of interest.
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2.4.2.1 Baculovirus preparation using a replication deficient bacmid
The BAC10:KO1629 bacmid is a plasmid that contains the baculovirus genes with
the exception of the essential ORF1629. However, upon homologous recombina-
tion with an expression vector encoding the ORF1629 (such as pTriEx or pDONR
vectors) this is restored, leading to baculovirus formation [320]. The baculovirus
produced will induce expression of the gene of interest.
2.4.2.1.1 BAC10:KO1629 bacmid preparation The replication deficient bacmid,
BAC10:KO1629, was prepared using the BacMAX purification kit (EpiCentre)
following the manufacturer’s instructions. A glycerol stock ofE.coliBAC10:KO1629
was streaked on a L-agar Petri dish containing kanamycin and choramphenicol. The
Petri dish was incubated at 37 ◦C O/N. An individual colony selected from the plate
was used to inoculate a small culture of LB medium (100 ml) supplied with 30
μg/ml kanamycin and 30 μg/ml choramphenicol. The bacterial culture was incu-
bated at 250 rpm, 37 ◦C, O/N and harvested by centrifugation at 5000 g for 10 min
at 4 ◦C.
The pellet was re-suspended in chilled BACMAX solution 1, subsequently BAC-
MAX solution 2 was added to lyse the cell. The solution was gently mixed before
adding chilled BACMAX solution 3 to the mixture. The mixture was incubated
for 15 min on ice, and centrifuged at 15300 g, for 10 min at 4◦C to pellet cellular
debris. The DNA present in the supernatant fraction was precipitated upon addition
of isopropanol. The nucleic acids were separated by centrifugation at 20800 g for
20 min at 4◦C (5417R, Eppendorf ), and it was re-suspended in TE buffer. The
RNase blend (RiboShredder) was added to the mixture and incubated at 37 ◦C for
30 min. The bacmid was diluted further in TE buffer before the addition of chilled
BACMAX solution 4. The mixture was incubated on ice for 15 min, and then cen-
trifuged at 20800 g, for 15 min at 4◦C. The supernatant was collected, mixed with
absolute ethanol, and the DNA precipitated by centrifugation at 20800 g for 20 min
at 4◦C (5417R, Eppendorf ). The pellet was dried and re-suspended in TE buffer.
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The DNA concentration was measured by absorbance at 260 nm. The DNA
purity was estimated by the absorbance ratio 260/280nm. The bacmid was stored at
-20◦C.
2.4.2.1.2 BAC10:KO1629 bacmid linearisation The bacmid (130 kbp) was
linearised exploiting the unique Bsu36I restriction site. The restriction digest was
prepared mixing: bacmid (50 μl), 10 × NEB buffer 3 (6 μl), 100 × BSA (0.6 μl),
Bsu36I (1 μl) and UF water (2.4 μl). The mixture was incubated at 37◦C for 2 h
and then the restriction enzyme was heat deactivated at 80◦C for 20 min. The com-
pletion of the linearisation was estimated by agarose gel electrophoresis analysis
(0.5% agarose gel).
The linearised bacmid was used immediately after the linearisation and if pos-
sible, or stored at -20◦C.
2.4.2.2 Baculovirus preparation using recombinant bacmid
In order to use the recombinant bacmid to produce baculovirus, the gene of interest
is cloned into a Bac-to-Bac plasmid and then transformed intoE.coliDH10MultiBac
cells which contain the bacmid and a helper plasmid encoding the transposase. Cells
containing successfully transposed bacmid are selected on transposition plates for
their capability to cleave bluogal.
2.4.2.2.1 Transposition of recombinant bacmid The competent cells , E.coli
DH10MultiBac, were used to obtain the recombinant bacmid. These cells were pre-
pared similarly to that described in section 2.3.1. The bacterial culture was grown in
LB medium supplied with antibiotics (10 μg/ml tetracycline, 50 μg/ml kanamycin,
and 100 μg/ml ampicillin) at 37 ◦C, 250 rpm until the OD595nm reached 0.375 a.u..
Cells were chilled on ice for 15 min and then spun down at 3724 g (Allegra X-15R,
Beckman Coulter), 4 ◦C. The pellet was washed twice in ice cold CaCl2 solu-
tion (80 ml), and the incubated on ice for 30 min. Cells were spun down at 3724
2.4 Protein expression in insect cells 89
g (Allegra X-15R, Beckman Coulter), 4 ◦C and resuspended in CaCl2 solution
(16 ml). The competent cells were aliquoted into sterile tubes, snap frozen and
stored at -80 ◦C until usage. E.coli DH10MultiBac competent cells (100 μl) were
transformed with the recombinant donor bacmid (1 μg) similarly to that described
in section 2.3.3. In this case, the heat shock was prolonged for 45 sec, the cells
were resuspended in SOC medium (900 μl) and incubated at 37 ◦C, 250 rpm for
6 h (Innova 4230, New Brunswick Scientific). The transfection mixture was
spread on transposition plates. Different concentrations of the transfection mixture
(7 ×, 1 ×, 10−1 and 10−2 in SOC medium) were plated in order to obtain colonies.
Transposition plates were incubated for 48 h at 37 ◦C in the dark.
2.4.2.2.2 Isolation of recombinant bacmid The colonies growing on the trans-
position plate are characterised by a white phenotype if they contain the bMON14272
bacmid or by a blue phenotype if they do not the bMON14272 bacmid. The white
colonies were streaked on a fresh transposition plate to verify the phenotype and
incubated for 48 h at 37 ◦C. The confirmed white colonies were analysed further to
verify the effective transposition.
2.4.2.2.3 Recombinant bacmid preparation The cells with white phenotype
were cultured to isolate the bacmid. The bacmid was first tested to confirm the
successful transposition by PCR and if so, it was used to prepare the baculovirus.
The confirmed white phenotype colonies were used to inoculate a small bacterial
culture (4 ml) in LB medium supplemented with antibiotics (50 μg/ml kanamycin, 7
μg/ml gentamicin, and 10 μg/ml tetracycline). The culture was incubated at 37 ◦C,
250 rpm for 24 h. Cells were harvested by centrifugation at 14000 g for 1 min and
the pellet used for bacmid purification. The pellet was resuspended in the bacmid
solution I (300 μl) and an equal volume of bacmid solution II (300 μl) was added
to it. The cells were lysed at RT for 5 min. The protein and the genomic DNA
were precipitated by adding 3 M potassium acetate pH 5.5 (300 μl) and placing the
2.4 Protein expression in insect cells 90
mixture on ice for 10 min. The pellet was separated by centrifugation at 14000 g
for 10 min. The supernatant was collected, mixed with propan-2-ol (800 μl) and
incubated on ice for 5 to 10 min to precipitate the recombinant bacmid of interest.
The DNA was pelleted by centrifugation at 14000 g for 15 min at RT and washed
with 70% EtOH (500 μl) by centrifugation at 14000 g for 4 min and removal of the
supernatant. The pelleted DNA was air dried for 10 min at RT. The bacmid DNA
was resuspended in 40 μl of TE buffer and stored at -20 ◦C.
2.4.2.2.4 Verification of transposition by PCR The successful transposition of
the insert into the bMON14272 bacmid was confirmed by PCR. The region of the
recombinant bacmid which contained the desired gene (between M13 sites) was
amplified using Taq polymerase (Quiagen) following the manufacture’s instruc-
tions. The Taq PCR amplification mixture was prepared mixing: purified bacmid
(4 ng/μl), M13 forward primer (5’-CCCAGTCACGACGTTGTAAAACG-3’) (0.3
μM), M13 reverse primer (5’-AGCGGATAACAATTTCACACAGG-3’) (0.3 μM),
dNTPs (2.5 mM each), Q solution (0.3% v/v), 10 × buffer Taq polymerase buffer
(1 × final concentration), Taq polymerase (0.02 U/μl), and UF water.
The PCR amplification reaction was carried out in a PCR machine with heated
lid using the cycling conditions in table 2.6.
Table 2.6. PCR amplification reaction using Taq DNA polymerase.
STEP TEMPERATURE AND TIME
1. polymerase activation 94 ◦C for 5 min
2. denaturation 94 ◦C for 30 sec
3. annealing 55 ◦C for 15 sec
4. elongation 72 ◦C for 1 min/Kbp
repetition of steps 2-4 35 times
The PCR products were analysed by agarose gel electrophoresis (1% agarose),
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see sec. 2.2.1. The amplified product of the empty bMON14272 bacmid is 300
bp, while the bMON14272 bacmid successfully transposed with pFastBac DUAL
is 2562 bp plus the insert size.
The bMON14272 bacmid successfully transposed with the desired insert was
used to transfect insect cells and to prepare baculovirus. A bacteria colony that
contain the desired recombinant bacmid was used to inoculate a small culture (1
ml). The bacterial culture was grown for 24 h, at 37 ◦C, 250 rpm in LB medium
supplemented with antibiotics (50 μg/ml kanamycin, 7 μg/ml gentamicin, and 10
μg/ml tetracycline) and used to prepare a glycerol stock 2.3.4.
2.4.3 Transfection of insect cells and baculovirus generation
The Sf9 culture was diluted in SF900IISFM medium to a cell density of 5 × 105
cells/ml. Sf9 cells (2 ml) were pipetted into two wells of a 6-well tissue culture
plate; one well for the transfection and one for the control. The samples were left
to settle for 1 h at RT to allow the cells to adhere to the bottom of the well. At the
end of the incubation time, the medium was removed and the transfection mixture
(1 ml) was added to the sample well, while SF900IISFM medium (1 ml) was added
to the control well. The 6-well tissue plate was placed into a humidified box and
incubated at 27 ◦C for 72 h in the dark. At the end of the incubation time, the
transfected culture was screened with the optical microscope (DMIL, Leica). If the
transfection was successful, large gaps and swollen cells were visible. The mixture
was pipetted into a falcon tube and spun down at 1508 g for 15 min at RT (RC3C
plus, Sorvall). The supernatant, which contained the viruses, was collected and
FCS was added up to a 2% w/w final concentration. The virus mixture was stored
at 4 ◦C.
2.4.3.0.5 Transfection mixture preparation Insect gene juice transfection reagent
(Novagen) was used to transfect insect cells according to the manufacturer’s guide-
lines. The protocol required little adaptation according to the vector used for trans-
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fection.
In order to transfect insect cells using pDONR vectors, two mixtures were pre-
pared separately. The first mixture contained the recombinant bacmid (5 μl) in
SF900IISFM (100 μl) and the second mixture contained insect gene juice (10 μl)
in SF900IISFM medium (100 μl). The two mixtures were added together and in-
cubated at RT for 15-45 min. SF900IISFM medium (800 μl) was added and the
transfection mixture was used immediately.
For the pTriEx vectors, the transfection mixture was prepared by mixing: lin-
earised BAC10:ko1629 bacmid (0.5 μg), an equivalent mass of plasmid (0.5 μg)
in SF900IISFM (100 μl). Separately, the insect gene juice transfection reagent (10
μl) was mixed with SF900IISFM medium (100 μl). The two mixtures were added
together and incubated at RT for 15-45 min. Extra SF900IISFM medium (800 μl)
was added to the transfection mixture before use.
2.4.4 Plaque assay
SF9 cells (1 × 106 cells), from a stock culture at a density of 5 × 105 cells/ml,
were seeded in small Petri dishes (3 cm in diameter) and incubated for 1 h at RT.
Subsequent viral dilutions (150 μl) in SF900IISFM medium were prepared from
10−1 to 10−7. The media in the Petri dish was removed and an aliquot of the diluted
virus (100 μl) was added to the corresponding dish. The samples were incubated for
1 h at RT and shaken every 15 min to ensure even coverage of the virus mixture. At
the end of the incubation time, the virus solution was removed and 1% agarose gel
in SF900IISFM medium (2 ml) at 40 ◦C was added drop-wise to each dish. After
the gel had set, SF900IISFM medium (1 ml) was added to each dish. The samples
were placed in a humidifying box and incubated at 27 ◦C for 72 h. At the end of
the incubation time, 0.02% neutral red in PBS (1ml) was added to each dish. The
samples were incubated at 27 ◦C for 2 h in a humidifying box. The supernatant was
aspirated, the dishes were left up side down O/N in the dark. The plaques in each
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well were counted and the titre was measured using the following relation:
T itre (pfu/ml) =
number of plaques
viral dilution
× viral inoculum volume (0.1ml)
2.4.5 Baculovirus amplification
The viruses were amplified in subsequent rounds until a titre in the order of 108
pfu/ml was obtained.
Sf9 cells (20 × 106) were pipetted into 175 cm3 flasks. The sample was in-
cubated for 1 h at RT allowing the cells to adhere to the bottom of the flask. The
medium was removed and the cells were infected at a 0.1 multiplicity of infection
(MOI) upon addition of the viral mixture (500 μl). The flask was incubated for 1 h
at RT and shaken every 15 minutes to ensure even coverage of the virus mixture.
At the end of the incubation time, SF900IISFM medium (10 ml) was added.
The flask was incubated at 27 ◦C for 72 h. The mixture was collected into a falcon
tube and spun down at 2500 g for 15 min at RT. The supernatant, which contained
the amplified virus, was then collected into a fresh falcon tube and FCS was added
to a 2% w/w final concentration to increase the viral stability over time.
After the third round of amplification, the pellets collected by centrifugation of
the viral mixture were re-suspended in sample buffer i (500 μl). An aliquot was
loaded onto SDS-PAGE to check if the protein of interest had been expressed.
The virus was amplified to a 108 pfu/ml titre in no more than four rounds of
amplification and a viral stock was prepared to be used for protein expression.
2.4.6 Viral stock
The viral working stock (100ml) was prepared by infecting, in suspension, a Sf9
culture at 1.8 × 106 cells/ml (100 ml). The culture was infected using the amplified
virus of interest and with a MOI of 0.1. The insect cell culture was incubated at 27
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◦C, 150 rpm for 72 h. The titre of the viral stock obtained was calculated using a
plaque assay.
2.4.7 Protein expression
2.4.7.1 Time course for expression and solubility analysis
An insect cell culture (50 ml) was infected with the virus of interest at the desired
MOI. Each culture was incubated at 27 ◦C, 150 rpm for the first 24 h and then incu-
bated at a different temperature if required for the remaining incubation time. The
protein expression and the protein solubility were monitored over 72 h if incubated
at 27 ◦C or over 144 h if incubated at a lower temperature.
The cell density was measured immediately before each sample collection which
took place every 12 h. An aliquot (66 × 105 cells) was collected to monitor the ex-
pression level and a second aliquot (3.3 × 106 cells) was collected to examine the
protein solubility.
The sample used for protein expression was spun down at 2500 g, for 10 min at
RT. The supernatant was aspirated whilst the pellets were re-suspended in sample
buffer (200 μl). An aliquot of the latter mixture (10 μl for Sf9 or Sf21 or 5 μl for
High5) was loaded on SDS-PAGE. The sample used for the solubility test was spun
down at 2500 g, for 15 min at RT. The supernatant was aspirated and the pellet
was re-suspended in 150 μl of CytoBuster (Novagen). Samples were mixed and
incubated at RT for 15 min. Samples were spun down at 15300 g, at 4 ◦C for 20
min. The supernatant, containing the soluble fraction, was pipetted into a fresh
Eppendorf tube, and mixed with sample buffer I (50 μl). An aliquot of the latter
mixture was loaded on SDS-PAGE (10 μl for Sf9 or Sf21 or 5 μl for High5). The
pellet, which contained the insoluble fraction, was re-suspended in sample buffer
(200 μl). An aliquot (10 μl for Sf9 or Sf21 or 5 μl for High5) was loaded on SDS-
PAGE.
The set of conditions that led to the highest level of solubility of the protein of
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interest were identified and adopted for the large scale protein expression.
2.4.7.2 Lysis buffer selection
Aliquots of infected Sf9 cultures (3 ml) were collected at the harvesting time and
lysed with different buffers (800 μl) to investigate their effects on protein recov-
ery and on protein solubility. The following lysis buffers were tested: CytoBuster,
washing buffer A and washing buffer A plus addition of detergent (1% v/w DM).
DNAseI (1 μl) and AEBSF (4 μl) were added to the lysis mixture. The samples
were incubated at 150 rpm, at 4 ◦C on ice for 1.5 h, and then spun down at 15300
g, 4 ◦C, for 20 min. An aliquot of the supernatant (400 μl) was pipetted into a
fresh Eppendorf tube and mixed with protamine sulfate (40 μl). Samples were
incubated for 15 min, at 4 ◦C and spun down at 15300 g, 4 ◦C, for 20 min. The
pellets collected before and after addition of protamine sulfate were re-suspended
in sample buffer i (600 μl). The supernatants (300 μl) collected before and after
addition of protamine sulfate were mixed with sample buffer (100 μl). Each sample
(10 μl) was loaded onto SDS-PAGE followed by Western blotting.
2.5 Protein purification
2.5.1 Cell lysate
The bacterial or insect cell pellets were resuspended in lysis buffer (25 ml/liter of
culture) and incubated on ice, at 4 ◦C, for 30 min with gentle shaking. Subsequently,
when detergent was used to break the plasma membrane, DNAase I (50 μl) and
Triton X-100 (5 ml, 10% v/v) were added to the lysate and incubated for 1 h at 4
◦C. Alternatively, when mechanical shear was used to break the cells, the sample
was transferred into a beaker and sonicated for 10 min at 60% amplitude with 10
sec bursts of sonication separated by 20 sec pauses. The lysate was clarified by
centrifugation at 14000 g for 30 min at 4 ◦C (RC6, Sorvall).
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The supernatant containing the protein of interest was immediately applied to a
chromatographic column according to the specific purification protocol.
2.5.2 Protein purification
The proteins expressed recombinantly were purified firstly by affinity chromatogra-
phy exploiting the tags, then by ion exchange chromatography and finally by size
exclusion chromatography.
2.5.2.1 Affinity chromatography
2.5.2.1.1 Nickel chelating HisTrap column A HisTrap FF crude chromatog-
raphy column (1 or 5 ml, GE Healthcare) re-loaded with nickel was used to
purify histidine tagged proteins. The column was connected to an FPLC (A¨KTA
explorer, GE Healthcare) and pre-equilibrated with chelating chromatography
washing buffer A (5 column volume, CV). The absorbance at 280 nm (A280nm)
was recorded down-stream of the column.
The clarified cell lysate of the over-expression culture was applied on the col-
umn with a flow rate of 1 ml/min for 1 ml, or 5 ml/min for a 5 ml column. The
protein bound to the column was washed with washing buffer A until the A280nm
was zero, and then eluted with a gradient elution up to 100% of buffer B. In order
to monitor the purification at each stage, samples were collected and analysed by
SDS-PAGE. The following samples were analysed: cell lysate loaded on the col-
umn, the first and last fractions of the flow through (to ensure that the column was
not saturated), the first and last fractions of the washing step (to ensure the column
was washed properly and that no protein was lost at this stage), and the elution
fractions characterised by an A280nm peak (to identify the fractions that contain the
target protein).
At the end of the purification the HisTrap FF crude chromatography column was
regenerated.
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The column was washed with UF water (2 CV), and then nickel ions were re-
moved with 100 mM EDTA pH 8.0 (3 CV). The column was washed with UF water
(2 CV) and then in more harsh condition with 1 M NaOH (1 CV). The column was
equilibrated in UF water (3 CV) and then loaded with nickel using a 100 mM NiCl2
solution (0.5 CV). The unbound nickel was removed by washing the column with
UF water (3 CV). The column was stored in UF water at 4 ◦C.
2.5.2.1.2 Strep-Tactin Proteins expressed with the strep II tag (WSHPQFEK)
were purified using a gravity flow column packed with Strep-Tactin (MacroPrep,
IBA) (50 nmol protein/ml resin) [321]. The column was pre-equilibrated with
StrepTactin washing buffer C (5 × 1 CV). The protein was applied on the resin and
the mixture was incubated O/N at 4 ◦C with shaking. At the end of the incubation,
the protein was allowed to flow through the column, the resin was washed with
washing buffer C (5 × 1 CV) and then the bound protein was eluted with elution
buffer D (6 × 0.5 CV).
The purification using the Strep-Tactin column was monitored by SDS-PAGE.
The following samples were collected and analysed: sample loaded on the column
(as reference), the flow through (to detect how much protein did not bind to the
column), the first and last washing fractions (to ensure that only non-specifically
bound protein was removed at this stage), the elution fractions (to ensure that the
protein of interest was eluted, and to asses the increase in purity).
The resin was regenerated by applying the regeneration buffer E (5 CV). The
color of the resin turned to red, indicating a good activity status; when the red color
of the resin on the top and on the bottom was of the same intensity, the regeneration
was considered complete. The regeneration buffer was removed and replaced by
storage buffer F (5 × 1 CV). The column was stored at 4 ◦C.
2.5.2.1.3 Amylose Resin The maltose binding protein (MBP) fusion constructs
were purified using a gravity flow column packed with amylose resin (3 mg pro-
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tein/ml resin). The column was pre-equilibrated with amylose resin washing buffer
H (5 × 1 CV). The protein was applied to the resin, the resin was washed with
washing buffer H (5 × 1 CV) and then the bound protein was eluted with elution
buffer I (6 × 0.5 CV).
The purification using the amylose column was monitored by SDS-PAGE as
described for StrepTactin columns.
The resin was regenerated using regeneration buffer J (5 CV), washed with UF
water and stored at 4 ◦C.
2.5.2.2 Ion exchange chromatography
The target protein was purified exploiting its surface charge. The elution fractions of
the previous purification step that contained the target protein were pooled together
and loaded onto an anion exchange chromatography column. The column: Heparin
HiTrap (5 ml, GE Healthcare), or Mono Q, was connected to an FPLC (A¨KTA
explorer, GE Healthcare) and pre-equilibrated with washing buffer H (5 CV).
The protein was loaded onto the column, the unbound protein was removed
by washing the column with washing buffer H (5 CV) and the bound protein was
eluted with a shallow gradient up to 100% elution buffer K. The absorbance at 280
nm (A280nm) was recorded downstream of the column. Various elution fractions
were collected and analysed by SDS-PAGE as described in sec. 2.5.3.1.
2.5.2.3 Size exclusion chromatography
Size exclusion chromatography was the last purification step for each protein prepa-
ration. The protein mixture was purified using the gel filtration column with the best
resolution in the size range of the target protein.
The column was connected to an FPLC (A¨KTA explorer, GE Healthcare) and
equilibrated with buffer G. The protein was loaded on the column and isocratically
eluted using buffer G. The absorbance at 280 nm (A280nm) was recorded down-
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Table 2.7. Summery of gel filtration column properties: maximum loading volume and
size resolution range.
Gel Filtration column loading volume M.W. resolution range
Superdex 75 26/60 ≤ 13 ml 5 × 102 - 3 × 104 KDa
Superdex 200 16/60 ≤ 5 ml 1 × 104 - 6 × 105 KDa
Superdex 200 26/60 ≤ 13 ml 1 × 104 - 6 × 105 KDa
stream of the column. Each eluted peak was characterised by a retention time. The
particle size was estimated on the basis of the retention time and according to the
column calibration data. The sample loaded on the column and the eluted peaks
were collected and analysed by SDS-PAGE.
An estimate of the purity of a protein preparation is given by comparison of
the loaded sample with the eluted fraction. The presence of the target protein in
the eluted fractions characterised by the target protein retention time was confirmed
by Western blotting. The eluted fractions which contained the purified target pro-
tein were concentrated in Vivaspin 20 centrifugal concentrator (Satorius Stedim
Biotech) with the cut-off specific to the protein size. The protein concentration was
measured according to the Bradford method (Bio-Rad protein assay, Bio−Rad).
The purified protein sample was collected in aliquots, frozen in liquid nitrogen
and stored at -80 ◦C until required.
Gel filtration columns were calibrated by loading a mixture of protein markers of
known composition and molecular weight (Gel filtration standard, Bio−Rad). The
column was calibrated under the same conditions used for the protein purification
in order for the retention time to be representative of the separation condition. The
columns were equilibrated with the buffer used for protein purification (buffer G),
loaded with the protein marker mixture, and the sample was eluted with buffer G,
using with the same flow rate used for protein purification.
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2.5.3 Protein characterisation
2.5.3.1 SDS-PAGE
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was per-
formed with different concentrations of acrylamide according to the molecular weight
of the protein to be analysed. The resolving gel was prepared and poured between
pre-assembled plates (1.5 mm or 0.75 mm thickness) up to 2 cm below the top.
Propan-2-ol was added on the top to obtain a flat surface. After gel polymerisa-
tion, the surface was rinsed with doubly distilled water and the stacking gel was
added. A comb was immediately inserted to form the loading wells. The loading
solutions were prepared by mixing the samples with loading buffer i and boiling
them for 5 min. The gels were transferred to the electrophoresis unit which was
loaded with electrophoresis running buffer i. The samples were then loaded on the
polyacrylamide gel together with the molecular weight standards (Precision Plus
protein Dual colour strands, Bio − Rad), and run at 100 V until the blue dye front
reached the bottom. The gel was stained with SimplyBlue safe stain (Invitrogen),
silver stained, or used for Western blotting.
2.5.3.2 Native gels
Native gels were prepared in a similar manner to the SDS-PAGE gels using the
appropriate resolving and stacking gel mixtures. The gel was cooled down to 4
◦C before use. The loading solutions were prepared by mixing the samples with
loading buffer ii (10% v/v). The gels were transferred to the electrophoresis unit
which was loaded with electrophoresis running buffer ii. The samples were then
loaded onto the polyacrylamide gel and run at 80 V at 4 ◦C until the blue dye front
reached the bottom. The gel was stained with SimplyBlue safe stain, silver stain, or
used for Western blotting.
2.5 Protein purification 101
2.5.3.3 2D gels
The iso-electofocusing (IEF) gel mixture was prepared and deionised with Amber-
lite MB-1 resin (Supelco) for 1 h. The IEF gel was filtered and mixed with CHAPS
(0.3 g), TEMED (15 μl) and 10% w/v ammonium persulfate (30 μl). The gel mix-
ture was poured into a cylinder containing the glass tubes for IEF electrophoresis
(75mm in length and 1.5 mm in diameter, from Hoeffer) until the glass tubes were
filled to within 7.5 mm of the bottom. After gel polymerisation, the glass tubes were
transferred to the electrophoresis units for IEF. The lower chamber was filled with
10 mM phosphoric acid, the upper chamber was filled with 20 mM NaCl. The pro-
tein sample was mixed with the loading buffer iii (1:1), and loaded onto the tube
gel. The IEF was run at 500 V for 4 h. The tube gel was stored at -20 ◦C until the
second dimension was carried out.
The second dimension was SDS-PAGE. The acrylamide gel for the SDS-PAGE
was prepared as described above. The rod IEF gel was gently extruded from the tube
and placed on the SDS-PAGE. The IEF gel was incubated with the equilibration
buffer (1 ml) in situ for 5 min. The buffer was drained off, and the molecular
weight standards were loaded. The SDS-PAGE was run at 80 V until the blue dye
front reached the bottom. The gel was stained with SimplyBlue safe stain, or silver
stained.
2.5.3.4 Western blotting
Western blotting was used as an analytical technique to identify the bands visi-
ble in a SDS-PAGE or in a native gel. Western blotting, using indirect detection
methods, was performed exploiting primary antibodies which specifically bound
epitopes within the protein of interest.
The proteins had previously been separated by SDS-PAGE or a native gel and
then transferred onto polyvinylidene difluoride membranes (Hybond-P PVDF, GE
Healthcare) which were preactivated in MeOH for 1 min and then washed with
2.5 Protein purification 102
water. The polyacrylamide gel was placed in direct contact with the membrane
in a sandwich between the two electrodes of the transferring units immersed in
transfer buffer. Electrophoretic transfer was carried out at 30 V, 4 ◦C, O/N. The gel
was stained with SimplyBlue safe stain (Invitrogen) or Coomassie blue to ensure
successful transfer. Non-specific binding was blocked with 5% milk in TBS T buffer
( or with 3% BSA in PBS T buffer when Strep II antibody was used) and incubated
for at least 1 h at RT. The primary antibody, according to the protein of interest, was
diluted in buffer and incubated for 2 h at RT, see table 2.8.
The secondary antibody was diluted in 5% w/v milk in TBS T buffer (typically
1:2000) and incubated for 1 h. The membrane was washed in TBS T buffer for 10
min at least four times.
The membranes were dried and immediately incubated with the detection reagent
(ECL, GE Healthcare) for 1 min.
The membranes were exposed to autoradiography MR film or to the more sen-
sitive XAR film (Kodak). The time of exposure was adjusted according to the
membrane content.
2.5.3.4.1 Membrane Re-probing If the sample is transferred onto a nitrocellu-
lose membrane it can be re-probed sequentially with different antibodies. In order
to immuno-detect the sample with different primary or secondary antibodies, the
membrane was stripped under harsh conditions before re-probing. The membrane
was incubated with stripping buffer (50 ml) at 50 ◦C for 30 min and washed five
times with TBST buffer for 10 min each time. At that point the membrane were
ready to be used for Western blotting following the same procedure described in
section 2.5.3.1 from the blocking step.
2.5.3.4.2 Membrane staining In order to visualise any protein bound to the
membrane, the membrane was stained by addition of amido black solution for 3
min and then destained with the destaining solution. The membrane was washed in
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Table 2.8. List of primary (α) and secondary (2) antibodies used for Western blotting. The
antibodies were diluted to the working concentration in 5% milk in TBST buffer, with the
excepion of the antibody marked with the star which was diluted in 3% BSA in PBS T
buffer.
ANTIBODY FROM DILUTION ANTIBODY TYPE
α His5 Quiagen 1:2000 mouse monoclonal
α StepII Novagen 1:1000 (*) mouse
α RA2 (PLC94/3d) in house 1:500 mouse
α RA1 in house 1:2000 mouse
α GAPDH Fitzgerald 1:10000 mouse monoclonal
α MBP Sigma− Aldrich 1:2000 mouse monoclonal
α Actinin Sigma 1:2000 mouse monoclonal
α RhoA 26C4 Santa Cruz 1:2000 mouse monoclonal
α Rac2 Santa Cruz 1:2000 rabbit polyclonal
α H-Ras (F235) Santa Cruz 1:2000 mouse monoclonal
α K-Ras (F234) Santa Cruz 1:2000 mouse monoclonal
α N-Ras Santa Cruz 1:2000 mouse monoclonal
α GFP (B2) Santa Cruz 1:2000 rabbit monoclonal
2 anti-mouse GE Healthcare 1:2000
2 anti-rabbit GE Healthcare 1:2000
destaining solution three times until the bands were clearly distinguishable from the
background. The membrane was air-dried.
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2.5.3.5 Protein dispersity
The quality of the purified protein preparation in terms of size homogeneity was
assessed by multi-angular light scattering analysis (MALS) and imaging by EM.
2.5.3.5.1 Multi-angular light scattering MALS analysis can calculate the size
and and size distribution of proteins particles in solution.
A DAWN HELEOS II 18-angle light scattering detector (Wyatt Technology
Corporation) was placed downstream of an analytical gel filtration column (BioSep-
SEC-S3000, Phenomenex), which was loaded with the purified protein and eluted
with buffer L. The UV280nm trace was recorded and MALS data were collected for
the eluted fractions. The MALS data, relative to the eluted fractions characterised
by the retention time of the target protein, were analysed using ASTRA software
(Wyatt Technology Corporation).
2.5.3.5.2 EM The quality of the protein preparation was assessed, in terms of
mono-dispersity and purity, by EM imaging of the protein in negative stain. For this
purpose negative glow discharged grids (coated as described below) and therefore
hydrophilic, were used. The protein preparation was diluted in buffer A to a concen-
tration in the order of 0.5-2 mg/ml. A drop of protein solution, a drop of UF water,
and a droplet of staining solution (2% w/w uranyl acetate in water) were positioned
in that order on Parafilm. The grids were prepared following a standard droplet
technique, by touching and allowing adsorption for a few seconds onto the carbon
coated side of the grid (this for each samples drop, in the order mentioned above).
The grids were gently blotted with filter paper (Whatman), dried and screened by
EM operated at 120 KV with a magnification between 52 K× and 110 K× (Technai
T12, FEI).
2.5.3.5.3 EM Grid Preparation Two different types of grid were used: quan-
tifoil and copper grids (Electron Microscopy Sciences).
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The grids were either coated with collodion and carbon or coated only with
carbon. Carbon films suitable for grid coating (typically in the order of 10 nm
thickness) were obtained by placing freshly cleaved mica supports (2 × 5 cm),
under a vacuum of ≈2 × 10−7 Torr, under a carbon source from which the carbon
was evaporated. Uncoated grids, washed with ethanol, were placed on filter paper
under UF water (shiny side up) in a Petri dish. The carbon-coated mica was slowly
immersed in the water, in such a way that the carbon film was released from the
mica and floated on the water surface. The filter paper with the grids sitting on it
was carefully lifted towards the carbon film, letting the carbon film settle on the
grids. The grids were dried and stored in at 34 ◦C until required.
Collodion and carbon coated grids were prepared by spreading a suitable amount
of collodion solution on a flat and clean water surface (10 μl of collodion for 80 cm2
surface). After collodion polymerisation, the grids were carefully settled on the col-
lodion film with the shiny side down. The grids were harvested on filter paper and
allowed to dry in the oven at 34 ◦C for at least two days. Dried grids were carbon
coated as above. Hydrophilic grids were prepared by glow discharging the coated
grids. These grids were negatively glow discharged for 20 sec at 20 mA under
vacuum (0.15 Torr) in glow discharge apparatus (K950X, Emitech).
2.6 Activity studies
2.6.1 PLC activity in vivo
The activity of PLC in vivo was measured in Cos7 cells as they are easy to transfect
and to culture. For each condition tested, three identical cultures were prepared.
Two cultures were used to carry out the activity measurement and the third culture
was used to analyse the efficiency of the transfection by Western blotting.
Cos7 cells (2.5 × 105 cell per well) were seeded in 10 cm2 wells of 6-well plates
and incubated for 16 h at 37 ◦C until they were 70-80% confluent.
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The Cos7 cultures were transfected using lipofectamine (Invitrogen) according
to the manufacture’s instructions. In brief, solution A (100 μl final volume) was
prepared mixing in the following order: Opti-MEM I, the plasmid of interest (in
the desired amounts) and PLUS reagent (1μl). A lipofectamine mixture (7% v/v in
Opti-MEM I) was prepared, incubated for 5 min at RT and added to mixture A 1:1
v/v. The transfection mixture was incubated for 20 min at RT.
The Cos7 cultures were washed with DMEM (2 ml) and then incubated at 37 ◦C
for 4 h with the transfection mixture (200 μl) and DMEM (800 μl). The transfection
mixture was removed and the Cos7 cultures were incubated with DMEM enriched
with FCS (10% v/v) and 1.8 mM glutamine at 37 ◦C for 20 h.
Transfection and expression levels analysis One Cos7 culture (per transfection
type) was used to monitor protein expression in the cell culture by Western blotting.
Each culture was washed with PBS (2 ml), scraped into loading buffer (4 ×) for
SDS-PAGE with complete protease inhibitor (250 μl) and transferred into a 1.5 ml
Eppendorf tube. An equal volume of each mixture (25 μl) was loaded on SDS-
PAGE and then transferred to a PVDF membrane for Western blotting. The samples
were probed with: house-keeping genes, such us α GAPDH or α actinin, to asses
the state of the cells and as loading control; the transfected GTPases (such as RhoA,
H-Ras, K-Ras) or PLC to asses the efficiency of the transfection and the degree of
expression.
PLC activity measurements The cultures used for the activity assay were la-
beled with tritiated substrate by incubating the Cos7 culture in inositol free DMEM
enriched with [3H]-myo-inositol 1.5 μCi/ml (1.5 ml per well). Cultures were incu-
bated at 37 ◦C for 20 h and then washed with inositol free DMEM to remove the
un-incorporated radioactive substrate. Cos7 cultures were incubated with 20 mM
LiCl in inositol free DMEM (1.2 ml final volume) for 1 h at 37 ◦C to allow accumu-
lation of inositol phosphates by inhibition of inositol phosphate phosphatases. The
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reaction was quenched by addition of 4.5% perchloric acid (1.2 ml). Cultures were
incubated for 30 min on ice. Cells were scraped off, transferred into 15 ml Falcon
tube and spun down at 2680 g, 4 ◦C for 20 min. The supernatant, containing soluble
inositides, was transferred into a fresh falcon tube. The pellets and the supernatant
were analysed separately.
Pellet preparation The pellets were resuspended in UF water (100 μl) and then
a mixture of CHCl3-MeOH-concHCl (100:200:15 v/v, 375 μl) was added to each
sample. The mixtures were vortexed, then CHCl3 (125 μl) and 0.1 M HCl (125 μl)
were added to each sample. To gain a better separation of the organic and inorganic
phases, samples were centrifuged at 2680 g, 4 ◦C, for 10 min. For each sample an
aliquot of the organic phase (20 μl) was pipetted into a small scintillation vial. The
scintillation fluid (2 ml, ultima flow, Perkin Elmer) was added to each scintillation
vial.
Supernatant preparation The supernatants were neutralised by adding a neu-
tralisation buffer (3 ml) and spun down at 2680 g, 4 ◦C, for 20 min to remove the
precipitate. The supernatant was transferred into a fresh tube and diluted with UF
water at 4 ◦C (10 ml). AG1-X8 (Bio − Rad) columns were equilibrated with UF
water at 4 ◦C (5 ml) and loaded with the supernatant. The columns were washed
with AG1-X8 washing buffer (15 ml), and then the inositol phosphates were eluted
in one step, applying the elution buffer (5 ml). The eluted fraction was directly col-
lected into a large scintillation vial and an equal volume of scintillation fluid (5 ml,
ultima flow, Perkin Elmer) was added to it.
The AG1-X8 columns were regenerated by applying the regeneration buffer (10
ml). The columns were washed with UF water (10 ml) and stored in UF water at
4 ◦C until the next use.
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Sample analysis The scintillation vials containing the pellets and the supernatants
were vortexed for 10 sec and then placed into a scintillation counter (Liquid scin-
tillation analyser 2500TR, Packard). The CPM and DPM were measured for each
sample.
2.6.2 PLC activity in vitro
Two different assays are available to measure PLC activity in vitro: the mixed mi-
celle assay, used to measure the specific activity of the enzyme, and the cell-free
assay, used to measure PLC activation upon GTPases interaction in a GDP/GTP
dependent manner.
2.6.2.1 The mixed micelle assay
This assay allows one to calculate the specific activity of purified PLC. Therefore
this assay was used to monitor the purification process, or to characterise and com-
pare different PLC constructs.
Each sample of the mixed micelle assay was prepared in duplicate. The assay
was performed according to the protocol [322]. In brief, the PLC mixture (6 μl),
or a buffer for the control (6 μl), was added to the master mixture (40 μl). At the
end, the substrate (4 μl), a mixture of hot and cold PtdIns(4,5)P2, was added to
each sample. Samples were vortexed and incubated at 37 ◦C in a water bath for
30 min. At the end of the incubation time, a mixture of CHCl3-MeOH-concHCl
(100:100:0.6 v/v, 250 μl) was added to each sample in order to quench the reaction.
Subsequently, 1N HCl (75 μl) was added to each sample in order to improve the
partition of the lipids into the organic phase. Samples were vortexed and spun
down at 1900 g for 5 min at RT to separate the two phases. An aliquot of the
inorganic phase (200 μl), which contains the water soluble product of the reaction
(IP3), was collected into a fresh scintillation vial. Scintillation fluid (ultima gold,
Perkin Elmer) was added to each vial (3 ml). A ’total count’ vial, which measures
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the total amount of substrate present in each reaction sample, was prepared mixing
the substrate (4 μl) and the scintillation fluid (3 ml) in a separate vial.
The CPM and DPM were measured for each reaction sample and for the total
amount of substrate in a scintillation counter (Liquid scintillation analyser 2500TR,
Packard). The substrate hydrolysed in the reaction samples was expressed as an
amount relative to the total substrate present in the reaction mixture.
The specific PLC activity was calculated using highly pure PLC and a known
amount of enzyme per sample.
2.6.2.2 The cell-free assay
The cell-free, or reconstitution assay, is designed to mimic the PLC-GTPase-substrate
interactions in vivo. This assay provides a simplified system to study the correlation
between PLC activity and lipid presentation or the interaction with the GTPases.
Each stage of cell-free assay is described in the following sections.
2.6.2.2.1 Preparation of post-translationally modified small GTPases from
Sf9 cell membranes Post-translationally modified small GTPases were expressed
in insect cells, the cells were harvested and the membranes were solubilased as in
Gandarillas, et al. [323] and Illenberger, D. et al. [324]. In brief, Sf9 cells were
seeded in 50 × 50 cm Corning tissue culture plates (1.2 × 108 cells per plate) and
left to settle for 2 h at RT. The medium was removed and the cells were infected
with the virus at MOI of 2. To maximise the infection efficiency, the cells were
initially incubated for 1 h at RT with a concentrated viral mixture (1 MOI/ml) and
subsequently diluted with fresh medium (60 ml). The plate was sealed with Parafilm
to prevent medium evaporation and incubated at 27 ◦C for 72 h. The medium was
collected and the cells were scraped into PBS at RT (50 ml). The medium and the
cell mixture were pooled together and centrifuged at 300 g for 5 min at 4 ◦C to
pellet the cells. Supernatant was removed and cells chilled on ice. The cells were
re-suspended in cell homogenisation buffer (200 μl per 10-15 × 106 cell), kept on
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ice for 30 min and vortexed often during the incubation time. Cells were lysed by
application of 20 strokes in a chilled cell homogeniser. The mixture was further
homogenised using shear forces by pipetting the mixture through a 0.45 μm thin
needle 10 times. Cellular debris and whole cells were removed by centrifugation at
300 g for 10 min at 4 ◦C and the supernatant was spun down at 12000 g for 15 min
at 4 ◦C to pellet the membrane fraction.
Sf9 membranes were washed twice in homogenisation buffer re-suspending the
pellet in homogenisation buffer (200 μl per 10-15 × 106 cells) and pelleting the
membrane fraction at 12000 g for 15 min at 4 ◦C. Sf9 membrane were re-suspended
in solubilisation buffer (30 μl per 10-15 × 106 cells) by constant stirring at 4 ◦C for
90 min. Insoluble material was removed by centrifugation at 12000 g for 15 min at
4 ◦C.
The supernatant containing Sf9 membrane extract was aliquoted, snap frozen
in liquid nitrogen, and stored at -80 ◦C. The presence of post-translationally mod-
ified, prenylated, GTPase in the Sf9 membrane extract was monitored by Western
blotting.
2.6.2.2.2 GTPases prenylation in vitro GTPases of the RhoA subfamily can be
prenylated in vitro by GGTase type I. In order to titre the GGTase type I and to find
the optimum conditions for the reaction, various reaction mixtures were prepared
increasing the amount of GGPPase type I.
The reaction mixtures (20 μl final volume) were prepared in glass tubes con-
taining: purified wild-type RhoA (5 μM), geranylgeranylpyrophosphate (5 M), 3H-
geranylgeranylpyrophosphate (0.05 μM) and various amounts of GGTase type I (0,
6.125, 12.5, 25, 50, 100 or 200 nM) The reaction samples were incubated for 30
min at 37 ◦C and then stopped upon addition of EtOH-HCl (9:1 v/v, 1 ml). Samples
were incubated for 30 min at RT to allow protein precipitation. Glass microfiber
filters (Whatman) were placed in a manifold device, soaked with UF water (2 ml)
and then washed twice with EtOH (2 ml). Each prenylation sample was further
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diluted into EtOH (6.2 ml) and then applied to the corresponding glass microfibre
filter. Each filter was washed 3 times with EtOH (2 ml) and then transferred into a
scintillation fluid vial. As a control the flow through (6 ml) was collected into a scin-
tillation vial. Scintillation fluid (10 ml, Ultima flow, Perking Elmer) was added
to each vial. The samples were well mixed and loaded in a scintillation counter
(Liquid scintillation analyser 2500TR, Packard) and counted for 1 min. The CPM
and DPM were measured for each sample.
2.6.2.2.3 Lipid vesicle preparation The vesicles were prepared from a lipid
solution of the desired lipids composition. Each chloroform lipid stock solution, in
the desired proportion and amounts, was pipetted into a 14×100 mm Pyrex glass
tube. The chloroform lipid solution obtained was evaporated under a stream of
nitrogen at RT to exclude air. The lipid film which was then resuspended in the
appropriate buffer (20 μl/assay) by intense vortexing to obtain a liposome mixture.
Unilamellar lipid vesicles were formed by sonication of the liposome mixture, or
by extrusion.
Vesicles with the following lipid compositions were prepared: 33.4 μM PtdIns(4,5)P2
/[3H] PtdIns(4,5)P2 (185 GBq/mol) and 536 μM PtdEtn final concentrations.
The lipid mixture was vortexed continuously for 30 min at RT and then soni-
cated for 5 min, 1% amplitude, 4 ◦C in a cup horn-type sonicator (XL Ultrasonic
Processor, Misonix). Alternatively, the lipid mixture obtained after vortexing was
extruded 31 times across a polycarbonate membrane (Nuclepore track-etched mem-
branes, Whatman) of a defined pore size (50 nm 100 nm 400 nm) using a mini
extruder (Avanti Polar Lipids). The lipid vesicles were immediately used for the
reconstitution assay.
An aliquot of the the vesicle mixture (10 μl) was used to image the lipid vesicles
by EM. Immediately after the vesicles were prepared, EM grids were prepared as
described in section 2.5.3.5.
The size distribution of lipid vesicles was analysed by dynamic light scattering
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(DLS), see section 2.7.2.
2.6.2.2.4 Determination of the free Ca2+ concentration The free Ca2+ con-
centration in the cell-free system at equilibrium was calculated using the software
EqCal (Biosoft). The free Ca2+ concentration is calculated based on initial con-
centrations of the bivalent ions in the system (Ca2+ and Mg2+), EGTA, EDTA and
the pH and the equilibrium constants between all the species in the system.
The initial concentrations of Mg2+, EGTA, EDTA, H+ (as pH), and the desired
free Ca2+ concentration at equilibrium were given as input. The initial concentra-
tion of Ca2+ required was obtained as output, and used for the free cell assay.
2.6.2.2.5 Samples preparation and activity measurements The reconstitution
assay was performed at a specific free Ca2+ concentration and protein concentra-
tion. The PLC was diluted in the presence of BSA to prevent possible non-specific
binding of the PLC to the tubes. All the samples were prepared with identical free
Ca2+ concentration with the exception of the set of samples measuring the maxi-
mum activity. These samples were prepared with a higher free Ca2+ concentration
and with detergent. Each set of samples was prepared in duplicate.
The reaction samples (60 μl final volume) contained: 3.6 mM GTPγS or GDP
(10 μl), a defined free Ca2+ concentration depending on the PLC used, GTPase
in membrane solubilisation buffer from Sf9 (5 μl) or in vitro prenylated GTPase
(5 μl). In the set of samples measuring the basal activity, the GTPase was substi-
tuted with GTPase buffer. The set of samples for the basal activity measurements
contained: 100 μM free Ca2+ final concentration and 2 mM sodium deoxycholate
(NaDC). The blank was prepared without PLC. The buffer used to prepare each set
of samples was chosen according to the PLC being analysed. The conditions of the
reconstitution assay are reported in the table 2.9.
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Table 2.9. Cell-free assay conditions. The buffer used, the free final Ca2+ concentration,
and the presence of detergent is reported according to the PLC used.
PLC buffer free final [Ca2+] free final [Ca2+]
minimum activity maximum activity
PLCβ 50 mM Tris maleate pH 7.3 300 nM [Ca2+] 100 μM [Ca2+]
70 mM KCl 2 mM NaDC
3 mM EGTA
2 mM DTT
PLC 50 mM Hepes pH 7.2 150 nM [Ca2+] 100 μM [Ca2+]
70 mM KCl 2.4 mM NaDC
3 mM EGTA
2 mM DTT
The reaction was started upon addition of the substrate included in the lipid
vesicles mixture (20 μl).
The reactions were incubated for 45 min at 30 ◦C and terminated by the addi-
tion of ice-cold CHCl3-MeOH-concHCl (100:100:0.6 v/v, 350 μl) followed by the
addition of 1 M HCI and 5 mM EGTA (100 μl). The samples were incubated for
10 min on ice and then spun at 20800 g for 1 min in a tabletop centrifuge (5417R,
Eppendorf ) to improve the phase separation. An aliquot of the aqueous phase (200
μl), which contained the water soluble product, InsP3, was pipetted into a scintil-
lation tube and mixed with scintillation fluid (4 ml, Ultima Gold, Perkin Elmer).
The samples were vortexed and loaded into a scintillation counting machine (Liquid
scintillation analyser 2500TR, Packard).
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2.7 Lipid-protein binding
2.7.1 GUV preparation
Giant unilamellar vesicles (GUVs) of controlled lipid composition were prepared
in different buffers by the swelling method [325]. Teflon discs were prepared by
roughening with fine glass paper and sonication in CHCl3-MeOH (3:1 v/v) for 5
min to remove any lipophilic contaminants. A lipid solution having the desired
molar ratio of the constituent lipids was prepared in CHCl3 and with a final con-
centration of 10 mg/ml. The lipid solution (40 μl) was spread on a teflon disc
(approximately 20 cm2) using an Hamilton syringe needle. The teflon disc, with
the lipid solution spread on it, was placed in a beaker and dried under vacuum for
4 h to ensure complete evaporation of chloroform and to prevent lipid oxidation.
When fluorescent lipids were used, the beaker was kept in the dark by wrapping it
in aluminum foil.
The lipid film was pre-hydrated for 10 min under a hydrated N2 flow, obtained
by bubbling N2 through a UF water bath at 37 ◦C. The GUV growing buffer con-
taining 200 mM Sucrose was prepared at a range of pHs (200 mM MES pH 6.2, 200
mM Tris pH 7.0, 200 mM Tris pH 7.4, or 200 mM Hepes pH 7.4). The GUV grow-
ing buffer was filtered with a 0.2 μm filter, pre-warmed to 37 ◦C and gently added
to the lipid film (3-10 ml). The samples were sealed with Parafilm and incubated at
37 ◦C O/N. The GUVs obtained (10-50 μm) were equilibrated at RT for three hours
before use.
2.7.1.1 GUV characterisation
GUV formation was checked by light fluorescence microscopy using 10 × to 63
× objective lenses. For this purpose 500 μl of the GUV mixture in sucrose buffer
was diluted four-fold with 200 mM glucose solution prepared in water or 200 mM
buffer. GUVs containing fluorescent lipids were imaged by confocal microscopy
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to analyse the lipid distribution in their bilayer and potentially detect domain for-
mation. For this purpose, 100 μl of the GUVs were diluted four-fold into an equi-
osmotic solution of glucose. The samples were placed in a 10.0 × 10.7 × 6.8 mm
well slide (Ibidi) and gently spun down at 50 g for 5 min. The GUVs contain-
ing rhodamine-PE fluorescent lipid were excited at a wavelength of 543 nm using
an HeNe laser. The excitation wavelengths were separated from the fluorescence
emitted using a dichroic beam mirror (HFT 488/543 nm). The wavelengths of 488
and 543 nm were reflected to excite the sample, while the other wavelengths passed
through. The fluorescence emitted by the sample was band pass filtered (BP 560-
615 nm) and the images were recorded using a 63× oil-immersion lens. Samples
containing NBD-PC fluorescent lipid were excited at 488 nm using an argon laser.
The excitation wavelengths were separated from the fluorescence emitted using a
dichroic beam mirror (HFT 458/514 nm), and the fluorescence emitted was band
pass filtered (BP 505-570 nm IR). The best settings were found for each set of sam-
ples, and were then kept constant to compare the images. Cross sectional images of
single GUVs were taken focusing on different planes along the Z direction. These
stack images were combined into one image which gave the 3D impression of the
fluorescent lipid distribution on the GUVs surface.
2.7.2 Dynamic light scattering
Dynamic light scattering (DLS) was used to characterise the size distribution of the
lipid vesicles mixtures used in the cell-free system (see sec. 2.6.2.2.3). The lipid
vesicle mixtures were analysed under the same conditions that were adopted in the
cell-free system (temperature, buffer, final lipid concentration). This ensured that
the vesicle population characterised by DLS was representative of the vesicle pop-
ulation in the cell-free assay. The data were taken using the DOPE refractive index
(1.410) since it is the major lipid component of the system. Each data point was the
average of two measurements and each measurement was obtained integrating the
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signal for 30 seconds. The vesicles sample was monitored for 45 min and data were
collected every 5 min. and an extra measurement was taken after 24 h. in order to
get information about the stability of the vesicle. A sample containing only buffer
was used as control.
2.7.3 Small angular X-ray scattering
The binary lipid mixture analysed by small angular light scattering (SAXS) were
prepared by mixing the individual lipid solution in CHCl3 to obtain the lipid mix-
tures of the desire lipid ratio (w/w). Each lipid mixture contained 4 mg of total lipid
and it was prepared in a glass tube. Each sample was lyophilisationed at -55◦ C on
vacuum O/N. Each lipid mixture are hydrated in 70 % w/w UF water or cell-free
buffer. Each sample was carefully homogenised by five freze-thaw cycles during
which each sample was vortexed for 20 sec, frozen in liquid nitrogen and thaw. The
samples are span down at 4500 g for 40 sec and then transfered into a capillary with
a 1.5 mm diameter for SAXS analysis. Evaporation was prevented by sealing (the
top end of) each capillary under a flame and by covering it with silicone. Each sam-
ple was placed in a in-house built beam line equipped with a X-ray generator with
copper target and nickel filters (Bede microsource). Each sample was exposed 4
times and each time for 60 sec at 30 ◦C. The X-ray diffraction images were acquired
on a Gemstar HS intensified CCD detector (Photonic Science). The spectra ob-
tained were merged and interpreted using the software Axcess in order to determine
the lipid phase and calculate the d spacing.
2.7.4 Protein-lipid binding by imaging
GUV mixtures (100 μl) were placed in a 10.0 × 10.7 × 6.8 mm well slide (Ibidi),
and fluorescent protein (His6-eGFP or eGFP) was added to a 19 μM final concen-
tration. The samples were diluted four-fold in diluting buffer (200 mM glucose,
200 mM Tris pH 7.4 buffer). The samples were transfered into slides for optical
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microscopy (Ibidi) and then gently spun down at 50 g for 5 min. The samples were
placed in a confocal microscope (Zeiss) and excited at a wavelength of 488 nm us-
ing an argon laser. The excitation wavelengths were separated from the fluorescence
emitted using a dichroic beam mirror (HFT 458/514-nm), and the fluorescence emit-
ted was band pass filtered (BP 505-570 nm IR). The best settings were found for
each set of samples, and they were then kept constant to compare the images. Cross
sectional images of single GUVs were taken using a 63 × oil-immersion lenses.
2.7.5 Protein-lipid binding by sedimentation
The GUV mixtures were well mixed, split into equivalent aliquots (500 μl each)
and the purified protein of interest or no protein (control) was added. The samples
were incubated at 4 ◦C O/N. They were spun down at 20817 g for 30 min (5417R,
Eppendorf ). The supernatant was collected in a fresh vial, and the pellets were
washed twice with the diluting buffer. The protein in the supernatant was precipi-
tated with trichloroacetic acid (TCA). To each supernatant, TCA and deoxycholic
acid were added to reach a final concentration of 6%-w/v and 0.02% w/v, respec-
tively. The protein was precipitated on ice for 15 min and subsequently spun down
at 20800 g for 20 min. The pellets were resuspended in Tris pH 8.0 (15 μl). Pel-
lets containing GUVs and the resuspended supernatant were diluted 1:1 in sample
buffer, loaded on SDS-PAGE and subsequently analysed by Western blotting as de-
scribed in sec. 2.7.5.
2.8 Functional studies
2.8.1 GTPase loading
Purified wild-type H-Ras (1-166 AA) was loaded with GDP or GTPγS, in order to
investigate the difference in PLC binding ability between the active (GTP) or the
inactive (GDP) forms. For this experiment the wild-type H-Ras was used therefore
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a non hydrolysable analogue of GTP, GTPγS, was used in order to minimise the
chances of GTP being hydrolysed to GDP by H-Ras.
The mixtures containing purified H-Ras (350 μM), GDP or GTPγS (6 mM)
were incubated for 2 h at 4 ◦C in shaking conditions. The reaction was stopped
upon addition of MgCl2 (50 mM). The unbound GDP or GTPγS was removed with
a NAP-10 desalting column (Amersham Biosciences). The NAP-10 desalting
column (Sephadex G-25) was equilibrated with GDP or GTPγS elution buffer (15
ml). The GDP (or GTPγS) H-Ras mixture was loaded onto the desalting column.
The elution fraction contained the H-Ras loaded either with GDP or GTPγS (1.5
ml). H-Ras was concentrated in a Vivaspin V6 (10000 MW cut off), aliquoted, snap
frozen in liquid N2 and stored at -80 ◦C until use.
2.8.2 Pull-down assay
Specific protein-protein binding between PLC and wild-type K-Ras was investi-
gated by performing a pull-down experiment. The experiment was designed to
exploit high affinity binding between nickel beaded and His-tagged PLC protein.
The binding affinity between PLC and untagged (GDP or GTPγS) mCherry-K-Ras
was assessed by mCherry-K-Ras detection in the pellets. Nickel chelating beads
(ProBond Resin, Invitrogen)(40 μl) were transferred to an Eppendorf tube and
washed with the pull-down loading buffer (500 μl) by spinning down at 6000 g, for 1
min, removal of the supernatant and resuspension in pull-down loading buffer. The
washing step ensured complete removal of the bead storage buffer, which contained
70% ethanol, and would therefore have caused protein denaturation and precipita-
tion. Purified His6-PLC-eGFP (6 μM) in pull-down loading buffer was added to
the nickel beads and incubated at 4◦C for 30 min on a rotating wheel. The unbound
His6PLC-eGFP was removed by suction of the supernatant after spinning down at
6000 g, for 1 min. Purified GDP or GTPγS wild-type mCherry-K-Ras (1-189 AA)
were added in increasing amounts to the beads mixtures (0.1 μM, 0.5 μM, 1 μM
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and 6 μM). The mixture was incubated at 4 ◦C for 30 min on the rotating wheel to
allow protein-protein binding to occur. The unbound GTPase was removed by three
subsequent washing steps. Each time the beads were washed with the pull-down
washing buffer (500 μl) and the supernatant was carefully removed without disturb-
ing the beads after spinning down at 6000 g, for 1 min. The beads were resuspended
in loading buffer (4 ×) for SDS-PAGE, boiled for 4 min, and the mixture’s content
were further analysed by SDS-PAGE and Western blotting.
The pull-down assay was repeated to detect binding between His6-mRFP-PLC-
eGFP and H-Ras. In this case, His6-mRFP-PLC-eGFP(1 μM) and purified GDP or
GTPγS wild-type H-Ras 1-166 AA (50 nmol, 200 nmol, 500 nmol) were used.
2.8.3 Förster resonance energy transfer
Förster resonance energy transfer (FRET) measurements were performed in solu-
tion using a multidimensional spectrofluorometer [326]. The measurements were
performed analysing the donor and acceptor fluorophore lifetimes in a glass cuvette
in the presence of His6-PLC-eGFP) at a final concentration of 3 μM in buffer. Data
were collected for His6-PLC-eGFP alone and after adding increasing amounts of
GTP or GDP loaded K-Ras-mCherry protein (0.5, 2, 3, 5 and 10 μM final concen-
tration). The donor (GFP) was excited at 488 nm and the emission was measured
at 510 nm. The acceptor (mCherry) was excited at 550 nm and the emission was
detected at 610 nm after donor excitation. For lifetime measurements, the emis-
sion was collected in a 50 ns time window with a polariser set at the magic angle
(54.7o). All the acquired decays were analysed by Dr. Margineanu using a global
analysis approach i.e. the two GFP decay times were linked and were the same for
all the samples, allowing only the pre-exponential factors to vary. Global analysis of
fluorescence intensity decays was done with the TRFA data processor (Scientific
Software Technologies Center).
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2.8.4 Time-resolved anisotropic decay
Variation in polarisation of the emitted light was monitored to gain an insight into
the rate of rotation of the fluorophore and of the size of the fluorophore or of the
molecule (or complex) the fluorophore was part of. The time-resolved anisotropic
decay, r(t), was measured upon excitation of the fluorophore with vertically po-
larised light and by measuring the emission in a plane parallel or perpendicular
to the excitation plane. The eGFP was excited at 488 nm and the emission was
detected at 510 nm. The mCherry (or mRFP) was excited at 550 nm and the emis-
sion was detected at 610 nm. All the acquired anisotropic decays were analysed by
Dr. Margineanu using a global analysis with the TRFA data processor (Scientific
Software Technologies Center).
2.9 Structural studies
2.9.1 2D crystal on a lipid monolayer
Lipid monolayer samples were prepared at the air/water interface in 2D trays con-
sisting of a teflon block with 9 wells, 0.50 mm diameter and 2 mm deep. The wells
were filled with purified protein or with buffer G for the control (15 μl). The lipid
mixture in CHCl3-Hexane (1:1 v/v, 2 μl) was carefully spread on top. The chlo-
roform was allowed to evaporate and the samples were placed in a humidifier box.
The box was carefully sealed with Parafilm in order to prevent sample evaporation
The samples were incubated at RT for a few hours or O/N in a humidifier box to
prevent evaporation.
2.9.2 2D crystal harvesting
The samples were harvested on hydrophobic carbon coated grids by touching the
surface of the drop and allowing absorption for 5 min. The grid was lifted gently,
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partially blotted with filter paper and negatively stained by gently pipetting of 2%
(w/v) uranyl acetate (10 μl) on the grid. The stain was incubated for 1 min, the grid
was partially blotted a second time and then again negatively stained by addition
of 2% (w/v) uranyl acetate (10 μl), then gently blotted. The hydrophobic EM grids
were obtained by incubation of carbon coated grids in the oven at 80 ◦C for 1 h prior
to sample harvesting.
2.9.3 2D crystal screening
The samples were screened with a transmission electron microscope operated at
120 KV, with a magnification between 52 K× and 110 K×.
Chapter 3
Purification strategies and
assessment of purity and
homogeneity of recombinantly
expressed PLC proteins
3.1 Introduction
One of the ultimate goals of this research is to gain structural information on PLC
using electron crystallography. This method requires two-dimensional crystals of
the target protein. The probability of obtaining crystals is closely linked to the
purity of the starting material. The higher the purity of the protein, the higher the
probability of crystallisation.
Aiming to purify PLC to homogeneity, or as close as possible to that, initial
effort was put into the optimisation of recombinant PLC expression and into the
design of the purification strategy.
Various expression systems, such as insect cells (Sf9, Sf21 and High5) and
bacteria (E.coli), were explored. For each of these expression systems the pro-
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tein expression level and the solubility of the protein expressed were compared.
Furthermore, different PLC constructs were tested, either to improve the expres-
sion levels, or for the advantages they offered during the protein purification. In
this respect, constructs of full length PLC or truncated PLC (of various lengths)
were examined. Furthermore, PLC was fused with different type of tags, either
for solubility (maltose binding protein, MBP [327]) or for purification (strepII or
His6 [321, 328, 329]). E.coli was preferred over insect cells as the expression sys-
tem because it enabled expression of a larger quantity of soluble protein and in a
shorter time. The PLC constructs that expressed a high level of soluble protein
were: His6-MBP-rPLC-strepII (1258-2225 AA) and His6-MBP-PLC (1258-2225
AA). The PLC (1258-2225 AA) truncation was important because it allowed ex-
pression of soluble protein and was also particularly relevant at a functional level
because it maintained intact the Rho and Ras activation, since the catalytic and the
RA2 domains were still present. These constructs were used for protein purification
optimisation and by working on a small scale. Each stage of the purification of these
PLC constructs was analysed in detail in an attempt to increase the level of purity
or the yield achieved at any of these stages. The optimal protein preparation was
then done on a large scale, and the purified protein preparation was characterized
by SDS-PAGE, 2D-PAGE (iso-electro focusing followed by SDS-PAGE), native
gel electrophoresis, size determination by multi angular light scattering (MALS)
and imaging by EM. In order to verify that the constructs of PLC were purified
in a functional state, the PLC activity was measured and then the specific activity
was determined using the mixed micelle assay (see 2.6.2.1). Ultimately the purified
protein was used for two-dimensional crystallisation trials and functional studies.
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3.2 Results
3.2.1 PLC constructs for insect cell protein expression
Insect cells are a widely used eukaryotic expression system. This expression system
enables recombinant expression of post-translationally modified protein and of large
constructs that would be difficult to express in bacteria. In this study, insect cells
were used for the expression of the large PLC constructs (up to 230 KDa)
Three expression clones of PLC were prepared in a pDEST10 vector. These
constructs had a histidine N-terminal tag (His6) followed by a TEV cleavage site,
which allows removal of the His6-tag. All of the expression clones encode for PLC
constructs starting from the CDC25 minimal domain (543 AA), but varying at the
C-terminus. They are truncated at the RA1 domain (2095 AA), at the RA2 domain
(2225 AA) or contain the full length of the C-terminal (2281 AA). The vector maps
are shown in figure 3.1.
Two additional PLC expression clones available in the laboratory were in the
pTriEx4 multi-system expression vector. The vector maps are shown in figure 3.2.
One expression clone encodes for almost the full length of PLC from the CDC25
(402 AA) to the RA2 domain (2225 AA). The other expression clone in the pTriEx4
vector encodes for the cleavable histidine tagged PLC construct starting from the
EF hands (1258 AA) and truncated at the RA2 domain (2225 AA).
The baculoviruses of these PLC constructs (in pDEST10 or in pTriEx4 vectors)
were obtained using a replication deficient bacmid as described in section 2.4.2.1.
Protein expression and solubility were monitored for each recombinant viral
clone over time; this indicated the set of conditions that led to the highest expression
of soluble protein for each PLC construct. The conditions tested are reported in
table 3.1.
Each recombinant clone in the pDEST10 vector showed protein expression un-
der standard conditions (MOI=2 at 27 ◦C) when expressed in Sf9, but it was notable
that a large amount of the expressed protein was detected in the insoluble fraction
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Table 3.1. Summary of the PLC expression in insect cells under different conditions.
The multiplicity of infection (MOI), the temperature of incubation, and the type of insect
cell used for the time course are reported in the table below. For each sample the level
of expression and the ratio of soluble versus insoluble protein have been determined as
described in section 2.4.7.1. The set of conditions that leads to expression of soluble
protein (S), insoluble protein (I), highest level of solubility (S∗), or absence of protein
expression (-) are reported.
Construct Sf9 Sf21 High5
pDEST10-PLC (543-2095 AA) MOI = 2, 27 ◦C S* MOI = 2, 27 ◦C I MOI = 2, 27 ◦C I
minimal CDC25 → RA1 MOI = 2, 10 ◦C I MOI = 2, 10 ◦C I
pDEST10-PLC (543-2225 AA) MOI = 2, 27 ◦C S MOI = 2, 27 ◦C I MOI = 2, 27 ◦C I
minimal CDC25 → RA2 MOI = 0.5, 10 ◦C –
MOI = 1, 10 ◦C S
MOI = 2, 10 ◦C S* MOI = 2, 10 ◦C I MOI = 2, 10 ◦C I
MOI = 2, 15 ◦C –
MOI = 3, 10 ◦C S
pDEST10-PLC (543-2281 AA) MOI = 2, 27 ◦C S MOI = 2, 27 ◦C I MOI = 2, 27 ◦C I
minimal CDC25 → C-terminus MOI = 0.5, 10 ◦C –
MOI = 1, 10 ◦C S
MOI = 2, 10 ◦C S* MOI = 2 10 ◦C I MOI = 2, 10 ◦C I
MOI = 2, 15 ◦C –
MOI = 3, 10 ◦C S
pTriEx4-PLC (1258-2225 AA) MOI = 2, 27 ◦C S*
EF → RA2 MOI = 0.5, 10 ◦C S
MOI = 2, 10 ◦C S
MOI = 5, 10 ◦C S
pTriEx4-PLC (402-2225 AA) MOI = 2, 27 ◦C S
CDC25 → RA2 MOI = 0.5, 10 ◦C S*
MOI = 2, 10 ◦C S
MOI = 5, 10 ◦C S
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A) B)
C)
pDEST10rPLC (543-2095 AA)
9571 bp
Amp(R)
Gm(R) TEV recognition site
6xHis
PH domain
cat.domain- X region
cat. domain - Y region
C2 domainRA1 domain
attB1
attB2
minimal CDC25  domain
EF hands
Polyhedrin forward primer
Pc promoter PH promoter
bla promoter
f1 origin
pUC origin
Tn7L
Tn7R
pDEST10rPLC (543-2225 AA)
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Figure 3.1. Maps of expression clones of PLC in the pDEST10 vector used for baculovirus
expression. The features of the pDEST10 vector are in blue: the polyhedrin promoter to
allow high expression level of the gene of interest; TEV recognition site to cleave the His6-
tag; the attB1 and attB2 sites flank the gene of interest, inserted by the LR recombination
reaction between the entry clone of PLC and the destination vector pDEST10; the ampi-
cillin [Amp(R)] and the gentamicin [Gm(R)] resistance genes to select the transformants
in E.coli or virus respectively; the bla promoter to express the ampicillin gene; the pUC
origin to allow high copy replication and maintenance of the plasmid in E.coli and the Tn7
sites (Tn7L and Tn7R) for transposition into the bacmid DNA. The domains of PLC are
highlighted in red.
(see fig. 3.3).
To try to shift the equilibrium in favor of more soluble protein, Sf9 cultures
were incubated at a lower temperature by analogy to what it is commonly done
with bacteria. In this first attempt, the infected cells were incubated at 27 ◦C for the
first 24 hours to avoid interfering with the infection kinetics. Only after that, the
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Figure 3.2. Maps of the expression clones of PLC in pTriEx4 vector used for baculovirus
expression. The features of the destination vector, pTriEx4, are shown in blue [the CMV
promoter which mediates expression in vertebrates, the T7, the lac promoter and the pUC
origin allow high plasmid yield in E.coli, the lef-2/603 and the ORF1629 sites that allow
high expression in baculovirus infected cells, the p10 promoter is used for recombination in
the bacmid DNA, the His6-tag and the S-tag (a 15 AA tag derived from the RNase S 122)
are highlighted, and are cleavable due to the presence of the thrombin cleavage site]. The
PLC domains are shown in red.
temperature was dropped to 10 ◦C. The protein expression was not affected by the
initial higher temperature since a previous time course indicated that no protein was
expressed in the first 24 hours after infection. The ratio of soluble/insoluble protein
was higher at 10 ◦C than at 27 ◦C, but still no more than 50% (see fig. 3.4). The
insect cell types Sf21, which require serum in the medium, and High5 were used
to investigate if different cell types could express more soluble protein. However,
neither Sf21 nor High5 expressed soluble protein under any conditions trialled (see
tab. 3.1).
No major differences among the PLC constructs in pDEST10 vectors were
highlighted by comparison of the expression levels and the amount of soluble pro-
tein. Therefore efforts were focused on the two constructs containing the RA2 do-
main because these produce protein with preserved Ras-PLC interaction.
A last attempt to increase the expression of soluble protein was carried out by
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Figure 3.3. Time course of PLC expression in Sf9 upon infection with virus at MOI = 2
and incubation at 27 ◦C. The expression levels and the protein solubility of His6-PLC 543-
2095AA (A), 543-2225 AA (B) and 543-2281 AA (C) were analysed by Western blotting.
The total amount of protein expressed (T), the insoluble fraction (P), and the soluble fraction
(S) of each construct were detected by α-RA1 antibody (see tab. 2.8). The fractions T, P, S
were obtained as described in section 2.4.7.1.
using a wide range of MOI values at an incubation temperature intermediate be-
tween the two previously tested: 15 ◦C. Using a high MOI (MOI = 5 or higher)
leads to simultaneous infection of the cells and protein expression, and this might
ultimately result in an increased protein expression level. The incubation tempera-
ture affects the kinetics of protein expression and of protein folding and this might
have an impact on the expression level and on the solubility of the protein. None of
the conditions tested by varying MOI and temperature gave better results in terms of
protein solubility. The protein expression and the protein solubility of the pTriEx4
expression clones were investigated in Sf9 insect cells. The time course was re-
peated, varying the incubation temperature and the MOI. In the case of the PLC
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Figure 3.4. Partial time course of recombinant viral clones in Sf9 upon infection with a
MOI = 2 and incubation at 10 ◦C. The expression and solubility levels of (A) His6-PLC
(543-2225 AA) and (B) His6-PLC (543-2281 AA) (arrow) analysed by Western blotting.
The total amount of protein expressed (T), the insoluble fraction (P), and the soluble fraction
(S) were probed with α RA2 antibody (see tab. 2.8). The fractions T, P, S were obtained
as described in section 2.4.7.1. The best results obtained for His6-PLC (543-2225 AA) or
His6-PLC(543-2281 AA) were obtained after 130 hours of incubation.
(1258-2225 AA), the temperature affected protein expression, but not the protein
solubility. Lowering the temperature to 10 ◦C caused a significant reduction in pro-
tein expression. The best set of expression conditions for the His6-PLC (1258-2225
AA) construct was infection of a Sf9 culture with virus at MOI = 2 and incubation
at 27 ◦C for 61 hours (see fig. 3.5).
The time courses of the pTriEx4-PLC (402-2225 AA) showed that the incu-
bation temperature affected both the protein expression and the protein solubility.
Despite the reduction in protein expression, an increase of the protein solubility was
observed on lowering the incubation temperature to 10 ◦C. This made the lower in-
cubation temperature (10 ◦C) preferred, since it is possible to compensate for the
reduced protein expression by scaling up the insect cell culture. The best expression
conditions for pTriExPLC (402-2225 AA) in Sf9 were a MOI = 0.5 and incubation
at 10 ◦C for 37 hours.
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Figure 3.5. Partial time course of pTriEx4 PLC expression analysed by Western blotting.
Expression and solubility levels of (A) His6-PLC (1258-2225 AA) (arrow) in Sf9 culture
upon infection with a MOI = 2 and incubation at 27 ◦C and (B) His6-PLC (402-2225 AA)
(arrow) in Sf9 culture upon infection with a MOI = 0.5 and incubation at 10◦C. The total
amount of protein expressed (T), the insoluble fraction (P) and the soluble fraction (S) were
probed by with α RA2 antibody (see tab. 2.8). The fractions T, P, S were obtained as
described in section 2.4.7.1. The best result for His6-PLC (1258-2225 AA) was obtained
after 61 h of incubation and for His6-PLC (402-2225 AA) after 37 h of incubation.
3.2.2 Expression of PLC in insect cells
The pTriEx4-PLC constructs were expressed in Sf9 on an intermediate scale (500
ml) according to the best conditions outlined by the time course studies. These
samples were used to screen various lysis buffers, the effect of protamine sulfate
and then to measure the PLC activity of the protein expressed. For each Sf9 cul-
ture infected, three lysis buffers were tested: CytoBuster, washing buffer A, and
washing buffer A plus addition of detergent (1% v/w dodecyl maltoside, DM), see
section 2.4.7.2. Cytobuster was found to allow a higher protein recovery with PLC
(1258-2225 AA), while the washing buffer A (see sec. 2.1) was found to be the
best choice for PLC (402-2225 AA). In the latter case, the protein recovery did
not increase in the presence of detergent. Having obtained similar results by us-
ing lysis buffer with or without detergent, the lysis buffer without detergent was
preferred since at a later stage the detergent could perturb the lipid monolayer in
two-dimensional crystallisation trials. In both samples protamine sulfate improved
the protein recovery.
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Activity measurements were performed to investigate whether PLC was ex-
pressed in its active form before proceeding to large scale expression. For this
purpose and to distinguish the basal from endogenous PLC activity, a suitable con-
trol needed to be used. A small GTPase, RhoB, was chosen as control for the
pTriEx4-PLC constructs because it was cloned in the same vector. RhoB was ex-
pressed in Sf9 under the same conditions as PLC (1258-2225 AA) (MOI = 2, at
27 ◦C for 61 hours) or of PLC (402-2225 AA) (MOI = 0.5, 10 ◦C for 37 hours).
The infected cells (500 ml) were harvested and lysed with washing buffer A. The
crude lysate of each construct, His6-PLC (402-2225 AA), His6-PLC (1258-2225
AA) and RhoB, were loaded in parallel on spin nickel chelating columns (CV =
200 μl, from Qiagen) and eluted in one step (2 min. at 890 × g). The elution frac-
tions containing PLC or RhoB were used to measure PLC activity using the mixed
micelle assay (see sec. 2.6.2.1). The comparison of these activity measurements
showed that the two PLC constructs, His6-PLC (1258-2225 AA) and His6-PLC
(402-2225 AA), were expressed in their active forms (data not shown), thus it was
reasonable to perform protein expression on a larger scale (6 × 500 ml) using these
methods to attempt protein purification and to analyse the state of the protein by
EM (data not shown).
The conditions of infection and incubation used for the His6-PLC (402-2225
AA) construct allowed reproducible expression of soluble protein (data not shown).
In the first attempt, a four-step protein purification was performed. Initially ion
exchange chromatography, using a (strong anion exchange) mono Q column, was
performed to remove traces of Sf9 medium because a component of this has been
reported to cause nickel leakage from the nickel-chelating column. The appropriate
elution fraction was loaded onto a nickel-chelating HisTrap column (affinity chro-
matography). At this stage, only a little material was recovered and without much
increase in purity (data not shown). In the following stage, the protein was loaded
onto a heparin column (ion exchange chromatography), and at the last stage onto
a size exclusion column (gel filtration chromatography). The column profile of the
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gel filtration showed one peak eluted in the void volume and a second peak with a
longer retention than expected for PLC (402-2225 AA) molecular weight (≈ 205
KDa). This suggested that the PLC (402-2225 AA) was either an aggregate or
degraded (data not shown).
Effort was then focused on purification of the His6-PLC (1258-2225 AA) pro-
tein. The conditions of infection and incubation used for His6-PLC (1258-2225
AA) allowed the reproducible expression of soluble protein (data not shown). The
strategy used to purify His6-PLC (402-2225 AA) was applied to the His6-PLC
(1258-2225 AA) construct with one adaptation. In this case, the initial ion exchange
chromatography (mono Q column) was skipped in order to increase the His6-PLC
(1258-2225 AA) recovery at the end of the purification process. Despite the lack of
the initial ion exchange purification step, nickel leakage from the HisTrap column
was negligible (based on the analysis of the flow through fraction and on the yield
of the protein after this first purification step) and sufficient protein was recovered
at the end of the purification process. However, the HisTrap elution fractions con-
taining PLC showed a lower degree of purity than was expected from an affinity
column (data not shown). In the following purification step, ion exchange chro-
matography was performed, using a heparin column, resulting in more concentrated
PLC, but the purity increased only marginally (data not shown). The elution frac-
tions that contained His6-PLC (1258-2225 AA), were pooled together and loaded
on a gel filtration column (Superdex 200 16/60). The major peak was observed at a
retention corresponding to about ≈ 100 KDa which matches the molecular weight
of the expressed protein (≈ 104 KDa), see figure 3.6, A. Western blotting showed
that His6-PLC was present in the main peak from gel filtration (see fig. 3.6, B).
However, the protein recovery at the end of the purification process was extremely
low (≈ 0.1 mg/l of bacterial culture).
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Figure 3.6. (A) Column profile showing the UV280nm trace (blue line) of the gel filtration
(Superdex 200 16/60) of His6-PLC (1258-2225 AA). The fractions analysed by Western
blotting are marked with the blue line. (B) Western blotting of the gel filtration elution
fractions (1, 2 and 3) probed with αHis antibody. The bands indicated by the arrow are
identified as His6-PLC (1258-2225 AA).
3.2.3 PLC constructs for bacterial protein expression
Constructs of truncated PLC (1258-2225 AA) with the same truncation as the con-
struct expressed in Sf9, were expressed in E.coli C41 DE3 cells in an attempt to
increase the level of expression or to reduce the time required for protein expression
(compared to Sf9 cells).
The PLC constructs available for bacterial protein expression have been cloned
(by Dr. Bunney, The Institute of Cancer Research) into a pIVEX-MBP vector,
which allows the recombinant expression of proteins with an N-terminal His6-tag
fused to maltose binding protein (MBP) that can be removed by TeV clevage. In
particular, the available constructs expressed His6-MBP-rPLC-strepII (1258-2225
AA) and His6-MBP-rPLC (1258-2225 AA), where the His6-tag was intended to
be used for the protein purification and the MBP to enhance the protein solubil-
ity [327]. The vector maps are in figure 3.7.
Initially, the expression of the His6-MBP-rPLC-strepII (1258-2225 AA) con-
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Figure 3.7. Vector maps of (A) pIVEX-MBP-rPLC-strepII (1258-2225 AA) and of (B)
pIVEX-MBP-PLC (1258-2225 AA) plasmids. The features of the pIVEX-MBP vector
are in blue [the Tn7 promoter (Tn7-P), the ribosomal binding site (RBS); the His6-tag, the
MBP gene; the TeV protease cleavage site; the ampicillin resistance genes (Amp-R) to
select the transformants in E.coli; the Tn7 terminator (Tn7-T)]. The strepII tag (NWSH-
PQFEK) binds to streptavidin reversibly with a Kd = 72 μM [330]. The domains of PLC
are highlighted in red.
struct was preferred as the tags at the N- and C-termini provided the potential for
full length selection. Each step in the expression and purification was analysed in a
systematic way to decide whether it was possible to optimise the procedure.
The pIVEX-rPLC-strepII (1258-2225 AA) and the pRARE plasmids were used
to co-transform E.coli C41 DE3 cells as described in section 2.3.2. The plasmid
pRARE over-expresses tRNA codons for Gly, Arg, Leu and Pro which are rarely ex-
pressed in E. coli, thereby improving the protein expression of His6-PLC-strepII
(1258-2225 AA). The solubility and the quality of the protein expressed were anal-
ysed on a time course. The time course was repeated for various OD600nm of induc-
tion, IPTG concentrations and temperatures of incubation (see fig. 3.8).
The cell density at the induction point affected the amount of protein expressed.
The expression level increased proportionally with the cell density until an OD600nm
= 0.5 and stabilised at higher absorbance values where the degradation products
were more evident. Harvesting at OD600nm = 1 allowed the maximum protein re-
covery. At higher values the degradation products predominated. No further in-
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Figure 3.8. Protein solubility time course of the His6-MBP-rPLC-strepII (1258-2225 AA)
construct (≈ 150 KDa). For different incubation times (0, 2, 4, 6 hours or O/N), the pro-
tein contained in the pellet (P) and the supernatant (S) fractions, was detected by Western
Blotting (α His5 antibody, see table 2.8). The band of His6-MBP-rPLC-strepII (1258-2225
AA) is indicated by the arrow.
crease in the expression level was detectable for higher IPTG concentrations (data
not shown). These analyses identified the set of conditions that led to the highest
expression level of soluble His6-MBP-rPLC-strepII. For this construct the best re-
sult was obtained by inducing the bacterial culture at an OD600nm = 0.5 with 1 μM
final concentration of IPTG, and incubating it at 20 ◦C until an OD600nm = 1.
This set of conditions was used to express His6-MBP-rPLC-strepII on a small
scale and then to optimise the purification strategy. To exclude the possibility that
the two purification tags of the constructs (His6-tag and strepII) were buried within
the protein and therefore not accessible, these two tags were probed by antibody
labeling under native conditions. Both tags were successfully detected by the αHis5
and αstrepII antibodies. This suggested that these tags were accessible to the anti-
body and probably exposed, therefore both of them could be used for purification.
Since one tag was placed at the N-terminus and the other at the C-terminus, in prin-
ciple the full length His6-MBP-rPLC-strepII construct could be selected in two
purification steps, one that targets the His6-tag and the other that targets the strepII-
tag.
The purification strategy was optimised working with 2 × 1 litre batches of
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bacterial culture. The purification was repeated on analogous batches changing only
one parameter at a time. The protein purity achieved for each attempt was compared
by SDS-PAGE in order to evaluate which was the best purification strategy.
The first step was affinity chromatography, which exploited the His6-tag using a
nickel chelating HisTrap column (see sec. 2.5.2.1). This purification step increased
greatly the purity of the target protein. The band of the target protein (≈ 150 KDa)
could hardly be identified in the mixture loaded on the column, but it became the
second strongest band (the major band was detected at ≈ 70 KDa) identified in the
SDS-PA gel of the elution fractions from the column. The HisTrap elution fractions,
which contained the His6-MBP-rPLC-strepII target protein, were pooled together
and loaded into a Strep-Tactin batch column. The His6-MBP-rPLC-strepII was
detected in the flow through (data not shown), even when the protein loaded on
the Strep-Tactin column was below the maximum capacity of the column thereby
suggesting that the strepII tag could have been inaccessible to the streptavidin im-
mobilised on the column, although His6-MBP-rPLC-strepII was successfully de-
tected by the anti-strepII antibody under native conditions. The protein recovery at
this stage was quite low and the level of purity did not significantly increase after
the second affinity chromatography column. For these reasons, the results obtained
with the second affinity column were considered unsatisfactory. Since the strepII tag
was not useful for purification, attention was shifted to the construct that expressed
His6-MBP-rPLC (1258-2225 AA). Wild-type His6-MBP-rPLC (1258-2225 AA)
was expressed in E.coli C41 DE3 pRARE cells. Protein expression was induced
at OD600nm = 0.5 with 1 μM final concentration of IPTG, and the bacterial culture
was incubated at 20 ◦C until OD600nm = 1. These were identified as the best set of
conditions for expression of soluble His6-MBP-rPLC (1258-2225 AA) by the time
course (data not shown).
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3.2.4 Purification optimisation of wild-type His6-MBP-rPLC (1258-
2225 AA)
All steps in the purification process of wild-type His6-MBP-rPLC (1258-2225
AA), ≈ 150 KDa, from the cell lysate preparation to the last chromatography
column, were systematically analysed in order to optimise the protein purification
strategy. The assessment of the results obtained for any purification attempt were
based on the appearance of the band for the purified protein by SDS-PAGE and
by EM imaging. The wild-type His6-MBP-rPLC (1258-2225 AA) was expressed
in E.coli C41 DE3 pRARE cells as described in section 3.2.3, and the cells were
harvested as described in section 2.3.5. The harvested cells were lysed either imme-
diately or after freezing. Immediate lysing was favored as it led to greater protein
homogeneity. Various methods to break the cells apart were compared. Mechani-
cal breaking, by sonication and by pressure, was compared with chemical breaking
using a detergent. When the French press was used to break the cells open by pres-
sure, a significant increase in protein recovery at the first step of purification was
observed. Despite the higher yield, this method was not continued as EM analysis
of the protein showed protein folding problems and aggregates. Sonication was pre-
ferred to detergent because the detergent might interfere with the lipid monolayer
of the two-dimensional crystallisation trials. The first stage of the purification was
affinity chromatography by using a HisTrap column (see sec. 2.5.2.1). This column
recognises and binds to the His6-tag of the protein. The protein was eluted over a
gradient of imidazole (from 20 mM to 300 mM, see fig. 3.9). At this stage, a slight
improvement in purity was achieved by increasing the imidazole concentration in
the cell lysate and in the washing buffer of the column.
The second stage in the purification process was ion exchange chromatogra-
phy. A MonoQ column and a heparin HiTrap column were tested. MonoQ is a
strong anion exchange column, while the heparin column is a cation exchange col-
umn. However, the heparin column can also be considered an affinity column since
3.2 Results 138
FT1 FT2 W1 W2
%
 e
lu
ti
o
n
 b
u
ff
e
r
0%
100%
1        2       3
EF
A)
B)
0
1000
2000
3000
4000
mAU
0 50 100 150 ml
250 KDa
W1FT1 FT2 E.F.W2
150 KDa
100 KDa
75 KDa
50 KDa
1        2       3
Figure 3.9. Profile of the nickel chelating HisTrap column visualised by absorbance at
280 nm (A) and by SDS-PAGE (B). The cartogram reports the absorbance at 280 nm (blue
line), the elution gradient of imidazole (green line), and the fractions collected (red dashed
line). The SDS-PA gel after Coomassie based staining shows the total protein present in
the mixture loaded (L) on the nickel chelating column, the first and the last flow through
(FT1-FT2), the first and the last washing (FT1-FT2) and the elution fractions (EF 1-3). The
bands indicated by the blue arrow are identified as His6-MBP-rPLC (1258-2225 AA).
its functional binding group (-SO3−) mimics the PLC substrate (-O-PO32−). The
MonoQ column was not found to be selective and PLC was detected in a few re-
solved peaks (data not shown). The heparin HiTrap column gave better results. This
column increased significantly the level of purity of His6-MBP-rPLC (1258-2225
AA) and the protein concentration. The band of the target protein was the most
intense band visible in the SDS-PAGE gel (see fig. 3.10). Only a few more bands of
weak intensity were detected in addition to the band for His6-MBP-rPLC (1258-
2225 AA), and these bands were detected at lower molecular weight than the target
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band. The native gel electrophoresis showed only one band thereby suggesting ho-
mogeneity of the protein preparation in terms of surface charge and shape.
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Figure 3.10. Profile of the heparin column visualised by absorbance at 280 nm (A) and
by SDS-PAGE (B). The stained native gel of the elution fractions (EF 1-3) of the heparin
column (C). The cartogram reports the absorbance at 280 nm (blue line), the elution gradient
of imidazole (green line), and the fractions collected (red dashed line). The SDS-PA gel
after Coomassie based staining shows the total protein present in the mixture loaded (L)
on the nickel chelating column, the first and the last flow through (FT1-FT2), the first and
last washing (W1-W2) and the elution fractions (EF 1-3). The bands indicated by the blue
arrow are identified as His6-MBP-rPLC (1258-2225 AA).
The last step in the purification process was a gel filtration chromatography (see
sec. 2.5.2.3), using the Superdex 200 column, which resolves proteins with sizes in
the range of the target protein (≈ 150 KDa), see section 2.5.2.3. The SDS-PA gel
showed a main band that corresponded to the full length of His6-MBP-rPLC, but
also bands of weaker intensity at a lower molecular weight.
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Figure 3.11. (A) Column profile showing the UV280nm trace (blue line) of the gel filtration
(Superdex 200 s6/60) of His6-MBP-rPLC (1258-2225 AA), the fractions collected (red
dashed line). (B) The SDS-PA gel after Coomassie based staining shows the total protein
present in the gel filtration elution fractions (EF 1-3). The bands indicated by the blue arrow
are identified as His6-MBP-rPLC (1258-2225 AA).
3.2.5 Wild-type His6-MBP-rPLC (1258-2225 AA) characterisa-
tion
The wild-type His6-MBP-rPLC (1258-2225 AA) preparation obtained at the end
of the purification process was further characterised by MALDI mass spectroscopy,
two-dimensional gel electrophoresis (the first dimension was iso-electro focusing
and the second dimensions was SDS-PAGE), the protein size and size distribution
by multi-angular light scattering analysis (MALS), in vitro activity measurements
and EM imaging.
SDS-PAGE on the His6-MBP-rPLC eluted from the gel filtration resolved only
a few additional bands of weaker intensity at lower molecular weight to the target
band. The contents of these bands where analysed by mass spectroscopy in order to
identify them. The main band visible by SDS-PAGE was identified as PLC (data
not shown). A few of the bands at lower molecular weight than the full length PLC
were also identified as PLC. These data suggested that problems occurred after the
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expression and related to the folding of the protein. The protein might be cleaved
in exposed loops, and while it holds together under native conditions, the fragments
separate in denaturing conditions. This is also in agreement with the observation
that the native gel showed only one band (recognised by Western blotting as PLC).
The charge and size homogeneity of the wild-type His6-MBP-rPLC (1258-
2225 AA) preparation was also evaluated by two-dimensional gel electrophoresis on
the elution fraction from gel filtration. The stained gel showed one main band of ≈
150 KDa and a very small band at similar molecular weight, but slightly shifted to-
ward an higher pI. This suggested that a very small portion of the protein molecules
have a different pI due to a difference in charge.
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Figure 3.12. Silver stained 2D gel loaded with wild-type His6-MBP-rPLC (1258-2225
AA) eluted from a gel filtration column, the last step of the purification process. The two-
dimensional gel electrophoresis consisted of isoelectro focusing electrophoresis on the first
dimension (where at pH values higher than the pI, the protein is negatively charged and is
driven toward the anode) and SDS-PAGE in the second dimensions. The protein migration
is represented by the dotted line.
MALS was performed on the elution fraction from the analytical gel filtration
column (BioSep-SEC-S3000) as described in section 2.5.3.5. The MALS data were
collected as a function of the UV280nm profile of the column. Only one peak was
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detected by UV280nm which had a retention time in agreement with the expected
molecular weight of His6-MBP-rPLC (1258-2225 AA). The molecular weight was
calculated to be 155.5 KDa ± 1% by MALS analysis across the central area of
the UV280nm peak (see fig. 3.13 and 3.15). This indicated that the protein was
homogenous in size.
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Figure 3.13. MALS analysis (green line) and UV280nm absorbance (red line) of the elution
fraction of gel filtration column (BioSep-SEC-S3000) loaded with the protein preparation
of wild-type His6-MBP-rPLC (1258-2225 AA).
Furthermore, these data were consistent also with EM imaging of the negatively
stained protein preparation (see fig. 3.14). The His6-MBP-rPLC (1258-2225 AA)
particles at the end of the optimised purification process appeared homogeneous in
size.
The PLC activity was measured in vitro using the mixed micelle assay (see
sec. 2.6.2.1). Measurements made at each step of the protein purification showed
an increase in PLC specific activity along the purification process (see fig. 3.16.
The activity measurements ensured that the purified protein was active and
the specific activity was calculated to be 26.7 ± 0.3 mmol of PtdIns(4,5)P2 hy-
drolised/mg of PLC/min.
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Figure 3.14. Single particles of wild-type His6-MBPrPLC (1258-2225 AA) in negative
stain imaged by EM. The green square highlights a typical particle of His6-MBPrPLC
(1258-2225 AA). The particles are approximately 10 nm in length. The EM grid was pre-
pared with fresh His6-MBPrPLC immediately after elution from the gel filtration column
and stained with 2% w/w uranyl acetate.
3.3 Discussion
The recombinant expression and strategy of purification of PLC were analysed in
detail in order obtain highly pure protein to pursue structural studies. Various con-
structs of PLC were expressed recombinantly. These constructs were designed to
have full length or truncated PLC fused to tags that increased the protein’s solu-
bility (MBP), or to improve the purification (His6 or strepII tags). Two different
expression systems were considered: insect cells (Sf9, Sf21 and High5) and bacte-
ria (E.coli C41 DE3). Almost full length PLC (402-2225 AA) could be expressed
in Sf9, but it could not be purified as a monomer. A truncated construct of PLC
(1258-2225 AA) could be successfully expressed in Sf9 and purified as a monomer.
The truncated PLC (1258-2225 AA) could also be expressed in E.coli C41 DE3
fused to MBP as His6-MBP-PLC (1258-2225 AA). The bacterial expression sys-
tem was favored over the insect cells since it gave higher amounts of protein in
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Figure 3.15. An example set of class averages of wild-type His6-MBP-rPLC (1258-2225
AA) particle images, which were obtained by EM.
a shorter time. The His6-MBP-PLC (1258-2225 AA) was purified close to homo-
geneity in three stages. The purity of His6-MBP-PLC (1258-2225 AA) was greatly
increased by exploiting the His6-tag and performing affinity chromatography. In-
deed, since the introduction of the His6-tag by Hochuli and co-workers [291], it has
become one of the most widely used tags for protein purification [328] [329]. In
the second stage of purification, ion exchange chromatography was performed. It
resulted in a further increase in purity of His6-MBP-PLC. The last stage of the
purification was gel filtration which separated the aggregates from the monomeric
protein.
The size and the size distribution of the final product of the purification was
analysed by MALS which indicated a homogeneous size average of 155.5 KDa ±
1% and which was in agreement with the molecular weight estimated based on the
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Figure 3.16. Total PLC protein recovered at each stage of protein purification and the
corresponding specific activity [mmol of PtdIns(4,5)P2 substrate hydrolysed]. The total
protein concentration was measured according to the Bradford procedure and the activity
according to the mixed micelle assay (see sec. 2.6.2.1). The data are presented as the mean
± 5% in which the individual values are contained. The specific activity of the purified
His6-MBPrPLC are comparable with data reported in literature [58].
sequence (150 KDa) and with the molecular weight indicated by SDS-PAGE. The
purified protein His6-MBP-PLC (1258-2225 AA) also showed high homogeneity
relative to the surface charge and the pI by native gel and 2D gel electrophoresis.
The stained native gel showed only one band. The 2D gel showed a main constituent
plus a very small proportion of another PLC related protein having a slightly dif-
ferent pI and smaller molecular weight.
The protein expressed and purified was functional and the activity was measured
in vitro. The specific activity was measured 26.7 ± 0.3 mmol of PtdIns(4,5)P2
hydrolised/mg of PLC/min, which is in agreement with data in the literature [58].
The yield of the recombinant expression in E.coli C41 DE3 and the recovery
of the soluble protein was satisfactory (≈ 0.5 mg/liter of bacterial culture). The
purification achieved with His6-MBP-PLC (1258-2225 AA) was sufficiently high
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to pursue structural studies. Besides protein purification, the His6-tag can serve
other applications such as protein immobilisation exploiting its affinity for metals,
which would be extremely useful for two-dimensional crystallisation. Furthermore,
although the PLC was truncated (1259-2225 AA), it maintained the Ras activa-
tion (Rho, Ras and Rap) making this construct particularly appealing for functional
studies (see sec. 4).
Chapter 4
Functional studies using FRET to
test protein-protein interaction and
possible conformational changes
4.1 Introduction
Förster Energy Transfer (FRET) is a widely used technique to study co-localisation
of two molecules in vivo as well as in vitro. It requires the labelling of the
molecules of interest with a compatible FRET pair of fluorophores identified as
donor and acceptor. A compatible FRET pair is identified by sufficient overlap
between the emission spectrum of the donor with the excitation spectrum of the ac-
ceptor. Such an overlap is necessary if sufficient energy transfer is to occur upon
excitation of the donor, given proximity to the acceptor (typically ≤ 10 nm [331]).
The FRET efficiency (E) is a function of the distance between the fluorophores (R)
as described by the equation 4.1 and visualised in figure 4.1:
E =
R60
R60 +R
6
(4.1)
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where: the Förster distance (R0) is the distance between the specific flurophore pair
for which the FRET efficiency (E) is half of the total.
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Figure 4.1. FRET efficiency (E) as a function of the distance between the donor and the
acceptor (R) for an arbitrary Förster radius R0.
Based on the correlation between FRET efficiency and the distance between the
fluorophores, FRET measurements can be used to determine the distance between
the two labeled molecules (inter-molecular FRET) or to study conformational dy-
namics when both dyes are in the same molecule (intra-molecular FRET).
In the literature, there are several examples where FRET has been used to clarify
signaling cascade and protein-protein interaction [123, 332–335]. The aim of this
work is to investigate the PLC-Ras interaction using inter-molecular FRET and to
use these data to determine the Kd of binding. In a following stage, the aim is to
clarify the activation mechanism in light of the two possible mechanisms that have
been proposed. It has been proposed that either translocation of the effector to the
membrane, as result of the interaction with the transducer, is sufficient to activate the
protein [336], or that both a conformational change and translocation are necessary
to achieve full activation of the effector [25, 36].
For this investigation, Ras and PLC constructs suitable to detect inter-molecular
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binding and possible PLC intra-molecular conformational changes by FRET in
vitro have been chosen.
In order to measure inter-molecular binding, the following constructs were used:
a truncated construct of PLC (which can be expressed in bacteria and maintain the
Ras activation) tagged at the C-terminus with enhanced green fluorescent protein
(eGFP) as the donor; K-Ras tagged at the N-terminus with monomeric cherry flu-
orescent protein (mCherry) as the acceptor. The constructs were expressed in bac-
teria and purified before proceeding with further experiments. In the first instance,
it was verified that the purified binding partners were able to recognise and bind
to each other using both sedimentation and inter-molecular FRET. Both techniques
indicated that K-Ras binds PLC in a guanine nucleotide dependent fashion. Fur-
thermore, based on the inter-molecular FRET data, the K-Ras-PLC binding con-
stant (Kd) was quantified for the specific conditions in which the experiment was
conducted.
The possibility of long range PLC inter-molecular conformational changes was
also investigated. A conformational change caused by H-Ras binding could result
in PLC activation. Such a finding would help to clarify the mechanism of activa-
tion. In this respect, a construct expressing truncated PLC flanked between mRFP
(on the N-terminus of PLC) and eGFP (on the C-terminus of PLC) was puri-
fied to homogeneity from bacteria and used for intra-molecular FRET. The inter-
molecular binding between PLC and H-Ras was verified by sedimentation assay;
intra-molecular FRET was monitored in the presence of increasing amounts of H-
Ras in vitro.
In these experiments, the FRET efficiency (E) was calculated based on the av-
erage lifetime (τm) of the donor in the presence (DAτm) and absence (Dτm) of the
acceptor [331] as follows:
E = 1−
DAτm
Dτm
(4.2)
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τm =
α1τ
2
1 + α2τ
2
2
α1τ1 + α2τ2
(4.3)
The distance between the two fluorophores (R) was calculated based on equation
4.1 and the Föster distance (R0), which has been reported in literature for the specific
FRET pair that was used here [337, 338].
Another measurable property associated with FRET that was monitored in these
experiments was the reduction of polarisation anisotropy of the emitted signal. The
polarisation anisotropy of the emission is correlated to the polarisation of the exci-
tation by its rotational correlation time. Variation in polarisation of the emitted light
gives the rotational correlation time (φ) of each fluorophore using the following
relationship:
r(t) =
n∑
1=1
βi exp
(−t/φi) (4.4)
where βi is the pre-exponential factor. Since the rotational correlation time is
a function of the size of the fluorophore, the calculated rotational correlation time
can give an insight into the size of the fluorophore or of the molecule (or complex)
to which the fluorophore belongs.
4.2 Results
4.2.1 Expression and purification of PLC construct
E. coli C42 DE3 were co-transformed as described in section 2.3.2 with pTriEx4-
PLC-eGFP (1258-2258 AA) (see fig 4.2, A) and pRARE (Novagen). The plasmid
pRARE over-expresses tRNA codons for Gly, Arg, Leu and Pro, which are rarely
expressed in E. coli, thereby improving the protein expression of His6-PLC-eGFP
(1258-2258 AA) [339]. The protein was expressed as described in section 2.3.5 and
the cell lysate was prepared as in section 2.5.1.
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Figure 4.2. (A) Vector map of pTriEx4-PLC-eGFP (1258-2258 AA) plasmid. The features
of the vector, pTriEx4, are shown in blue (the CMV promoter, the T7 promoter, the lac pro-
moter and the pUC origin allow high plasmid yield in E.coli; the lef-2/603, the ORF1629
sites, the ampicillin resistance gene, the p10 promoter, and the His6-tag); the features of the
expressed protein are shown in red. (B) Coomassie stained SDS-PA gel of the purification
precess of His6-PLC-eGFP (1258-2258 AA); (C) specific activity of the purified wild-type
His6-PLC-eGFP (1258-2258 AA). Data are presented as the mean ± standard deviation
of three independent measurements. (D) Coomassie stained native gel of His6-PLC-eGFP
(1258-2258 AA) at the end of the purification process.
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The protein was purified close to homogeneity in three chromatography steps
(see fig. 4.2, B). The first step was affinity chromatography which exploited the
His6-tag (see sec. 2.5.2.1). This purification step increased greatly the purity of the
target protein. The band of the target protein could hardly been identified by SDS-
PA gel in the mixture loaded on the column, but it became the second strongest
band (the major band was detected at ≈ 70 KDa) identified in the SDS-PA gel of
the elution fractions from the column (see fig. 4.2, top gel). The second step was an
ion exchange chromatography using an Heparin column (see sec. 2.5.2.2). With this
second purification step the major band detected at ≈ 70 KDa in the previous gel
was removed increasing the level of purity of the target protein (see fig. 4.2, middle
gel). Furthermore, this second purification step was exploited to concentrate the
target protein by using a steep elution gradient. The third step was gel filtration
chromatography using a Superdex 200 16/60 column, which is suitable to resolve
proteins in the size range of the target protein (≈ 150 KDa) (see sec. 2.5.2.3).
The elution fractions, characterised by the retention time of the target protein, were
analysed by SDS-PAGE (see fig. 4.2, bottom gel). The major band detected on
the SDS-PA gel had the molecular weight of the monomeric target protein. These
data (the UV trace and SDS-PA gel) ensured the target protein was in a monomeric
state under native conditions. The band of the target protein was by far the major
band detected on the gel (a little above 150 KDa marker). Only three minor bands
corresponding to proteins with a molecular weight between 150 KDa and 100 KDa
were detected. Comparison between the band intensities of the target protein and
of the other three bands indicated a sufficiently high the level of purity of the target
protein to proceed with further experiments. To ensure that the protein was purified
in its active functional state, the specific activity was measured as described in sec.
2.6.2.1.
With singly labeled PLC in hand, the pTriEx4-mRFP-PLC-eGFP plasmid (see
fig. 4.3, A) coding for doubly labeled wild-type His6-mRFP-PLC-eGFP (1258-
2258 AA) was used to co-transform E .coli C42 DE3 with pRARE cells. The protein
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of interest was expressed and purified similarly to His6-PLC-eGFP as described
above.
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Figure 4.3. (A) Vector map of pTriEx4-mRFP-PLC-eGFP (1258-2258 AA) plasmid; (B)
Coomassie stained SDS-PA gel loaded with the pool of the elution fractions containing
wild-type His6-mRFP-PLC-eGFP (1258-2258 AA) (arrow) out of each chromatography
stage [affinity chromatography (1), ion exchange chromatography (2) and size exclusion
(3)]; (C) specific activity of the purified His6-mRFP-PLC-eGFP (1258-2258 AA). Data
are presented as the mean ± standard deviation of three independent measurements.
The elution fractions of the first purification column containing the target pro-
tein were pooled together and analysed by SDS-PAGE. The SDS-PA gel of this
mixture showed the band of the target protein (≈ 180 KDa) and a band of com-
parable intensity at slightly lower molecular weight (see fig. 4.3, B-1). After the
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second purification step, a reduced number of the minor bands (especially for the
bands detected in the area between the 75 KDa marker and the front of the gel)
were visualised on the SDS-PA gel (see fig. 4.3, B-2). The elution fractions from
the size exclusion chromatography characterised by the retention time of the tar-
get protein were analysed by SDS-PAGE. In these fractions, the band immediately
below the target protein was hardly detectable on SDS-PA gel (see fig. 4.3, B-3),
resulting in an increased level of purity of the target protein. The activity measure-
ments proved that the purified wild-type His6-mRFP-PLC-eGFP (1258-2258 AA)
was catalytically active (see fig. 4.3, C).
4.2.2 Expression and purification of Ras constructs
E. coli C42 DE3 were transformed as described in 2.3.2 with pTriEx4-mCherry-
K-Ras (1-189 AA) encoding for wild-type His6-mCherry-K-Ras full length (1-189
AA) of which the His6 could be removed by thrombin digestion (see fig. 4.4, A).
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Figure 4.4. (A)Vector map of pTriEx4-mCherry-K-Ras, (B) Coomassie stained SDS-PA
gel loaded with the pool of the elution fractions containing mCherry-K-Ras (1-189 AA)
wild-type (arrow) after the first affinity chromatography (1) and size exclusion (2).
The protein was expressed as described in section 2.3.5 and the cell lysate was
prepared as in section 2.5. The protein was purified in three chromatography steps.
In the initial affinity chromatography step (see sec. 2.5.2.1), the His6-tagged pro-
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tein was selected using a nickel chelating column, increasing greatly the purity of
the protein (see fig. 4.4, B-1). The His6-tag cleavage was almost complete upon
over-night thrombin digestion at 4 ◦C (data not shown). The cleaved mCherry-K-
Ras (1-189 AA) was separated from the residual non cleaved protein by repeating
the affinity chromatography as described above, but this time collecting the flow
through. In the third step of purification, gel filtration chromatography was per-
formed using a Superdex 75 26/60 column because it is able to resolve proteins in
the size range of the target protein (≈ 50 KDa). This step increased the level of
purity of mCherry-K-Ras and only two bands in addition to the band of the target
protein were detected on the SDS-PA gel (see fig. 4.4, B-2).
The pTriEx4-hH-Ras plasmid expressing wild-type His6-H-Ras (1-166 AA) was
used to transform E.coli C42 DE3 cells. The protein of interest was expressed and
purified as described above (see fig. 4.5).
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Figure 4.5. (A) Vector maps of pTriEx4-H-Ras, (B) Coomassie stained SDS-PA gel loaded
with GDP and GTP loaded purified H-Ras (1-166AA).
4.2.3 Binding studies between mCherry-K-Ras and PLC-eGFP
The donor (eGFP) and the acceptor (mCherry) fluorophores of the FRET pair were
expressed on the C-terminus of PLC and N-terminus of K-Ras respectively. These
specific positions of the fluorophores are commonly used, however they can lead to
false negative readouts if the distance between the fluorophores is above the FRET
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threshold of ≈ 10 nm [331], even if the two molecules are in fact bound to each
other. For this reason, it was necessary to ensure binding between the mCherry-K-
Ras and PLC-eGFP using an alternative and additional method. The binding ca-
pability of the two purified proteins was tested by pull-down using nickel-chelating
beads as described in section 2.8.2. An equal amount of His6-PLC-eGFP (6 μM)
was immobilised on the nickel chelating beads via the His6-tag as shown by West-
ern blotting (see fig. 4.6, A). For each concentration of either GDP (or GTPγS)
loaded mCherry-K-Ras tested, mCherry-K-Ras was detected bound to the immo-
bilised effector. No GDP or GTPγS mCherry-K-Ras was sedimented in the absence
of the effector (and vice versa), thereby verifying the specificity of binding (data not
shown). This experiment not only verified that inter-molecular binding was taking
place, but it also demonstrated in a semi-quantitative manner the guanine nucleotide
dependency of the binding. Thus, for equivalent amounts of PLC-eGFP bound to
the beads, a significantly higher proportion of GTPγS loaded mCherry-K-Ras was
detected bound to the immobilised effector than GDP loaded mCherry-K-Ras at
the same concentration (see fig. 4.6, B). The GDP/GTP dependency tends to be
less evident for increasing concentrations of the GTPases, suggesting an increase in
unspecific binding.
PLC-eGFP and (GDP or GTPγS loaded) mCherry-K-Ras binding was now
studied and characterised by inter-molecular FRET. The inter-molecular FRET be-
tween His6PLC-eGFP and mCherry-K-Ras was measured by analysing the donor
and acceptor fluorophore lifetimes as described in section 2.8.3.
In the control experiment, using only His6-PLC-eGFP, two lifetime compo-
nents were detected. Therefore the eGFP fluorescence intensity decay, I(t), was
analysed as a sum of two exponentials:
I(t) =
n∑
1=1
αi exp
(−t/τi) (4.5)
where αi are the pre-exponential factors and τ i are the fluorescence lifetimes
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Figure 4.6. Western blotting analysis of the mCherry-hK-Ras PLC-eGFP pull-down sam-
ples obtained as descibed in section 2.8.2. (A) The His6-PLC-eGFPas (150 KDa) bound
to nickel chelating beads was detected by αPLC14h antibody (see table 2.8) showing com-
parable amounts; (B) the mCherry-K-Ras (50 KDa) bound to the effector was detected
by αK-Ras(F234) antibody (see table 2.8). For identical concentration of mCherry-K-Ras
(0.1μM, 0.5μM, 1μM and 6μM) incubated with the effector, higher amount of GTPγS
loaded mCherry-K-Ras (T) was bound to the effector than of GDP loaded (D).
and for the control n = 2. The main contribution comes from a decay time τ 1 =
2.70 ns, and the additional contribution of about 10% comes from a decay time τ 2
= 0.76 ns. These two eGFP decay times are in agreement with the data reported in
literature [340].
The fluorophore lifetimes were monitored in vitro for mixtures containing 3μM
PLC-eGFP and increasing concentrations of GDP loaded mCherry-K-Ras up to 10
μM. Equivalent mixtures were prepared for GTPγS loaded mCherry-K-Ras. All
the acquired decays have been analysed using a global analysis approach (see sec.
2.8.3).
In the presence of mCherry-K-Ras, both GFP lifetimes are expect to be quenched
if FRET occurs. Therefore, a four-exponential analysis should be performed on
these data. The non-quenched eGFP lifetimes (τ 1 = 2.70 and τ 2 = 0.76 ns) were
kept fixed, and the fitting program returned two additional values: τ 3 = 2.46 ns and
τ 4 = 0.70 ns. Because the values of τ 2 and τ 4 are very close, the program gave
very large errors in estimating the corresponding contributions. Therefore, it was
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decided that the short eGFP lifetime (τ 2 = 0.76 ns) does not participate significantly
to FRET and a three-exponential analysis was performed. The results are shown
in figure 4.7. The contribution of the component due to FRET (τ 3 = 2.46 ns) in-
creases in the presence of GTPγS loaded mCherry-K-Ras up to 34%, indicating
an increase in the number of mCherry-K-Ras molecules bound to PLC-eGFP. On
the other hand, in the presence of GDP loaded mCherry-K-Ras, the increase is very
small and is mainly observed at the highest Ras concentration.
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Figure 4.7. (A) Examples of temporal emission eGFP fluorescence intensity decays de-
tected at 510 nm after excitation at 488 nm. The instrument response function, IRF, is in
gray. The residual shows the discrepancy between the experimental data and the curve ob-
tained by the data fitting. (B) Contributions and their confidence intervals of the two decay
times of eGFP as a function of the concentration of mCherry-K-Ras.
The dissociation constant Kd between the His6-PLC-eGFP and mCherry-K-Ras
was measured based on the contribution of the FRET eGFP component (τ 3). The
contribution of the FRET eGFP is proportional to the fraction of His6-PLC-eGFP
engaged in the binding. Furthermore, an equal amount of mCherry-K-Ras is as-
sumed to be engaged in the binding since it is expected to bind to His6-PLC-eGFP
with a 1:1 stoichiometry. Based on the calibration of the eGFP FRET component
the estimated Kd value is ≈ 3.8± 1.0 μM , see figure 4.8. The estimated maximum
binding based on the eGFP FRET component goes up to only 45%, and this could
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be due to the fact that not all mCherry-K-Ras molecules contribute to FRET be-
cause they are not fully maturated. Previous studies in the literature estimated that
50% of the mCherry molecules fail to maturate [341].
Y = B max * x / (k1 + x)

2 = 0.00037
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Figure 4.8. Kd calculation from the contribution of the short GFP lifetime. The equation
used for fitting is also shown, where Bmax is the maximum binding.
The time resolved anisotropy decay, r(t), was monitored for each fluorophore as
described in section 2.8.4. These data showed a mono-exponential decay, therefore
the initial anisotropy ro was equal to the pre-exponential factor according to equa-
tion 4.4. For both fluorophores, the calculated values of initial anisotropy ro eGFP=
0.364 ro mCherry= 0.397 were in good agreement with the literature values [342],
see table 4.1. Analysis of the time resolved anisotropy decay gives the rotational
correlation time (φ) of each fluorophore based on equation 4.4. The rotational cor-
relation time is a function of the size of the fluorophore, therefore it can give an
insight into the size of the fluorophore or of the molecule to which the fluorophore
is joined.
The following values of rotational correlation time were obtained φeGFP = 28
ns (tagged to PLC), φmCherry = 18 ns (tagged to K-Ras), see table 4.1. These
rotational correlation times are both longer than the rotational correlation times of
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the correspondent untagged fluorophore (eGFP or mCherry) reported in literature,
see table 4.1. Fluorescent proteins (such as mRFP or mCherry) derived by point
mutation of GFP have a rotational correlation time in a small range close to φGFP
[343,344]. As expected, longer rotational correlation times were measured because
each fluorophore was coupled to another protein and therefore it was part of a larger
molecule [345].
Table 4.1. Initial anisotropy (ro) and rotational correlation time (φ). Literature values are
labeled with the (*) sign.
ro φ
eGFP (*) 0.370 16 ns [345]
ex.400 nm / em. 514 nm
PLC-eGFP 0.364 28 ns
ex.480 nm / em. 510 nm
mCherry-K-Ras 0.397 18 ns
ex.550 nm / em. 610 nm
PLC-eGFP + 10 μM GTPγS mCherry-K-Ras 0.364 22 ns
ex.480 nm / em. 510 nm
PLC-eGFP + 10 μM GTPγS mCherry-K-Ras 0.397 17 ns
ex.550 nm / em. 610 nm
The rotational correlation time of the two fluorophores did not change signifi-
cantly when His6-PLC-eGFP and mCherry-K-Ras (10 μM) were mixed together
φeGFP = 22 ns and φmCherry = 17 ns. Since complex formation occurred, an in-
crease of the rotational correlation times was expected due to the larger molecular
weight of the complex compared with the single proteins. In addition, φeGFP and
φmCherry within the complex were expected to be similar. Nevertheless, the values
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of φeGFP and φmCherry differed from each other suggesting that one fluorophore (or
both) had, to some extent, rotational freedom from the complex.
4.2.4 Monitoring possible PLC long-range conformational changes by
intra-molecular FRET
The structural and biochemical studies on GTPases and their effectors have focused
mainly on their mechanism of activation. In this respect, the translocation of the
effector to the membrane interface has been hypothesised to be responsible for ef-
fector activation together with a conformational change. There are two potential
mechanisms of activation. Examples supporting both mechanisms of activation
have been reported in literature. Subcellular distribution studies on PLCγ2 sup-
port the hypothesis that translocation mediated by Rac is sufficient to activate the
effector [336]. While more recently, it has been proposed that Rac1 binds PLCβ2,
inducing translocation to the membrane and optimising the orientation of the ef-
fector relative to the membrane, but it is only a conformational change that occurs
upon interaction with the membrane that is finally responsible for the full activation
of the effector [25].
In order to investigate by intra-molecular FRET if H-Ras induces a long range
conformational change in PLC, the following proteins have been expressed and pu-
rified: wild-type H-Ras (1-166 AA) and wild-type His6-mRFP-PLC-eGFP (1258-
2225 AA). The two proteins were prepared as described in section 4.2.1 and section
4.2.2. Sedimentation was used to verify that His6-mRFP-PLC-eGFP (1258-2225
AA) and H-Ras (1-166 AA) were purified in a functional state that allowed inter-
molecular binding. His6-mRFP-PLC-eGFP (1258-2225 AA) was immobilised on
nickel chelating beads via the His6-tag and GDP (or GTP) H-Ras (1-166 AA) was
added at three different concentrations, see figure 4.9. Inter-molecular binding was
confirmed and it was possible to appreciate GDP/GTP binding dependency. More
GTP-H-Ras was detected bound to the effector than GDP-H-Ras for comparable
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concentrations. This result suggests a stronger affinity of GTP-H-Ras for the effec-
tor than for GDP-H-Ras.
A) His6-mRFP-PLC -eGFP
H-Ras
250 KDa
150 KDa
100 KDa
75 KDa
20 KDa
0.3 µM
0.3 µM 0.6 µM 1.5 MµB)
Figure 4.9. Sedimentation of GDP (or GTP) H-Ras and of His6-mRFP-PLC-eGFP (1258-
2225 AA) on nickel chelating beads. (A) His6-mRFP-PLC-eGFP (≈ 180 KDa) bound to
nickel chelating beads was detected by Western blotting using αPLC14h antibody (see table
2.8) showing comparable amounts; (B) H-Ras (1-166 AA)(≈ 20 KDa) bound to the immo-
bilised effector was detected by αH-Ras(F235) antibody (see table 2.8). Higher amounts of
GTP loaded H-Ras (T) were bound to the immobilised effector than of GDP loaded H-Ras
(D) for identical concentrations.
The FRET fluorophore pair need to be placed on PLC to monitor variation of
the distance between the two fluorophores in the presence of H-Ras (1-166 AA).
The truncated PLC was inserted between the two FRET fluorophores; the acceptor
(mRFP) at the N-terminus and the donor (eGFP) at C-terminus. Using this design,
long range conformational changes would be likely to affect the distance or the
orientation of the two fluorophores with respect to each other. Such changes would
result in a change in the FRET interaction which would be detected by monitoring
the lifetime of both fluorophores. The lifetime of the donor, the time that the donor
remains in its excited state, is shorter (on average) when in proximity to the acceptor.
All the samples were prepared at a fixed concentration of PLC of 1.4 μM, the Kd
for H-Ras binding reported in literature [36]. The lifetime measurements (donor
and acceptor) were recorded in the absence or in the presence of H-Ras. The effect
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of increasing concentrations of GDP (or GTP) H-Ras on the correlation between
lifetime variation was used to follow the binding between H-Ras and PLC. In the
absence of H-Ras, the donor (eGFP) lifetime was fitted using equation 4.5 and two
exponential decay times, τ 1 2.68 ns and τ 2 1.06 ns.
From equation 4.3 the donor average lifetime in absence of the acceptor (Dτm)
has been calculated to be 2.68 ns (using PLC-eGFP, see sec. 4.2.3) and in the
presence of the acceptor DAτm = 2.49 ns (using mRFP-PLC-eGFP in absence of
H-Ras). This leads to a FRET efficiency of 7.1%.
The distance between the two fluorophores (R) was calculated based on the
FRET efficiency (E) and the Föster distance (R0) using equation 4.1. For the FRET
pair used here, eGFP-mRFP, the R0 has previously been reported in literature to
be 4.7 nm [346]. The distance between the two fluorophores was found to be 7.2
nm in absence of H-Ras. The distance between the two fluorophores of mRFP-
PLC-eGFP in the presence of 10 μM GTP-H-Ras was calculated using the average
life time DAτm = 2.50 ns. Although in the presence of GTP there was a trend
toward a reduction in FRET (i.e. a decrease in the contribution of the short eGFP
component), the change in the average life-time in the absence or in the presence
of 10 μM GTP-H-Ras (DAτm) was minimal and near to the confidence interval of
the measurements. This could not bring clear evidence of a change in the distance
between the fluorophores (the donor and the acceptor).
In the presence of GDP-H-Ras, the percentage of molecules undergoing FRET
remains constant, with a very small decrease at high Ras concentrations (10 μM).
The acceptor decay showed a long component τ 1 2.53 ns (probably an interme-
diate lifetime between mRFP and the eGFP leaking into the acceptor channel) and
a short component τ 2 0.29 ns with a negative contribution, which is indicative of
FRET, see figure 4.10. The donor decay has the same trend as the acceptor decay:
no significant change in the short component was detected in the presence of GDP
bound H-Ras, while a reduced contribution of the short component was detected in
the presence of GTP bound H-Ras. A reduction of the short component is indicative
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of less FRET, but the reduction was minimal and it could hardly provide evidence
of a change in the distance between the donor and the acceptor upon Ras binding.
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Figure 4.10. Donor and acceptor decays as function of H-Ras concentration. Each contri-
bution is presented with the confidence interval.
The time resolved anisotropy decay of the acceptor, r(t)mRFP , was monitored
(see fig. 4.11, A). The data were fitted using equation 4.4 and using two components
(fast and slow) (see fig. 4.11, B). The contribution of the fast component represented
by β1 and φ1 accounts for the FRET. The values of β1 and φ1 decreased slightly
upon addition of H-Ras, see table 4.2.
This reduction translates into a small reduction of FRET efficiency reinforcing
the evidence that no large conformational changes were detected for the specific
experimental design used here. The contribution of the slow component of the
r(t)mRFP is represented by β2 and φ2, see table 4.2. This contribution accounted for
the rotation mRFP as part of mRFP-PLC-eGFP. Based on this, the average angle
between eGFP and mRFP was calculated using equation 4.6
β2 = r0
3(cos2 θ)− 1
2
(4.6)
The angle between the two fluorophores within His6-mRFP-PLC-eGFP in the
absence of H-Ras was 33o (β2 = 0.203 ro=0.37 from the literature [342]) and in
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Figure 4.11. (A) Parallel (red) and perpendicular (black) fluoroscence intensity decay of
mRFP in mRFP-PLC-eGFP before and after the addition of 10 μM H-Ras. The instrument
response function, IRF, is in blue. (B) The calculated anisotropic decay curves before (blue)
and after (green) the addition of 10 μM H-Ras.
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Table 4.2. Pre-exponential and rotational correlation time (ns) relative to the acceptor
mRFP.
mRFP-PLC-eGFP alone mRFP-PLC-eGFP + 10 μM H-Ras
ex.488 nm / em. 610 nm ex.488 nm / em. 610 nm
β1 0.126 0.103
φ1 0.874 ns 1.063 ns
β2 0.203 0.228
φ2 22 ns 22 ns
ro 0.8 ns 1 ns
presence of GTP H-Ras (10 μM) was 30o (β2 = 0.228 ro = 0.37 from the literature
[342]).
4.3 Discussion
The choice of using constructs containing GFP or mRFP (or mCherry) was par-
ticularly favourable in terms of probe preparation. Indeed, such probes could be
expressed recombinantly in E.coli, and possible truncated products containing the
fluorophores, which could have altered the lifetime measurements, were removed
during the purification process. At the end of the purification process, the probes
were ready to be used for the FRET experiments and no further chemical labelling
was necessary.
The FRET efficiency was measured by monitoring the fluorescence lifetime (of
the donor or of the acceptor) rather than measuring emission intensity of the ac-
ceptor. Indeed, by choosing the life time approach the corrections for the donor
fluorescence leaking into the acceptor channel, or for the direct excitation of the
acceptor at the donor excitation wavelength, are not required [347].
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The K-Ras-PLC interaction between recombinantly expressed and purified bind-
ing partners was verified by sedimentation and characterised by inter-molecular
FRET. Sedimentation confirmed that the probes had been purified in a functional
state and that the fluorophores did not compromise the recognition site as expected
(and that the location of the fluorophores was appropriate). The presence of FRET
ensured that the value of the Kd obtained ( Kd ≈ 3.8 μM) is in the range reported
in the literature. For example, the interactions between PLCβ2 and members of the
Rho family (Rac1 Rac2 or Rac3) has been reported to have a Kd of 5-10 μM [66].
Moreover, the affinity of H-Ras-RA2 binding has been reported to have a Kd ≈ 1
μM [36]. These values are similar to the Kd value measured here, and they are
thought to be relevant in physiological conditions. Measuring the Kd using inter-
molecular FRET is an appealing approach because it does not required separation
of the complex from the unbound molecules, since this can be estimated based on
the life-time change of the donor.
The implications of the K-Ras-PLC binding in terms of mechanism of acti-
vation have been investigated further. The hypothesis of conformational changes
leading to PLC activation was tested by intra-molecular FRET. The construct used
was His6-mRFP-PLC-eGFP (1258-2225 AA). The fluorophores were strategically
placed at the ends of the molecules, expecting that any conformational change
could be amplified and result in the greater distance variation between the two fluo-
rophores. It was verified that the presence of two fluorophores on the same protein
did not affect protein folding or its functional state.
The data relative to the mechanism of activation indicated the absence of a long
range conformational change within the effector. However, it is not possible to ex-
clude short range conformational changes that are limited to a specific area, as they
will not affect the spatial localisation of the fluorophores in this construct. Further-
more, it is conceivable that a conformational change occurs only in the presence of
the three components of the activation process: the transducer, the effector and the
membrane surface containing the substrate. To study further the activation mecha-
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nism and investigate the possibility of short range conformational changes by inter-
molecular FRET, it will be necessary to change the location of the fluorophores on
the construct of PLC: one fluorophore at one end (C- or N-terminus) and the other
(possibly a small dye such as ReAsH) internal to the molecule, similarly to what
will be proposed in section 6.3.7. Alternatively, it would be interesting to investi-
gate intra-molecular FRET in the presence of vesicles containing the substrate. In
this case it would be necessary to use prenylated GTPases to promote translocation
of the effector to the membrane interface. Successful translocation and the proxim-
ity of the effector to the membrane could be verified by introducing a third dye in
the lipid bilayer. Such a system, (upon careful choice of the fluorophores is possi-
ble to prevent crosstalk [348]) can be used to monitor FRET between two different
FRET pairs simultaneously, for example using Cerulean (or CyPet), mOrange, and
mPlum [344, 349, 350]. Internal conformational changes can be monitored mea-
suring the FRET occurring between the FRET pair on the effector, while effector
translocation to the membrane surface can be monitored independently measuring
FRET occurring between the dye in the lipid bilayer and one of the fluorophores on
the effector.
Chapter 5
Analysis of PLC regulatory
mechanisms in vivo and optimisation
of a cell-free system
5.1 Introduction
In vivo assays to measure PLC activity and PLC stimulation by small GTPases are
well established and have allowed extensive characterisation of the effects of GT-
Pases on PLCs [65] [35]. A few members of the PLC family (PLCβ, PLCγ, and
PLC) have been shown to be stimulated by small GTPases, for more details refer
to section 1.1.3. However, an in vivo assay cannot prove whether the interaction
between the PLC and the GTPase is direct or indirect. More recently, much effort
has been put into the development of a minimal cell-free system which supplied
evidence for a direct interaction between GTPases and their specific effectors. The
cell-free system was reliable in reproducing the in vivo data and it proved very
powerful to measure PLC activity as a function of the GTPases [351] [324]. The
minimal cell-free system requires four essential components PLC (enzyme), GT-
Pase (transducer), Ca2+ (cofactor), and PtdIns(4,5)P2 (substrate).
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A cell-free system has previously been reported to measure the activity of PLC
as function of RhoA [323]. In this cell-free system, the RhoA was obtained from
Sf9 insect cells, since the GTPases must be post-translationally modified in order
to activate the PLCs (sec. 1.2). In particular, the membrane extract of Sf9 express-
ing RhoA was used in the system. In addition to RhoA, PLC purified from bacteria
and PtdIns(4,5)P2 substrate incorporated into lipid vesicles were used. However, the
membrane extract of Sf9, necessarily combined with the post-translationally mod-
ified GTPases, carries into the system other uncontrollable elements. These extra
elements (membrane proteins, lipids, detergent) could affect the activity measure-
ments in a non systematic way. The finer the control of each constituent of the sys-
tem, the more sensitive the system is in response to variation of any of the compo-
nents. In order to make the cell-free system more robust and more sensitive, the use
of purified GTPases from a bacterial source (and therefore not post-translationally
modified) followed by in vitro prenylation would be preferred over Sf9 membrane
extract. An analogous strategy has been previously reported for PLCβ and Rac and
has proved to be successful [351] [336]. The need for a more sensitive system is
even more urgent in this work because the final goal is to study the PLC activity as
a function of the substrate presentation using the cell-free system as a model for the
in vivo system. With this aim in mind, the interaction between PLC and RhoA, a
member of the Rho subfamily of GTPases, was used to test the cell-free system.
Initially, the effect of RhoA co-expression on PLC activity as function of RhoA
was studied in vivo using the Cos7 cell line. Subsequently, the cell-free system de-
scribed in the literature [323] was used to test the suitability of each component
and to verify the capability of such a system to reproduce the in vivo data obtained
in Cos7 cells. The cell-free system was then taken a step further and more radical
changes were made using in vitro prenylated RhoA. RhoA was geranylgeranylated
at the C-teminus by a prenyltransferase enzyme such as GGTase type I; refer to
section 1.2 for more details. The RhoA prenylation reaction was characterised and
optimised before being applied to the cell-free system. The modified cell-free sys-
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tem employing in vitro prenylated RhoA was used to measure PLC activity in a
GTPase dependent manner. The aim was to determine if the behaviour of the mod-
ified cell-free system could corroborate the current interpretation of the control of
an analogue system in vivo.
5.2 Results
5.2.1 PLC activation by RhoA in vivo
Activity measurements based on inositol phosphate accumulation in Cos7 cells
identified the GTPases capable of stimulating PLC if co-expressed. It has pre-
viously reported that PLC can be stimulated independently and concomitantly by
certain Rho and Ras family members because they interact directly with distinct re-
gions of the effector [58]. The intensity of the stimulation by RhoA, RhoB, RhoC,
and H-Ras or Rap is comparable. In the assay, constitutively active mutants of the
GTPases are used which by abolishing the GTPase activity, prolong the interaction
and therefore the stimulation of the effector [352]. The capability of constitutively
active RhoAG14V to stimulate PLC activity was analysed in Cos7 cells. These cells
were radiolabeled by incorporation of [3H]-myo-inositol. The activity was moni-
tored by accumulation of [3H]-inositol phosphates in the presence of LiCl, followed
by separation of the reaction products and substrate ([3H]-IPx and [3H]-PtdInsPx),
then quantification (see sec. 2.6.1). An indication of the degree of PLC stimulation
was obtained by comparison of the activity measured in cells transfected with just
full length PLC, or co-transfected with full length PLC plus constitutively active
RhoA (RhoAG14V ) which showed ≈ 5-fold of stimulation, see fig. 5.1.
This increased activity was compared with the activity measured in cells trans-
fected with a truncated version of PLC (1258-2225 AA) alone or co-transfected
with RhoAG14V . A similar level of stimulation was observed for the truncated ver-
sion of PLC (1258-2225 AA). This analysis confirms that the truncation does not
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Figure 5.1. PLC activity measured by accumulation of inositol phosphates in Cos7 cells.
PLC activity was measured as production of inositol phosphatases (IP) as a percentage of the
total phosphatidyl inositol. The values shown are the mean ± standard deviation of the error
mean (s.e.m.) for duplicate samples. Cos7 cells non-transfected with any PLC construct
(control) or Cos7 cells transfected with the PLC constructs (2 ng DNA) as indicated in
the bar chart (PLCFL = full length PLC, PLC (1258-2225 AA) = truncated PLC) are
in blue, Cos7 cells co-transfected cells with the PLC constructs plus RhoAG14V (0.5 ng of
DNA) are in red. The expression of the transfected constructs was confirmed by Western
Blotting.
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compromise the stimulation process by the transducer (RhoA). These observations
made the truncated construct of PLC (1258-2225 AA) representative for full length
PLC as far as the study of the stimulation by RhoA is conceived. It was therefore
possible to expect that the behaviour of the truncated PLC would be representa-
tive of the full length PLC in Cos7 cells, as well as in the in vitro system. The
possibility of using the truncated PLC (1258-2225 AA) in the in vitro system was
an advantage because PLC (1258-2225 AA) could be expressed and purified in
E.coli, while the full length could not. The use of purified protein provides a better
control over the content of the in vitro system.
5.2.2 The cell-free assay using solubilised Sf9 membranes as a
source of GTPases
The cell-free system used here was based on the system previously described by
Gandarillas et al. [323] with minor modifications. This cell-free system, enabling
measurements of PLC activity as a function of RhoA, was used as a model for
in vivo regulation of PLC. It was necessary to optimise some parameters of the
system according to the specific experimental setting adopted here. A construct
encoding for His6-MBP-PLC (1258-2225 AA) was expressed recombinantly in
E.coli. The protein was purified in two steps: affinity and ion exchange chromatog-
raphy, then incubated with thrombin to cleave the protein between the MBP and
the PLC (1258-2225 AA). The cleaved product was further purified close to ho-
mogeneity by affinity and gel filtration chromatography, as described in section 2.5,
see fig. 5.2, A. Post-translationally modified GTPases were obtained from Sf9 cells
as described by Gandarillas et al. [323], see section 2.6.2.2. The membrane frac-
tion of Sf9 containing the GTPase was solubilised with sodium cholate. Here, Sf9
expressing neutral sphingomyelinase I were processed in the same manner and used
in the control samples. Indeed, the membrane extract of transfected Sf9 expressing
neutral sphingomyelinase I should more closely resemble the membrane extract of
5.2 Results 174
un-infected Sf9 expressing the GTPase than non-transfected Sf9 cells. Furthermore,
neutral sphingomyelinase I is expected non to affect the PLC activation pathway.
Each membrane extract mixture was homogenised by pipetting through a thin nee-
dle several times before been aliquoted and stored at -80 ◦C. Examples of membrane
fractions of Sf9 containing RhoA and neutral sphingomyelinase I (control) can be
seen in figure 5.2, B.
The lipid vesicles were prepared with the lipid composition used by Gandar-
illas et al. [323]: PtdEtn:PtdIns(4,5)P2:[3H]-PtdIns(4,5)P2 10:1:0.0005 w/w. The
lipid mixture was dried under a flow of nitrogen to prevent oxidation of the lipids.
The lipid film obtained was suspended in buffer to form liposomes. The liposome
mixture was sonicated to form unilamellar vesicles, but different sonication settings
were adopted to these of Gandarillas et al., 5 min at 4 ◦C and 1% amplitude in a cup-
horn sonicator. These settings allowed a greater control over the vesicle preparation.
The lipid vesicles were imaged by EM to initially characterise the lipid system, see
fig. 5.2, C. They showed a similar morphology, they appear as unilamellar vesicles,
circular in shape, but of various sizes.
In order to further characterise the size distribution of the lipid vesicles, the
vesicle mixture was analysed by dynamic light scattering (DLS) as described in
section 2.7.2. The DLS analysis shows that the population is heterogeneous in
size and three populations could be identified with an average size of 30 nm, 80
nm or 300 nm, see fig. 5.3. Immediately after preparation, the average size of
the main vesicle population is 80 nm, but the size average of the main population
decreases toward 30 nm over time. The vesicle population with size average of 300
nm is characterised by high intensity variability over time. The size heterogeneity of
the lipid vesicles detected by DLS analysis was consistent with the vesicle images
obtained by EM. In addition, the DLS analysis indicated that the vesicle mixture
had some degree of instability.
The experiments were conducted in the presence of an excess of GDP or GTPγS.
The un-hydrolysable GTPγS analogue was used to ensure a prolonged activation of
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Figure 5.2. (A) Coomassie stained SDS-PA gel loaded with purified PLC (1258-2225AA);
(B) Western blotting of membrane extracts of Sf9 superimposed with the stained PVDF-
membranes; the samples expressed RhoA, K-Ras, N-Ras or sphingomyelin (control) and
they were probed with α RhoA 26C4, α K-Ras (F234) or α N-RAs (see tab. 2.8); (C) EM
image of negatively stained lipid vesicles used in the cell-free assay. The scale bar is 100
nm.
the GTPase, although the intrinsic GTPase activity of the Ras family proteins has
reported to be very low [353].
Initially, the enzyme concentration and the free Ca2+ concentration were opti-
mised: a range of enzyme concentrations were tested (0.16-3.33 ng/μl) to obtain a
linear response (data not shown). The optimal PLC concentration was found to be
1.66 ng/μl (100 ng per tube) of PLC in the presence of RhoA and N-Ras (the same
as [323]), but 3.33 ng/μl in the presence of K-Ras. Various values of free Ca2+ con-
centration (calculated as described in sec. 2.6.2.2.4) have been tested ranging from
5 nM to 200 nM, and a 25 nM concentration was found to be the best value to detect
PLC stimulation in the presence of RhoA. While a lower free Ca2+ concentration
was better to detect stimulation in the presence of N-Ras or K-Ras.
The background activity measured in the absence of PLC was almost negligible,
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Figure 5.3. DLS analysis of the lipid vesicles used in the cell-free system. The intensity of
the scattering was plotted as a function of the vesicle size, data were collected at 30◦C after
the incubation time indicated in the bar chart.
but the value obtained was subtracted from all other measurements. Basal activity
of PLC was measured in the presence of either GDP or GTPγS nucleotide in the
absence of GTPases. Equivalent values (within the error bar) to the basal activity of
PLC were obtained showing that the nucleotides do not interfere with PLC activ-
ity, see column 1 and 2 in figure 5.4. In the presence of Sf9 membrane extract, but
without PLC, equivalent measurements were obtained regardless of the guanine
nucleotide in the sample (see fig. 5.4). In the samples containing both PLC and
GTPases (in Sf9 membrane extract), a substantial variation in activity was detected
in a guanine nucleotide dependent fashion. These variations in activity were due to
the interaction between the active form of the GTPases and the effector since such
effects were absent in the previous controls. PLC was stimulated in the presence of
the GTPγS RhoA, K-Ras and N-Ras. The PLC activity in the presence of GTPγS-
RhoA indicated 2.8-fold (± 0.8 s.e.m.) stimulation compared to PLC activity in
the presence of GDP-RhoA, see fig. 5.4, columns 5 and 6. This value was based on
three independent experiments (and two duplicate samples per experiment). Simi-
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larly, PLC showed 2.1-fold (± 0.3 s.e.m.) and 1.9-fold (± 0.6 s.e.m.) stimulation
in the presence of N-Ras or K-Ras respectively, see columns 9 and 10 or columns
13 and 14 in figure 5.4.
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Figure 5.4. PLC activity measurements in vitro after sample incubation at 30 ◦C for 45
min. The samples contained: purified PLC (1258-2225 AA) at the quantity reported in the
bar chart, PE:PIP2:[3H]-PIP2 lipid vesicles 10:1:0.0005 w/w, 25 nM or 5 nM free calcium
concentration, 100 μM GDP (blue bars) or 100 μM GTPγS (red bars) and Sf9 membrane
extract (as reported in the bar chart). The bar chart shows the average activity measured in
two duplicate samples ± s.e.m.
However, comparing the activity measured in the presence of GDP and either
PLC alone or PLC and Sf9 membrane extract, a clear reduction of PLC activity
can be observed (columns 1 and 5 in figure 5.4). While comparison of the activity
measured in samples containing GTPγS shows an activation of the PLC (columns
2 and 6 in figure 5.4). The inhibitory effect may be in part due to the dilution of the
substrate upon addition of the membrane extract of Sf9. A number of other factors,
such as inhibitors within the membrane extract or the effects of detergent, could
also be responsible for this inhibition. This inhibitory effect emphasised the fact that
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there were factors within the system that could not be controlled. These factors were
a source of systematic variability which represented a serious weakness and made
the system non ideal for the study of PLC activity as a function of lipid presentation.
A different source of GTPases could provide a more powerful system, suitable for
our needs. Instead of using GTPases contained in a Sf9 membrane extract, the
GTPase was purified from bacteria and subsequently prenylated in vitro. RhoA
was selected as a model for the in vitro prenylation. Indeed RhoA, as a member
of the Rho GTPase family, is geranylgeranylated and post-translationally modified
RhoA could be obtained in vitro in one step reaction while two reactions would be
required to obtain full post-translationally modified N-Ras, which is farnesylated
and S-acylated (or palmitated), see section 1.2. Furthermore, K-Ras is localised
at the plasma membrane thanks to the farnesyl chain and the six lysines, but the
localisation at the membrane might have not be as efficient with the simplified lipid
system used in the cell-free system.
5.2.3 RhoA expression purification and prenylation in vitro
A construct coding for His6-RhoA full length (wild type) was used to express the
GTPase; the His6-tag was exploited for the purification, and the full length ensures
the presence of the -CAAX box at the C-terminus for the prenylation. RhoA was
expressed recombinantly in E.coli C41 DE3 cells as described in section 2.3.5.
The His6-RhoA present in the cell lysate was immobilised on a nickel chelating
column, washed and then eluted. Analysis of the eluted fractions by SDS-PAGE
showed a large main band at ≈ 30 KDa, with only a few other bands that were far
weaker than the main band. The molecular weight of the main peak corresponds to
the estimated molecular weight of His6-RhoA, suggesting that highly purified His6-
RhoA was obtained with the first purification step, see fig. 5.5, A. The protein was
further purified by size exclusion chromatography (Superdex 75). The UV trace
of the size exclusion column showed one major peak for which the retention time
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corresponded to a protein (non denatured) of ≈ 30 KDa (data not shown). The
analysis by SDS-PAGE of the elution fractions of the main peak showed a major
band at ≈ 30 KDa (denatured), confirming the monomeric state of the protein. The
gel also confirmed the high level of purity by comparison of the ≈ 30 KDa band
intensity with the intensity of the other bands detected on the gel, see fig. 5.5, B.
The main band was identified as His6-RhoA by Western blotting (data not shown).
Therefore, monomeric His6-RhoA after the two purification steps was purified close
to homogeneity with a yield of ≈ 3 mg/litre of bacterial culture.
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Figure 5.5. Purification process for full length RhoA (1-193 AA). (A) SDS-PAGE of the
elution fractions (E.F.) for the first step of affinity chromatography; (B) SDS-PAGE of the
elution fractions for the second step of size exclusion chromatography.
The purified RhoA was stored at -80 ◦C until required for the cell-free assay, in
which case, the RhoA was prenylated in vitro immediately before being added to
the cell-free assay samples. RhoA is a member of the Rho GTPase family and is
geranylgeranylated by GGTase type I. GGTase type I is a heterodimer consisting of
an α (≈ 48 K Da) and a β (≈ 42 K Da) subunit. GGTase type I requires Zn2+ to
stabilise and orient the protein and to catalyse prenylation [354]. Product release
is the rate-limiting step of prenylation reaction and requires binding of a second
isoprenyl chain before it can proceed. For this reason the prenylation reaction was
done in an excess of GGPP.
The purified enzyme GGTase type I was kindly provided by Prof. Seabra (Im-
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perial College London). The enzyme was titred as described in section 2.6.2.2.2. In
brief, increasing amounts of enzyme (from 0 to 80 nM) were added to the mixture
of purified GTPase (3 μM), 3H-GGPP (0.05 μM) and GGPP (5 μM). The samples
were incubated for 30 min at 37 ◦C and at the end of the incubation time, the GTPase
was isolated and the degree of GTPase prenylation was quantified by scintillation
counting, see fig. 5.6, A.
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Figure 5.6. (A) Titration of the GGTase type I ; detection of [3H]geranylgeranylated RhoA
after separation of the prenylation reaction mixture by (B) SDS-PAGE or (C) native gel
electrophorisis; (D) comassie stained native gels loaded with RhoA prenylation reaction
mixtures containing increasing concentrations or GGTases type I (from left to right: 0,
6.125, 12.5, 25, 50, 100 nM.)
The crude prenylation reaction (with 40 ng of GGTase type I) was separated by
SDS-PA or native gel electrophoresis. The gels were analysed by fluorography to
confirm successful RhoA prenylation, see fig. 5.6, B and C. Only one radioactive
band was detected in both gels. The radioactive band on the SDS-PA gel corre-
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sponded to a molecular weight of ≈ 25 KDa similar to the molecular weight of
RhoA. The fact that only one band was detected in the native gel indicated high ho-
mogeneity (in terms of size and surface charge) of the prenylated RhoA population.
The prenylation reaction mixtures of RhoA containing increasing concentrations of
GGTase type I were analysed by native gel electrophoresis, see fig. 5.6, D. The band
for unprenylated RhoA (in absence of GGTase type I) was detected in the first half
of the gel and the RhoA band was shifted toward the bottom of the gel in presence
of GGTase type I. The intensity of the lower band increased for increasing concen-
trations of GGTase type I in the prenylation reaction and this band became the only
band visible for a concentration of GGTases type I above 50 nM. Therefore, it is
realistic to think that the lower band corresponds to the prenylated RhoA.
5.2.4 Localisation of prenylated-RhoA at the lipid interface
In vivo protein prenylation is essential for protein localisation at the membrane (see
sec. 1.2), therefore it is reasonable to think that the same happens in vitro in the
presence of a suitable lipid system. To verify that the presence of a geranylgeranyl
chain on RhoA can cause RhoA to translocate to the outer layer of the lipid vesi-
cles, the location of RhoA with a lipid system, such as giant unilamellar vesicles
(GUVs), was investigated. Sucrose loaded GUVs of the zwitterionic lipid DOPC
were prepared by the swelling method as described in section 2.7.1. The GUVs
were incubated with prenylated RhoA (or un-prenylated RhoA protein as control),
and the mixture was sedimented by centrifugation as described in section 2.7.5. The
pellet and the supernatant contents were analysed by Western blotting (see fig. 5.7,
A). RhoA (prenylated or un-prenylated) was detected in both pellet and supernatant.
However, a larger amount of protein was detected in the pellets of GUVs incubated
with prenylated RhoA, see figure 5.7, B. Based on these results, it is reasonable to
think that geranylgeranyl prenylated RhoA is associated with the vesicles.
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Figure 5.7. Un-prenylated RhoA (RhoA) and geranylgeranylated RhoA (GG-RhoA) in the
pellets (P) or in the supernatant (S) of sedimented of GUVs detected by Western blotting
(A), where RhoA was probed with primary α RhoA 26C4 (1:2000) and secondary anti-
mouse (1:2000) antibody or by staining the PVDF-membrane (B).
5.2.5 The cell-free system using in vitro prenylated RhoA GT-
Pase and PLC
The cell-free system was adapted to the use of in vitro prenylated RhoA instead of
Sf9 membrane extract. This required optimisation of each component of the system
with the only exception of the lipid vesicle and the substrate concentration (vesicles
composition: PE:PtdIns(4,5)P2:[3H]-PtdIns(4,5)P2 10:1:0.0005 w/w).
A range of PLC concentrations (5 ng - 150 ng) were tested. Less PLC (25 ng)
was required than when Sf9 membranes extracts were employed (data not shown).
Various values of free Ca2+ concentration were tested ranging from 25 nM to
150 nM (calculated as described in sec. 2.6.2.2.4), where the greatest PLC stim-
ulation was detected in presence of 25 nM Ca2+ (data not shown). The free Ca2+
concentration was found to affect non-stimulated PLC more severely than stimu-
lated PLC. The lower the Ca2+ concentration, the lower the PLC activity in the
presence of GDP-GTPase, while a lesser effect of Ca2+ on PLC activity was ob-
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served in the presence of GTPγS-GTPase. Therefore, lower Ca2+ concentration
leads to higher relative activation by lowering the activity of PLC in the presence
of GDP-GTPase, rather than increasing PLC activity in the presence of GTPγS-
GTPase.
Various amounts of prenylated RhoA (obtained upon prenylation of 2.5 ng to
100 ng of un-prenylated RhoA) were added to the cell-free system, maintaining all
the other components constant. The higher the amount of prenylated RhoA, the
bigger the stimulation of PLC.
The optimal set of conditions for the cell-free system were: 1.6 ng/μl of total
RhoA (≈ 0.6 μM prenylated RhoA), 0.4 ng/μl PLC (≈ 2.7 nM ), 25 nM free Ca2+
concentration per sample, see figure 5.8. Under these conditions, identical values
for PLC basal activity were obtained in the presence of either GDP or GTPγS,
and un-prenylated RhoA did not affect PLC basal activity. Furthermore, ≈ 2-fold
stimulation of PLC was detected only in the presence of GTPγS-GTPase proving
that the modified cell-free system is robust and supports in vivo evidence for PLC
regulation.
An inhibitory effect was evident by comparison of the basal activity of PLC and
PLC activity in the presence of GDP RhoA supplied as an Sf9 membrane extract.
This inhibitory effect was observed in equivalent samples where RhoA was supplied
as the in vitro prenylated GTPase. However, in the latter case, the inhibitory effect
was less pronounced. Furthermore, it was noted that the inhibition was independent
of the concentration of prenylated RhoA because, for increasing concentrations of
RhoA used, the inhibitory effect remained constant.
5.2.6 Alternative methods to quantify PLC activity based on
Ins(1,4,5)P3 detection
The PLC activity in the cell-free system was measured by scintillation count-
ing (see sec. 2.6.2.2.5). This method of measurement required the use of [3H]-
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Figure 5.8. PLC activity measurements obtained with the cell-free system as a function
of the amount of prenylated RhoA. The bar chart reports the average activity measured in
two duplicate samples ± s.e.m. The samples contained: purified PLC (1258-2225 AA)
(25ng), PE:PIP2:[3H]-PIP2 lipid vesicles 10:1:0.0005 w/w, 25 nM free calcium concentra-
tion, 100 μM GDP (blue bars) or 100 μM GTPγS (red bars) and different amounts of in
vitro prenylated RhoA.
PtdIns(4,5)P2, although only in small amounts, making this experiment quite expen-
sive. Two other methods were considered to quantify the PLC activity: inorganic
phosphate detection by malachite green assay, or Ins(1,4,5)P3 titration by competi-
tive assay. The malachite green assay is a colorimetric type of assay that quantifies
the inorganic phosphate, therefore the product of PLC activity, Ins(1,4,5)P3, needs
enzymatic pre-treatment by alkaline phosphatase. The reaction catalysed by the
alkaline phosphatase is:
Ins(1,4,5)P3 + alkaline phosphatase → 3 PO43− + inositol
Since each Ins(1,4,5)P3 is a source of three phosphates, this method was par-
ticularly appealing because it lowered the limit of detectability compared to the
scintillation counting. However, the Ins(1,4,5)P3 extraction at the end of the activ-
ity assay requires harsh conditions (very low pH and solvents), so it was necessary
to evaporate the solvent and the acid. Before Ins(1,4,5)P3 treatment by alkaline
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phosphatase, each sample was dried in a speed vacuum device at 30 ◦C overnight,
suspended in buffer and then used for the colorimetric assay. Control samples con-
taining PO43− proved the high reproducibility and accuracy of the malachite green
assay, but non-linear responses were obtained for the unknown samples (data not
shown). A few attempts were made to identify the components incompatible with
the malachite green assay. Troubleshooting proved to be time consuming and the
improvements obtained did not make this method nearly as robust as the scintilla-
tion counting method, therefore efforts in this direction were halted.
A kit from GE healthcare was used to detect Ins(1,4,5)P3 specifically by a com-
petitive assay. This method was reliable and effective, but roughly as expensive as
the scintillation counting since it still required [3H]-PtdIns(4,5)P2. Furthermore, it
introduced more passages which were potential sources of error and, overall, pro-
longed the time needed to analyse the samples. This method was therefore not
considered a suitable alternative to scintillation counting.
A third method was considered: thin layer chromatography (TLC) detection.
This method ensured separation of PtdIns(4,5)P2, Ins(1,4,5)P3, and DAG giving a
better view of the lipid composition within the cell-free system at any time. How-
ever, TLC detection is a semi-quantitative method and it could hardly detect the
differences in activity that scintillation counting can easily distinguish. It would
have been valuable to use TLC detection in parallel with the scintillation counting
to characterise the lipid system, but this was not pursued due to time constraints.
5.3 Discussion
Activity studies in Cos7 cells have identified PLC as an effector of RhoA, RhoB
and RhoC, and excluded PLC as an effector of Rac1, Rac2, Rac3 or CDC42 [50].
The analogous measurements reported here with full length PLC and RhoAG14V ,
showing ≈ 5-fold of stimulation, are in line with the activities previously reported
in literature [50].
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Activity studies on the truncated mutants of PLC (1258-2225 AA) showed an
identical behaviour to the full length PLC in terms of RhoA stimulation. This
implies that PLC activation and the regulation by RhoA remained unaltered re-
gardless of the truncation of part of the protein. These findings are in agreement
with the identification of a specific region (≈ 65 residues, 1669-1730 AA) in the Y
region of the catalytic domain responsible for the RhoA interaction [50].
The observation that both constructs of PLC used, truncated and full length,
were stimulated ≈ 5-fold by RhoAG14V was very important in establishing the cell-
free system. Indeed, unlike full length PLC, truncated PLC can be expressed
recombinantly and purified and therefore used in the cell-free system.
5.3.1 The potential of the system to investigate protein lipid in-
teractions
The cell-free system has been proven capable of monitoring PLC activity as a func-
tion of the GTPase, and of supporting studies on the in vivo system as an alternative
to the Cos-7 system. Furthermore, PLC stimulation by RhoA (K-Ras or N-Ras)
measured in the cell-free system corroborates the evidence of a direct interaction
between PLC and RhoA (K-Ras or N-Ras). Previously, it was suggested by in
vitro binding studies that this interaction was direct [50] and supported by the fact
that the region associated with RhoA interaction (within the Y region of the cat-
alytic domain) is predicted to be exposed on the surface, based on the structure of
PLCδ (see fig. 5.9). This same region, which is unique in PLC among all the
other isozymes, is also necessary for Gα12/13 or Gβγ stimulation. Nevertheless,
it still needs to be clarified if they interact directly with the effector, or whether
the stimulation is achieved through Rho since Gα12/13 has been shown to activate
RhoGEFs [42, 45, 355, 356]. The cell-free assay used here has been proved to be
robust enough to address such a question, but further optimisation of the compo-
nents of the cell-free system might be necessary to study the effect of Gα12/13 or
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Figure 5.9. Structure of PLCδ1 (ID = 1DJZ) oriented with the membrane binding plane
facing out of the page and sequence alignment between PLC (ID = Q99P84) and PLCδ1
(ID = P10688). RhoA binds to a specific region within the catalytic domain (Y region) of
PLC (1669-1730 AA). This specific region of PLC is not present in PLCδ1 and it would be
inserted in the area indicated by the arrow between the residues G514 and Q515 of PLCδ1.
This region, according to PLCδ1 structure, is exposed on the surface.
Gβγ on PLC activity. Indeed, different concentrations of PLC, GTPase, Ca2+ or
PtdIns(4,5)P2) in the cell-free system were required depending on the GTPase used
(RhoA, K-Ras or N-Ras).
At an initial stage, the cell-free system supplied with the membrane extract of
Sf9 cells (see sec. 5.2.2) was used to study the PLC-GTPase stimulation and us-
ing truncated PLC (1258-2225 AA) as a model. The truncated PLC (1258-2225
AA) showed ≈ 2.8-fold (± 0.8 s.e.m.) of stimulation upon RhoA interaction in a
GDP/GTP dependent manner. These results where in the range of the data reported
in literature showing ≈ 2-fold of stimulation [323]. The same was also observed
studying PLC-K-Ras interaction, in this case ≈ 1.9-fold (± 0.6 s.e.m.) of stimu-
lation was measured in a GDP/GTP dependent manner and ≈ 2-fold of stimulation
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have been previously reported in literature for similar conditions [323]. However, an
inhibitory effect was evident in the cell-free system when the activity measured in
samples containing PLC was compared with the activity measured in samples con-
taining PLC and Sf9 membrane extract of Sf9 that expressed RhoA. This inhibitory
effect was thought to be at least in part caused by the dilution of the substrate upon
addition of the Sf9 membrane extract which contains other lipids. These lipids were
difficult to be characterised in terms of amounts and composition, therefore the ad-
dition of the Sf9 membrane extract was difficult to be controlled. The approach
chosen to overcome this inhibitory effect and control more tightly the cell-free sys-
tem was to use purified and prenylated in vitro GTPase rather than a membrane
extract of Sf9 cells expressing the GTPase (RhoA, N-Ras and K-Ras). This modi-
fied version of the cell-free system was developed using RhoA prenylated in vitro
among the GTPases used in the cell-free system (RhoA, N-Ras and K-Ras) reported
above. RhoA was selected for this purpose because it could be prenylated in vitro
in one step, while N-Ras would require two steps (farnesylation and S-acylation or
palmitoylation), and K-Ras is farnesylated, but its localisation at the membrane is
mediated by electrostatic effects which might not be as efficient in the vesicles used
in the cell-free system. The activity measurements obtained using PLC and the in
vitro prenylated RhoA did not show any drastic inhibitory effect. This is in line
with the hypothesis that the inhibition was caused by substrate dilution. The use of
in vitro prenylated GTPases makes the cell-free system more powerful, enabling
tight control over each component. Furthermore, the modified cell-free system ob-
tained was proved to be a suitable model system to investigate PLC activity as a
function of the lipid component and of the substrate presentation. In particular, this
system could be used to test recently advanced hypotheses regarding the mecha-
nism of activation of PLCs. In this respect, the transducer-effector interaction alone
has been thought not to be sufficient to induce full PLC activation. In this light, a
general auto-inhibitory model has been proposed which suggests that concomitant
transducer-effector and effector-lipid interactions are necessary to fully activate the
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PLCs [25].
Chapter 6
Analysis of PLCβ2 regulatory
mechanisms, lipid presentation and
protein-membrane interaction
studies
6.1 Introduction
PLCs are stimulated by post-translationally modified GTPases when the latter are
in the GTP bound form. The post-translationally modified GTPase is localised at
the plasma membrane and it induces translocation of the PLC from the cytosol to
the plasma membrane interface when the GTPase (in the GTP-bound form) inter-
acts with the PLC. However, the PLC-GTPase interaction might not be sufficient to
cause full PLC activation. In that light, an auto-inhibitory model has been proposed
which suggests the necessity of concomitant PLC-GTPase and PLC-lipid interac-
tion to fully activate the PLC.
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6.1.1 The auto-inhibition model
The auto-inhibition model was recently proposed by Sondek and Harden [25]. This
model was based on PLCβ2 structural information and activity data. They hypoth-
esised an auto-inhibitory function for the linker between the two halves of the cat-
alytic domain [25]. Subsequently the model was extended to the other PLCs based
on the similarities of the X-Y linkers within the PLC family and enhanced activity
of PLC mutant members lacking part of the X-Y linker.
The X-Y linker of PLCβ2 extends for 70 amino acids (466-537AA) between the
X and the Y halves of the catalytic domain. Only part of the X-Y linker (22 amino
acids), the C-terminus (516-537AA), is ordered in the crystal structure of PLCβ2.
However, from both structures of PLCβ2 available [25] [67], it is clear that the X-Y
linker partially occludes the catalytic pocket and it is stabilised in its location by
hydrogen bonding with the catalytic TIM barrel (see fig. 1.7 and 6.1).
This finding lead to further questions about the mechanism of activation. In the
attempt to bring light to the mechanism of activation, the structures of PLCβ 2 in
isolation [25] or bound to GTP Rac1 [67] have been solved and compared. The
comparison of the two PLCβ2 structures (in isolation or bound to GTP-Rac1) high-
lights PLCβ2 conformational changes induced by the binding of GTP-Rac1. These
changes could also be responsible for the PLCβ2 activation. This comparison did
not highlight any long or short range conformational rearrangement within the struc-
tured part of PLCβ2 (see fig. 6.2), but other activation mechanisms remain to be
studied more in detail.
The function of the X-Y linker and its possible role in the activation process
was investigated further by Sondek and Harden. They compared the PLC activity
measured in Cos7 cells of PLCβ2 wild type and several PLCβ2 mutants. These
mutants had part of the X-Y linker destabilised (G530P) or part of the X-Y linker
deleted (Δ516-537 AA, Δ 470-515 AA or Δ 470-524 AA). The PLCβ2 G530P
mutant showed 5-fold higher basal activity compared with the wild type and the
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Figure 6.1. Structures of PLCβ2 PLCβ2 co-crystallized with GTP-Rac1 (PDB ID = 2FJU)
[67]. The PLCβ2 structure is orientated with the side up facing the membrane and it shows
that the X-Y linker partially occluding the catalytic pocket (arrow). The PLCβ2 domains
are color coded the PH domain is in green, the array of EF hands is in fuchsia, the X and
the Y regions forming the catalytic domain are in yellow and the structured part of the X-
Y linker (516-537 AA) is in red; the co-factor, Ca2+ ion, is in orange. The electrostatic
potential of the PLCβ2 with and without the X-Y linker is shown below each structure. The
electrostatic potential correspondent to the the X-Y linker region (yellow circle) is negative,
while the electrostatic potential for the correspondent region of PLCβ2 lacking the X-Y
linker (yellow circle) is positive.
deletion mutants showed an increase of basal activity proportional to the deletion
(the Δ516-537 AA deletion mutant (Δ20) has 5-fold and the Δ 470-524 AA (Δ55)
has 50-fold higher basal activity compared to the wild type) [25]. Increased ac-
tivity was also observed in Cos7 cells or in vitro for the equivalent deletion in
PLCβ1. It was also observed that the deletion maintained unaltered the activation
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Figure 6.2. Comparison of the structures of PLCβ2 in isolation (PDB ID= 2ZKM) [25] and
PLCβ2 bound to GTP-Rac1 (PDB ID = 2FJU) [67]. The Rac1 switch 1 is in green and the
switch 2 is in pink, the GTPγS is in cyan. The comparison of these two PLCβ2 structures
did not highlight any long or short conformational rearrangement within the structured part
of PLCβ induced by GTP-Rac1 binding although the proteins were crystallized in different
conditions.
by Rac3, Gβ1γ1 or Gαq and this led them to exclude a role for the X-Y linker in the
interaction with the transducer, but instead in the auto-inhibition of the PLC. They
suggested that the X-Y linker is occluding the catalytic site in the auto-inhibition
conformation of the PLC. However, as soon the PLC binds the GTPase and translo-
cates to the plasma membrane interface, the X-Y linker relocates (see purple arrow
in fig. 6.3) making the catalytic site accessible for the substrate as a consequence
of the charge repulsion (between the negatively charged linker and the negatively
charged plasma membrane) and the stearic hindrance [25].
Similar activity modulation in Cos7 was observed for other PLC subfamilies.
Deletions of the X-Y linker equivalent to the deletion studied in PLCβ were tested
in PLCδ (Δ44) and PLC (Δ 110). Both showed an increase in activity (10 and 20
fold respectively) compared with the respective wild type forms [25]. Furthermore,
sequencing analysis of the X-Y linker across PLC members highlights clusters of
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Figure 6.3. Structures of PLCβ2 obtained in isolation (PDB ID= 2ZKM) [25] and GTP-
Rac1 (PDB ID = 2FJU) [67]. The Rac1 switch 1 is in green and switch 2 is in red. According
to the PLC auto-inhibitory mechanism proposed by Hicks and co-workers [25], PLCβ2
would translocate to the plasma membrane interface upon GTP bound GTPase (here GTP-
Rac1) where the charge repulsion between the X-Y linker and the plasma membrane would
induce a conformational rearrangement of the X-Y linker. As result of this conformational
rearrangement, the catalytic pocket of the PLC (here PLCβ2) would become accessible to
the PtdIns(4,5)P2 substrate.
negative charged residues (PLCη1, PLCη2), a predominant content of negatively
charged residues (PLCβ, PLC), or highly basic residues (PLCζ). The activity data
together with the sequencing analysis of the X-Y linkers in all the PLC sub-families
brought Sondek and Harden to extend the auto-inhibitory function of the X-Y linker
to all the isozymes as well as the activation mechanism that involves X-Y linker
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translocation. A role in the mechanism of activation for the X-Y linker in PLCs has
also been proposed by McLaughlin based on PLCζ studies [237]. In this case, the
data suggested PLC activation results from the protein-membrane anchoring medi-
ated by electrostatic interaction between the basic cluster of residues within the X-
Y linker and acidic lipids such as PtdIns(4,5)P2 [237]. The electrostatic interaction
would preferentially drive PLC anchoring to the plasma membrane (inner leaflet)
rather than to internal membranes because the former has a higher negative elec-
trostatic potential (being enriched of monovalent acidic lipids) and contains higher
amounts of PtdIns(4,5)P2 [237].
The importance of the X-Y linker and its possible role in protein membrane
binding has already been suggested by comparative studies between PLCδ1 and
PLCζ in 2007 [237]. The PLCζ is highly similar (47% sequence similarity) to
PLCδ1, but PLCζ lacks the PH domain which is responsible for lipid binding in
PLCδ1 and contains a cluster of basic residues in the XY linker. This cluster is be-
lieved to mediate the interaction with acidic lipids within the plasma membrane via
electrostatic interaction [237], therefore it does not distinguish between PI(3,4)P2 or
PI(4,5)P2. PLCδ1 localizes to the plasma membrane, probably because the PH do-
main mediates protein membrane anchoring by specifically binding PI(4,5)P2 [357].
PLC interaction and anchoring to the membrane is considered crucial for PLC ac-
tivity. Indeed, PLCs experience a substrate concentration ≈ 1000 fold higher when
bound to the membrane, and this causes the enzymatic activity to increase signifi-
cantly [2, 5, 190]. It is possible that different PLCs adopt different mechanisms to
bind to the membrane. Indeed, some are known to have specific domains that bind
PtdIns(4,5)P2 such as the PH domain in PLCδ, others exploit protein-protein inter-
actions such as PLCβ, PLCγ or PLC binding to GTPases, and others are thought
to anchor the membrane directly through the X-Y linker such as PLCζ .
The work described here investigates the mechanism of activation and regula-
tion of PLC in respect of the auto-inhibitory mechanism that has been proposed
and described above. Furthermore, the dependency of PLC activity on the lipid
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presentation is investigated using PLCβ2 as a model protein.
In order to meet the aims, it was necessary to use a flexible system to measure
PLC activity that also allows tight control of the lipid presentation. For this pur-
pose, adaptations were made to an activity assay already in use for PLCs (see sec.
2.6.2.2) in which the GTPase-PLC activation and the PLC-substrate interaction are
reconstituted in vitro [351]. In this system, the cell-free system, purified PLC pro-
tein is mixed with the substrate: PtdIns(4,5)P2 which is included in lipid vesicles
of PE:PIP2 10:1 w/w, and the GTPases contained in the membrane extract of insect
cells which expressed the specific GTPase. The cell-free system allows measure-
ments of PLC activity and PLC activation by GTPase interaction in a guanine nu-
cleotide dependent manner. Initially it was investigated whether the lipid curvature
of the vesicle containing the substrate affects PLC activity. This was achieved by
changing the method of unilamellar vesicle preparation and the post-translationally
modified GTPase source. Instead of using unilamellar vesicles obtained by soni-
cation and therefore heterogeneous in size (see 5.3), the vesicles were prepared by
extrusion. Extrusion allows preparation of vesicles characterized by a defined size
and a narrow size distribution of the vesicle population. Purified GTPases from bac-
teria (kindly provided by Dr. Bunney, ICR) were prenylated in vitro as described in
sec. 2.6.2.2.2 and used in the cell-free assay. After having found the optimal condi-
tions for the cell-free system, this system was used to investigate the auto-inhibitory
mechanism and the effect of the charge repulsion on the X-Y linker translocation.
The PLC activity was monitored using lipid vesicles the properties of which were
carefully altered. The effect of the electrostatic potential and of the elastic stress
on the protein-membrane interaction and on the protein-membrane insertion were
decoupled and investigated separately.
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6.2 Results
It has been reported that PLCβ is activated by members of the Rho family such as
Rac1, Rac2 and Cdc42 [68]. The PLCβ2-Rac2 interaction was used as a model to
test the auto-inhibitory hypothesis in the cell-free system.
6.2.1 The Rac2 GTPase-PLCβ2 cell-free system
In order to test the auto-inhibitory model, activity measurements of PLCβ 2 (2-803
AA) upon interaction with in vitro prenylated Rac2 were performed using the cell-
free system as described in Bunney et al. [351] and in section 2.6.2.2. The construct
of PLCβ2 (2-803 AA), which is lacking the C-terminal homodimerization region
was purified from insect cells and kindly provided by Prof. Gierschik. The PLCβ2
(2-803 AA) basal activity (in the absence of GTPase) was the same in the presence
of GDP or GTPγS in the sample (columns 1 and 2 in fig. 6.4).
The addition of un-prenylated Rac2 to the cell-free system caused a negligible
increase in PLC activity and the PLC activity did not change in the presence of GDP
(columns 1 and 3 in fig.
Before proceeding in testing the auto-inhibitory model, the PLC activity was
measured for a range of PLCβ2 (2-803 AA) concentrations (0.5 ng/μl - 0.05 ngμl)
in the presence of either GDP or GTPγS geranylgeranylated Rac2. All the other
parameters were kept constant. This was done to find the linear range of PLCβ2
(2-803 AA) response in the cell-free system.
The range of concentrations of PLCβ2 (2-803 AA) tested were in the linear
range, see figure 6.5. Based on the response curve obtained, 0.25 ng/ was the PLCβ2
(2-803 AA) concentration that was used in the subsequent experiments aiming to
test the auto-inhibitory model. Indeed, this enzyme concentration in the cell-free
system allowed detection of both activation and inhibition of PLCβ 2 (2-803 AA).
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Figure 6.4. Activation of PLCβ2 by GTP bound prenylated Rac2 in the cell-free system.
The bar chart reports the average activity measured in duplicate samples ± the s.e.m. mea-
sured upon sample incubation at 30 ◦C for 45 min. The samples contained: purified PLCβ2
(2-803 AA) (0.5 ng/μl), PE:PIP2:[3H]-PIP2 lipid vesicles 10:1:0.0005 w/w, 300 nM free
calcium concentration, 100 μM GDP (blue bars), of 100 μM GTPγS (red bars), and 1.6
ng/μl Rac2 after in vitro prenylation.
6.2.2 PLCβ2 activity as a function of the membrane curvature
PLCs might meet the requirements of membrane sensing proteins. Indeed, the PLC
catalytic pocket has hydrophobic rims that are thought to insert into the membrane
(see sec. 1.1.2) and the EF hands domain is believed to provide flexibility to the
protein. Furthermore, extending the analysis to the GTPase-PLC complex, the like-
lihood that PLC activity could be indirectly regulated by the membrane curvature
is even higher, because the prenyl chain of the GTPase is know to insert into the
membrane. Hence, the capability of geranylgeranyl-modified Gβ1γ2 to sense the
membrane curvature has been recently demonstrated [358]. The membrane curva-
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Figure 6.5. The response curve of PLCβ2 (2-803 AA) using the cell-free system. Different
concentrations of PLCβ2 were tested (0.5, 0.25, 0.1 or 0.05 ng/μl) by adding different
amounts of enzymes (30 ng, 15 ng, 6 ng or 3 ng) and maintaining constant the final volume
of the samples (60 μl). All the other conditions are as in fig. 6.4. The bar chart reports the
average activity measured in duplicate samples ± the s.e.m..
ture could affect directly the PLC-membrane interaction or indirectly by modulating
the GTPase membrane insertion which subsequently will result in changes of PLC
stimulation. These hypotheses were investigated further. An in vitro system needs
to be used to study whether a protein senses membrane curvature because membrane
curvature cannot be measured in vivo [234, 238, 359]. The cell-free system used to
measure PLC activity could be easily tuned to investigate the PLC-membrane cur-
vature sensing and regulation. For this specific purpose, the cell-free system was
adapted using lipid vesicles of a well defined size obtained by extrusion rather then
sonication. Lipid vesicles of different sizes (50, 100 and 400 nm in diameter) and
therefore characterized by different membrane curvature were compared.
The liposome mixture was extruded 31 times (see sec. 2.6.2.2.3) to ensure nar-
row distribution of the vesicle size across the filter pore size (50, 100 and 400 nm).
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The average size and size distribution of each vesicle mixture was monitored by
dynamic light scattering (DLS), see section 2.7.2. Only one vesicle population was
detected in the lipid mixture extruded with the 50 or 100 nm pore size filters. The
size average of these two vesicle mixtures matched the filter pore size and their size
distributions were very narrow across the average value, see fig.6.6, A.
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Figure 6.6. (A) DLS analysis of lipid vesicles prepared by extrusion using filters with
different pore sizes (50, 100 or 400 nm). EM images of the lipid vesicles obtained by
extrusion using filter with pore size of 50 nm (B). The vesicles were negatively stained
using 2% uranyl acetate. The scale bar is 300 nm.
On the other hand, two vesicle populations were detected in the lipid mixture
extruded with the 400 nm pore size filter. The main population had an average size
of 400 nm and the other population had an average size of 150 nm. The size dis-
tributions were wider if compared with the vesicles of 50 or 100 nm in diameter.
Although there was some overlap between the size distributions of the three vesicle
mixtures, the overlap was limited and the size distributions were considered suffi-
ciently different to enable detection of PLC activity as function of the vesicle size.
Therefore, the use of these vesicle mixtures in the cell-free assay could effectively
compare the effect of the vesicle size (or curvature) on the PLCβ2 activity. The vesi-
cles of each mixture were visualised by EM, (see fig.6.6, B). The morphology of
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each vesicle mixture was very similar. The vesicles appeared unilamellar (data not
shown) and with a symmetrical shape. There was only a limited degree of size het-
erogeneity within each sample and the size distributions were broadly compatible
with the size distributions obtained by DLS analysis.
These lipid vesicle mixtures prepared by extrusion were used in the cell-free
system. All the others conditions were maintained constant (PLCβ 2 concentration,
lipid composition, free Ca2+ concentration). For each vesicle mixture (which differ
only in size (50, 100 or 400 nm), activity measurements were made in the presence
of PLCβ2 and either GDP or GTPγS prenylated Rac2 and then PLCβ2 activity mea-
surements were compared. Similar activity measurements (within the error bars)
were obtained regardless the size of the lipid vesicles (see fig. 6.7). The activity
of unstimulated (GDP-Rac2) or stimulated (GTPγS-Rac2) PLCβ2 measured using
vesicles prepared by extrusion reflected those measured using vesicles obtained by
sonication (see fig. 6.7).
6.2.3 PLCβ2 activity as a function of the membrane charge
According to the auto-inhibitory function of the X-Y linker, described above, the
negative charge of the membrane plays an important role in the PLCβ2 activation
mechanism. To test this, unstimulated (in presence of GDP-Rac2) and stimulated (in
presence of GTPγS-Rac2) PLCβ2 activity was monitored using the cell-free system.
For this purpose, the lipid composition of the vesicles used in the cell-free system
was changed to increase gradually the positive (or negative) charge. The overall pos-
itive charge of the lipid vesicles was increased by substituting progressive amounts
of PtdEtn (zwitterionic lipid) with dioleoyl-glycero N-nitrilotriacetic-acid succinyl
nickel ion (DOGS-NTA(Ni2+), positively charged lipid), but maintaining constant
the PtdIns(4,5)P2 substrate concentration (PE + DOGS-NTA(Ni2+)):PIP2:[3H]-PIP2
lipid vesicles at 10:1:0.0005 w/w). The comparison of the activities measured as a
function of the positive charge of the lipid vesicles showed a decrease in PLC stim-
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Figure 6.7. Effect of lipid bilayer curvature on PLCβ2 activity. The activity was monitored
using the cell-free system and adopting lipid vesicles of different size. The lipid vesicles
were prepared by extrusion using various pore size filters (50, 100, 400 nm) or by sonication.
The samples contained: purified PLCβ2 (0.25 ng/μl), 300 nM free calcium concentration,
100 μM GDP (blue bars), of 100 μM GTPγS (red bars), geranylated Rac2 (GG-Rac2) and
lipid vesicles. All the other conditions are as in fig. 6.4. The graph shows the average
activity measured in duplicate samples ± the s.e.m..
ulation. The PLCβ2 stimulation in the presence of GG-Rac2 and GTPγS decreased
as the positive charge on the lipid vesicles increased (see columns 2, 4, 6, 8 and 10
in fig. 6.8). The trend was less clear for unstimulated activity in the presence of
GG-Rac2 and GDP (see columns 1, 3, 5, 7 and 9 in fig. 6.8. This activity response
to the increase in positive charge of the vesicles was in line with the hypothesis of
an auto-inhibitory mechanism suggested by Hicks and co-workers [25].
The effect of negatively charged lipid vesicles on the PLCβ2 activity was in-
vestigated in a similar manner. In this case, the overall negative charge of the
lipid vesicles was increased by substituting progressive amounts of PtdEtn with
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Figure 6.8. Effect of positively charged lipid vesicles on PLCβ2 activity. The overall pos-
itive charge of the lipid vesicles was increased by substituting progressive amounts of Pt-
dEtn (zwitterionic lipid with no net charge) with DOGS-NTA(Ni2+) (positively charged
lipid). The lipid vesicles of each set of samples shown in the bar chart (from left to
right) have the following PE:DOGS-NTA(Ni2+) ratios 10:0, 9.9:0.1, 9.5:0.5, 8:2 and 5:5
w/w. The PIP2 substrate amount in the vesicles was maintained constant (PE+DOGS-
NTA(Ni2+)):PIP2:[3H]-PIP2 10:1:0.0005 w/w). The lipid vesicles were prepared by ex-
trusion (using pore size filter 50 nm). All the other conditions are as in fig. 6.7. The graph
shows the average activity measured in duplicate samples ± the s.e.m.
phosphatidylserine (PtdSer, negatively charged lipid), but maintaining constant the
PtdIns(4,5)P2 substrate concentration (PE + PS):PIP2:[3H]-PIP2 lipid vesicles 10:1:0.0005
w/w. The activity of GG-Rac2 GTPγS stimulated PLCβ2 decreased as the negative
charge on the lipid vesicles increased (see columns 2, 4, 6, 8 and 10, fig. 6.9). There
was little significant change in activity with unstimulated PLCβ 2 (see columns 1, 3,
5, 7 and 9, fig. 6.9). The inverse proportional response of the PLCβ2 stimulation to
the overall negative charge of the lipid vesicles did not support entirely the working
hypothesis. According to the working hypothesis, a directly proportional response
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was expected. Indeed, an increase of the over all negative charge of the lipid vesi-
cles was expected to enhance the charge repulsion between the X-Y auto-inhibitory
linker of PLCβ2 and the lipid membrane. This charge repulsion would result in
dislocation of the auto-inhibitory loop enhancing the activity of PLCβ 2.
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Figure 6.9. Effect of negatively charged lipid vesicles on PLCβ2 activity. The overall
negative charge of the lipid vesicles was increased by substituting progressive amounts of
PtdEtn (zwitterionic lipid) with PtdSer (negatively charged lipid). The lipid vesicles of each
set of samples shown in the bar chart (from left to right) have the following PE:PS ratio
10:0, 7:3, 5:5, 3:7 and 0:10 w/w. The PIP2 substrate in the vesicles was maintained constant
(PE+PS):PIP2:[3H]-PIP2 10:1:0.0005 w/w). All the other conditions are as in fig. 6.8. The
graph shows the average activity measured in duplicate samples ± the s.e.m..
To investigate if there were other variations within these lipid vesicles in ad-
dition to the negative charge, the lipid phase of equivalent non-radiolabeled lipid
mixtures of PE:PS (7:3, 5:5 and 3:7 w/w) was monitored by small angular X-ray
scattering (SAXS) as described in section 2.7.3. The data relative to PE:PS 7:3 and
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5:5 w/w lipid mixtures were fitted and the lipid phase identified to be in lamellar
phase. The data for each lipid mixture are reported in table 6.1.
The SAXS data collection and analysis had also a qualitative significance by
suggesting that the lipid mixtures used in the cell-free system were likely to be
in lamellar phase. The lamellar phase is representative of the lipid phase within
biological membranes (see sec. 1.4.2.2), the vesicles of the cell-free system were
meant to be a good model for biological membranes. Since, lipid phase variations
could be excluded, the decrease in PLC activity was likely a response purely to the
variation of the vesicle negative charge. The decrease in PLC activity as function of
the vesicle negative charge observed here did not support the role of the electrostatic
repulsion in promoting the PLC activation.
For the lipid mixtures analysed to determine their lipid phase, the d spacing was
also analysed. The d spacing increased for increasing proportions of PtdSer over
PtdEtn within the lipid mixture, see table 6.1. The d spacing increased for lipid
composition with higher proportion of PtdSer due to the increased charge repulsion
that occurs between the adjacent (more and more) negatively charged lipid layers.
Table 6.1. The lipid phase and the d spacing values measured for each lipid composition.
The data relative for PE:PS 3:7 w/w in UF water lipid mixture was not fitted and the
lipid phase could not be determined, but lipid compositions in that range (for several lipid
chains) are reported to be in lamellar phase [360].
lipid mixture composition lipid phase d spacing
PE:PS 7:3 w/w lamellar phase 129.212 ± 1.448 Å
PE:PS 5:5 w/w lamellar phase 121.867 ± 0.603 Å
PE:PS 3:7 w/w no fit -
The shielding effect of ions was exploited to attempt to recover PLC activity
when negatively charged lipid vesicles were used. In this case, lipid vesicles of
PE:PS:PIP2 3:7:1 w/w were used with increasing concentrations of NaCl (from
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5.8 mM to 416 mM). However, the increase in NaCl concentration did not help
to recover the PLC activity. The Rac2-stimulated and unstimulated PLCβ2 activ-
ity showed little significant change over the range of NaCl concentrations (see fig.
6.10). This did not support the role of the electrostatic repulsion that has been
suggested [25]. Nevertheless, other potential mechanisms of activation could be
suggested in line with these data. For example, an insertion of the auto-inhibitory
loop into the membrane bilayer could make the PLC catalytic pocket accessible to
the substrate resulting in PLC activation.
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Figure 6.10. Effect of charge shielding on PLCβ2 activity. The lipids or PLC surface charge
was shielded by increasing the NaCl concentration. The samples contained: purified PLCβ2
(15 ng), 300 nM free calcium concentration, 100 μM GDP (blue bars), of 100 μM GTPγS
(red bars), geranylgeranyl prenylated Rac2 (GG-Rac2) and lipid vesicles (PE:PS:PIP2:[3H]-
PIP2 3:7:1:0.0005 w/w). All the other conditions are as in fig. 6.8. The graph shows the
average activity measured in duplicate samples ± the s.e.m..
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6.2.4 PLCβ2 activity as a function of the stored curvature elastic
stress
The possibility that PLC activity is regulated by the insertion of rims or loops into
the membrane bilayer was investigated by monitoring the PLCβ 2 activity using
vesicles characterized by a different stored elastic curvature stress. Vesicles charac-
terized by a different stored elastic curvature stress can be prepared varying the lipid
composition of the vesicles [361]. The lipid composition of the vesicles used in the
cell-free system has a high percentage of PtdEtn. PtdEtn is a type II lipid (see sec.
1.4.2) which due to its structural parameters and hydrogen bond formation between
the head groups, confers high curvature stress to vesicles that contain a high per-
centage of PtdEtn, see figure 1.16. The high curvature stress makes an insertion at
the lipid membrane interface highly probable because it is energetically favourable
(see sec. 1.4.2.3). The stored elastic curvature stress within the lipid vesicles was
reduced by substituting progressive amounts of PtdEtn with PtdChl (DOPC) and
then with DMPC (see fig. 6.11). The substitution of PtdEtn with DOPC, a ’type
0’ lipid, results in a decrease of stored elastic curvature stress due to the differ-
ence in space occupancy of the two lipids types, while the substitution of DOPC
with DMPC results in a decrease of stored elastic curvature stress due to the tighter
packing of the saturated hydrophobic chains.
These lipid vesicles were used in the cell-free system. The PLCβ2 activity was
monitored as described in section 6.2.1 without changing any parameter other than
the lipid vesicle composition. The lower the percentage of PtdEtn over DOPC in the
lipid vesicles, the lower the PLCβ2 stimulation. The PLCβ2 stimulation decrease
was even more pronounced when the DOPC in the lipid vesicles was substituted
with DMPC, see figure 6.12. Since lipid phase variations can be excluded, the
drastic decrease in stimulated PLCβ2 activity was likely a response purely to the
variation of the vesicle stored elastic curvature stress. The decrease in PLC activ-
ity as a function of the stored elastic curvature stress, which was observed in the
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Figure 6.11. Chemical structure of PtdEtn (PE) and PtdChl (DOPC or DMPC) used to
prepare the lipid vesicles adopted in the cell-free system.
present study for the first time, would suggest a regulatory mechanism dependent
on membrane insertion. However, it is not possible to say if the insertion of the PLC
or of the prenylated GTPase or both are responsible for this regulatory mechanism.
To investigate if there were other variations within these lipid vesicles rather
than the stored elastic curvature stress, the lipid phase of equivalent lipid mixtures to
those used for the lipid vesicles in the cell-free system was analysed. The lipid phase
of the PE:DOPC:PIP2 (7:3:1, 5:5:1 and 3:7:1 w/w) and of the DOPC:DMPC:PIP2
(7:3:1, 5:5:1 and 3:7:1 w/w) lipid mixtures was monitored by small angular X-ray
scattering (SAXS) as described in section 2.7.3. All the lipid mixtures containing
PtdEtn and DOPC or DOPC and DMPC in different ratios were in lamellar phase,
see fig. 6.13, B-D and F-H.
The lipids were in lamellar phase either when hydrated with UF water or with
the buffer used in the cell-free system. Based on this observation, the lipid phase
was expected to be representative of the lipid phase within the vesicles of the cell-
free system. The lipids were in fluid lamellar phase in the vesicles of any PE:DOPC
or DOPC:DMPC lipid composition used to measure the PLC activity as a function
of the elastic curvature stress.
The d spacing increased for increasing proportions of DOPC over PE, see figure
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Figure 6.12. Effect of the elastic curvature stress of lipid vesicles on PLCβ2 activity.
The elastic curvature stress of the lipid vesicles was decreased by substituting progres-
sive amounts of PtdEtn (type II) with DOPC (type 0) and then decreased even further by
substituting progressive amounts of DOPC (unsaturated lipid chain) with DMPC (saturated
lipid chain). The lipid composition of vesicles tested for each set of samples shown in the
bar chart (from left to right) was PE:DOPC ratio 10:0, 8:2, 7:3, 5:5, 3:7 and 0:10 w/w and
then DOPC:DMPC ratio 7:3, 5:5, 3:7 and 0:10 w/w. The PIP2 substrate in the vesicles
was maintained constant (PE + DOPC + DMPC):PIP2:[3H]-PIP2 10:1:0.0005 w/w). All
the other conditions are as in fig. 6.8. The graph shows the average activity measured in
duplicate samples ± the s.e.m.. An analogue enzyme modulation as function of the elas-
tic curvature stress was reported in a recent study on CTP:phosphocholine cytidylyltrans-
ferase (CCT) [217]. CCT inserts into the lipid bilayer thereby undergoing a conformation
change [362] which activates CCT.
6.14. The d spacing decreases when the lipid mixtures were hydrated in the same
buffer used in the cell-free system. This effect is probably due to the shielding effect
of the ions present in the buffer.
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Figure 6.13. SAXS power diffraction patterns of: (A) silver behenate used for calibration,
(B) PE:DOPC 7:3 w/w, (C) PE:DOPC 5:5 w/w, (D) PE:DOPC 3:7 w/w, (E) PE:PS 3:2 w/w,
(F) DOPC:DMPC 7:3 w/w, (G) DOPC:DMPC 5:5 w/w and (H) DOPC:DMPC 3:7 w/w .
The power diffraction patterns of the lipid mixtures (B-H) are obtained by adding the signal
of four exposures. All the lipid mixtures were hydrated in UF water.
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Figure 6.14. The graphs reports the d spacing values and their confidence intervals mea-
sured for each lipid composition (w/w) as reported in the graph. The data points were
obtained using lipid mixtures re-hydrated with UF water (in blue) or with buffer (in red).
6.2.5 Modeling PLCβ2 membrane interaction
The PLCβ2-membrane interaction was modeled using MAPAS software [363]. The
MAPAS software predicts several possible protein-membrane interactions based on
the structure of the protein. The orientation of the protein with respect to the mem-
brane is given as output together with indexes of the affinity of the protein for the
membrane. The PLCβ2 structure in isolation (ID = 2ZKM) and co-crystallized
with GTP-Rac1 (ID = 2FJU) were given as input. For each structure, several possi-
ble protein-membrane interactions and the relative protein orientation with respect
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to the membrane were indicated (see fig. 6.15, A and B). However, none of the
indicated protein-membrane interactions would orient the enzyme as such to enable
hydrolysis of the substrate, PtdIns(4,5)P2, localized at the membrane. This observa-
tion is in line with the hypothesis that a conformational change in PLCβ 2 is required
to fully activate the enzyme [25].
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Figure 6.15. Examples of the PLCβ2 orientation with respect to a model membrane pre-
dicted by MAPAS software. The following structures were given as input: (A) PLCβ2
structure in isolation (ID = 2ZKM), (B) co-crystallized with GTP-Rac1 (ID = 2FJU). The
affinities of the protein for the membrane are indicated by the following indices: mem-
branephilic residue score (MRS), membranephilic area score (MAS) and the coefficient
of membranephilic asymmetry (Kmpha). A value of MRS ≥ 4 defines the protein as
membrane-contacting, a value of MAS ≥ 50% strongly suggests that there is a contact
plane between the protein and the membrane, a value of Kmpha ≥ 2.5 strongly suggests
that the protein is membrane-contacting.
The possibility of a conformational change that involves the X-Y linker [25]
was further analysed using protein-membrane interaction modeling by MAPAS. For
this purpose the PLCβ2 structure limited to the catalytic domain was given as input.
When the membrane interaction of the TIM barrel (311-669 AA) was analysed,
several possible protein-membrane interactions were indicated. As observed with
the whole enzyme, the orientations of the PLCβ2 TIM barrel when in contact with
the membrane could not possibly result in PtdIns(4,5)P2 hydrolysis (see fig. 6.16,
A).
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Figure 6.16. Examples of the catalytic domain (or TIM barrel) of PLCβ2 orientation with
respect to a model membrane predicted by MAPAS software giving as input (A) the TIM
barrel with the X-Y linker (311-669 AA of ID = 2ZKM), or (C) the TIM barrel without
the X-Y linker (311-465 AA and 537-669 AA of ID = 2ZKM). The affinity of the protein
for the membrane are indicated by the following indexes: membranephilic residue score
(MRS), membranephilic area score (MAS) and the coefficient of membranephilic asymme-
try (Kmpha). The orientation of the PLCβ2 would have in respect to the membrane given
the orientation of the TIM barrel with the X-Y linker (B), or of the TIM barrel without the
X-Y linker (D).
These possible membrane interactions were compared with the membrane in-
teraction of the TIM barrel lacking the X-Y linker (311-669 AA). Also in this case,
MAPAS software models several possible interactions. However, according to one
modeled interaction, the orientations of the PLCβ2 TIM barrel when in contact with
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the membrane would allow PtdIns(4,5)P2 hydrolysis and it is feasible with the ori-
entation of the entire protein in respect to the membrane (see fig. 6.16, B and D).
The fact that, upon removal of the X-Y linker, MAPAS could model the PLCβ2 cat-
alytic domain interaction with the membrane with an orientation compatible with
substrate hydrolysis reinforced the hypothesis that a conformational change affect-
ing the X-Y linker is necessary to achieve full PLCβ2 activation.
6.2.6 The auto-inhibitory function of the X-Y linker in vivo
The auto-inhibitory effect of the X-Y linker of PLCβ2 was tested using the in vivo
system (as described in sec. 2.6.1). In the in vivo system, Cos7 cells were used to
monitor PLCβ2 activity and PLCβ2 stimulation as a function of constitutively ac-
tive Rac2 (Rac2G12V ). For this purpose, the Cos7 cells were transfected with PLCβ2
(2-803 AA) w.t. alone or co-transfected with the constitutively form of Rac2G12V
as described in section 2.6.1. The same was repeated using the deletion mutants
of PLCβ2 which lack part of the X-Y linker, PLCβ2 (2-803 AA) Δ(470-529) and
PLCβ2 (2-803 AA) Δ(470-540). The constructs encoding for these deletion mu-
tants were obtained by site direct mutagenensis in a pTriEx4 vector as described in
section 2.2.6. The analysis of the total cell lysate of the Cos7 cells by Western blot-
ting confirmed expression of the desired constructs in each sample (see fig. 6.17).
Furthermore, it was observed that the expression of each construct was very similar
across the different samples. This ensured that the samples and their activities could
be compared.
The activity measured in cells transfected only with PLCβ2 (2-803 AA) w.t.
constructs was similar to the activity measured in un-transfected cells (column 1
and 3 in fig. 6.17). A small decrease in PLC activity was observed in Cos7 cells
transfected with Rac2G12V .
The comparison of the activities measured in Cos7 cells transfected with PLCβ2
(2-803 AA) w.t. alone and co-transfected with Rac2G12V , showed ≈ 2-fold of stim-
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Figure 6.17. (A) PLC activity measured by accumulation of inositol phosphates in Cos7
cells. The values shown are the mean ± s.e.m. for duplicate samples. In blue, Cos7 cells un-
transfected with any PLCβ2 constructs (control) or Cos7 cells transfected with the PLCβ2
(2-803 AA) wild type, PLCβ2 (2-803 AA) Δ(470-540 AA) or PLCβ2 (2-803 AA) Δ(470-
529 AA) construct (1 μg DNA), in red Cos7 cells co-transfected cells with the PLCβ2
(2-803 AA), PLCβ2Δ(470-529 AA) or PLCβ2 (2-803 AA) Δ(470-540 AA) construct and
Rac2G12V (0.5 μg of DNA). The expression of the transfected constructs was confirmed by
Western blotting.
ulation (see column 3 and 4 in fig. 6.17). The activity measured with PLCβ 2 (2-803
AA) Δ(470-540 AA) was ≈ 1.9-fold higher than the activity measured with PLCβ2
(2-803 AA) w.t. alone (see column 3 and 5 in fig. 6.17), and equal (within the error
bars) to PLCβ2 (2-803 AA) w.t. stimulated by Rac2G12V (see column 4 and 5 in fig-
ure 6.17). The increase in activity was even higher (≈ 4.8-fold) when the activity of
PLCβ2 (2-803 AA) Δ(470-529 AA) was compared to the activity of PLCβ2 (2-803
AA) w.t. (see column 3 and 7 in figure 6.17). Both of the PLCβ2 deletion mutants
(lacking part of the auto-inhibitory X-Y linker) had higher activity than PLCβ 2 w.t.
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(in respect to the X-Y link). These observations support the auto-inhibitory function
of the X-Y linker proposed by Hicks et al. [25]. PLCβ2 (2-803 AA) w.t. showed
2-fold of stimulation in the presence of Rac2G12V while PLCβ2Δ(470-540 AA)
showed only 1.4-fold (column 5 and 6 in fig. 6.17) and PLCβ2Δ(470-529 AA)
1.2-fold of stimulation (column 7 and 8 in fig. 6.17). These data suggest that the
deletion of the X-Y linker in PLCβ2, Δ(470-529 AA) or Δ(470-540 AA), affect the
mechanism of PLCβ2-Rac2 regulation.
6.2.7 The auto-inhibitory function of the X-Y linker in vitro
The auto-inhibitory effect of the X-Y linker of PLCβ2 and the role of the linker
in the regulation of the Rac2 interaction was further tested in vitro using the cell-
free system (see sec. 2.6.2.2). For this purpose, the deletion mutants of PLCβ2,
PLCβ2Δ(470-529 AA) and PLCβ2Δ(470-540 AA) need to be purified. The con-
structs encoding for these enzymes were in a pTriEx4 vector backbone and therefore
they are compatible with bacteria as well as with mammalian cells. The deletion
mutants were expressed in E.coli C41 DE3 cells and purified close to homogene-
ity (see fig. 6.18, A). The mixed micelles assay was performed (see sec. 2.6.2.1)
using the PLCβ2 (2-803 AA) Δ(470-529 AA) PLCβ2 (2-803 AA) Δ(470-540 AA)
obtained at the end of the purification process. Both deletion mutants as well as the
PLCβ2 (2-803 AA) w.t. showed high PLC activity (see fig. 6.18). This ensured
that they were purified in an active functional state and therefore suitable to be used
in the cell-free system. The cell-free system was used to measure the activity of
each PLCβ2 construct in the presence of GDP (or GTPγS) GG-Rac2, which was
geranylgeranylated in vitro (see sec. 2.6.2.2).
Different concentrations of PLCβ2 (2-803 AA) Δ(470-540) were tested in order
to find the condition that gives a similar response to PLCβ 2 (2-803 AA) w.t. in the
cell-free system. A similar stimulation response (in the presence of GTPγS-GG-
Rac2) to that with 0.25 ng/μl PLCβ2 (2-803 AA) w.t. was obtained using just half
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Figure 6.18. (A) Comassie stained SDS-PA gel loaded with the purified PLCβ2 (2-803 AA)
w.t. provided by Prof. Gierschik or with the pool of the elution fraction of size exclusion
chromatography (last step of the purification process) which contain PLCβ2 (2-803 AA)
Δ(470-529 AA) or PLCβ2 (2-803 AA) Δ(470-540 AA) (harrow)); (B) Specific activity of
(1) PLCβ2 (2-803 AA) Δ(470-529 AA), (2) PLCβ2 (2-803 AA) Δ(470-540 AA) or (3)
PLCβ2 (2-803 AA) w.t. The PLC activity was measured using the mixed micelles assay.
Data are presented as the mean ± s.e.m. of individual measurements.
that concentration (0.125 ng/μl) of PLCβ2 (2-803 AA) Δ(470-540), see columns 2
and 4 in figure 6.19.
Furthermore, in the presence of GDP-GG-Rac2, the activity of PLCβ2 (2-803
AA) w.t. was lower than the activity of PLCβ2 (2-803 AA) Δ(470-540), see columns
1 and 3 in figure 6.19. This observation is in line with what was previously ob-
served in Cos7 cells transfected with the same PLCβ2 constructs. In both cases, the
deletion of a portion of the linker produced an enzyme more active regardless of the
interaction with Rac2. Having determined the concentrations of PLCβ2 (2-803 AA)
w.t. and PLCβ2 (2-803 AA) Δ(470-540) needed to be used to obtain a comparable
response in the cell-free system, the cell-free system was used to further investi-
gate the function of the X-Y linker. For this purpose, vesicles with different surface
charge or stored elastic curvature stress were used. The responses of PLCβ2 (2-803
AA) w.t. and of PLCβ2 (2-803 AA) Δ(470-540) were compared. Both constructs
showed an equal decrease in stimulated and unstimulated activity in lipid vesicles
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Figure 6.19. PLC activity measurements obtained using the cell-free system. The graph
reports the average activity measured in duplicate samples ± the s.e.m. measured upon
sample incubation at 30 ◦ C for 45 min. The samples contained: purified PLCβ2 (2-803 AA)
w.t. (0.25 ng/μl) (or purified PLCβ2 (2-803 AA) Δ(470-540), 0.125 ng/μl), PE:PIP2:[3H]-
PIP2 lipid vesicles 10:1:0.0005 w/w, 300 nM free calcium concentration, 100 μM GDP
(blue bars), of 100 μM GTPγS (red bars), and 1.6 ng/μl Rac2 after in vitro prenylation.
containing PtdSer, or PtdChl (data not shown).
6.3 Discussion
6.3.1 The cell-free system
The cell-free system was successfully used to monitor unstimulated and stimulated
PLCβ2 (2-803 AA) w.t. activity as a function of the Rac2. The PLCβ2 stimulation
by Rac2 measured here was ≈ 3-fold and it was in line with previously reported
data [351]. The cell-free system confirmed that only GTPγS bound Rac2 (and not
GDP bound) stimulates PLCβ2 (2-803 AA). Furthermore, upon in vitro prenyla-
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tion of Rac2, it was observed that the geranylgeranylation of Rac2 (GG-Rac2) is
essential for PLCβ2 (2-803 AA) activation. The cell-free system, performed using
the purified PLCβ2 (2-803 AA) and the purified Rac2 (subsequently prenylated in
vitro, GG-Rac2), confirmed that Rac2 binds directly to PLCβ2 as previously re-
ported [65, 351]. In addition, the cell-free system as such allowed a fine control
over all the parameters of the system (PLCβ2, PtdIns(4,5)P2, free Ca2+ concentra-
tions). The fine control over each parameters of the system guaranteed a very high
reproducibility of the data and made it possible to use the cell-free system to extend
the investigation of PLCβ2 mechanism of regulation to the protein-lipid interaction
and not just to the protein-protein interaction. The cell-free system was not only
proved to be suitable to study the protein-protein (PLCβ2-Rac2) and protein-lipid
[PLCβ2-PtdIns(4,5)P2] interactions, but also easily adaptable for this purpose. The
response curve indicated that a concentration of 0.25 ng/μl of PLCβ2 (2-803 AA)
was optimal to measure the stimulation of PLCβ2 as a function of Rac2 and of the
lipid composition of the vesicles. For this concentration, either increase or decrease
of PLCβ2 (2-803 AA) stimulation as result of the lipid interaction could be detected
using in the cell-free system.
6.3.2 The membrane curvature
In recent years there has been growing evidence of proteins that can sense the mem-
brane curvature and that membrane curvature can regulate the activity of peripheral
or membrane proteins [232]. The best candidates to be regulated as such are the
proteins that can induce or adapt to the membrane curvature either by insertion of
protein moieties or by a scaffolding mechanism (see sec. 1.4.2.3). The proteins
characterized by intrinsic flexibility are thought to be capable of sensing the mem-
brane curvature by adapting to the membrane curvature. PLCs could meet this
requirements, indeed PLCs are thought to insert the hydrophobic rims of the cat-
alytic domain into the membrane [26]. A highly curved membrane has a higher
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number of hydrophobic areas exposed, and therefore a higher number of sites to
which the hydrophobic moieties of a protein can bind to (see sec. 1.4.2.3). Fur-
thermore, the EF hand domain is believed to provide the enzyme with sufficient
flexibility. In addition, it has been shown that membrane insertion of prenylated
proteins, such as geranylgeranyl-modified proteins [235], is sensitive to the mem-
brane curvature [364]. For these reasons, it was investigated if PLCβ2 can sense the
membrane curvature and if PLCβ2 catalytic activity was curvature dependent.
The membrane curvature cannot be quantitatively measured in vivo, therefore
previous studies that addressed the correlation of protein activity and the membrane
curvature have been designed in vitro using liposomes [238, 365]. Liposomes of
different sizes and therefore of different curvature can be obtained by extrusion.
Liposomes have been used in biochemical assay to measure enzyme activity, and
comparison of the activity as a function of the liposome size was used to study the
effect of the lipid curvature on the enzyme activity [234]. This same approach has
been used in the cell-free system. Using the cell-free system adaptation it proved to
be straightforward to analyse the PLCβ2 activity and stimulation upon Rac2 inter-
action as a function of the membrane curvature.
The data generated at this stage did not show significant variation in the PLCβ 2
activity in the presence of GDP Rac2 and no variation in PLCβ2 stimulation (3-
fold) when in presence of GTPγS Rac2 using lipid vesicles of different sizes. It is
therefore possible to think that there is little dependency of PLCβ2 activity and the
membrane curvature.
6.3.3 Characterisation the structural parameters of the fluid bi-
layer
To understand the protein-lipid interaction it is essential to characterise the struc-
tural parameters of the fluid bilayer and the type of interaction of the protein. Struc-
tural parameters of the fluid bilayer such as: the lipid bilayer thickness (dl) and the
6.3 Discussion 221
the lipid area (A) are crucial to interpret the protein-membrane interaction (see sec.
1.4.2.2). Small-angle X-ray diffraction spectra of the lipid mixtures of the vesicles
were used to characterise the phase of the lipid and to measure the unit cell spacing
(d). The lipid mixtures equal in composition to the lipid vesicle (used in the cell-free
system) were analysed by SAXS in order to have an indication about the lipid phase
assumed by the lipid mixture within the unilamellar vesicles. Each lipid composi-
tion tested was predicted to be in fluid lamellar phase as the biological membrane.
This ensured that the vesicles used in the cell-free system were a suitable model for
a biological membrane at least for what concerned the lipid phase.
6.3.4 Protein-membrane interaction
The electrostatic potential for each protein is a function of the pH, the temperature
and the solvent. Often the variations of enzyme activity dependent on the pH arise
from electrostatic potential variation of the enzyme [366]. This is especially true
when residues whose charge change according to the pH are involved in the cat-
alytic activity. Variations of the charge of these residues might alter the substrate
binding, the transition state or the product release thereby affecting the overall ac-
tivity also in a drastic manner. These could be the case for PLCs which have two
histidine residues that are key for the catalytic activity (see sec. 1.3) and indeed
the PLCs activity varies as a function of the pH in vitro [322]. The effect of the
electrostatic potential perhaps is not just limited to the catalytic residues charge,
but according to the auto-inhibitory model of Hicks et al., the charge repulsion
between the plasma-membrane and the X-Y linker causes a conformational rear-
rangement of the linker that leads to activation of PLCβ [25]. For these reasons,
the effect on the surface charge of the lipid layer was investigated by varying the
surface charge of the vesicles used in the cell-free system. Positively charged vesi-
cles or negatively charged vesicles affected the stimulation of PLCβ2 (2-803 AA)
by Rac2. The PLCβ2 (2-803 AA) stimulation from 3-fold (in PE:PIP2:[3H]-PIP2
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10:1:0.0005 w/w vesicles) decreased progressively and eventually disappeared in
positively charged vesicles (in DOGS-NTA(Ni):PE:PIP2:[3H]-PIP2 4.5:4.5:0.0005
w/w vesicles) and in more highly negatively charged vesicles (in PS:PIP2:[3H]-PIP2
10:1:0.0005 w/w vesicles). At a late stage, the ionic strength was increased, by in-
creasing the NaCl concentration, to decrease the effect of the electrostatic potential.
The higher the concentration of the salt, the lower the effective charge at the mem-
brane or protein surface. Indeed, doing so the salt ions shield the charge of the
lipid and of the protein. The data collected varying the vesicles charge fit with
the regulatory mechanism advanced by Hicks [25], but not entirely. According to
this regulatory mechanism, PLCβ2 stimulation should increase by increasing the
negative charge on the vesicle. However, the activity data collected here showed
a threshold (PE:PIP2:[3H]-PIP2 10:1:0.0005 w/w vesicles) after which further in-
crease of the negative charge result in a decrease of PLCβ2 stimulation. Therefore,
it was thought that other mechanisms, together with the charge repulsion between
the linker and the membrane, might play a role in the mechanism PLCβ 2 activa-
tion. The electrostatic potential has been shown to control protein membrane ab-
sorption. Proteins characterised by clusters of basic residues (present in several
proteins) are capable of adsorbing to a membrane thereby generating a positive
electrostatic potential that lead to sequestration of multivalent acidic lipids such as
PtdIns(4,5)P2 [174,186,349]. This has been reported to be the case for PLCζ [237]
in which case the PtdIns(4,5)P2 sequestration is driven by electrostatic interaction
(and therefore salt dependent). As a direct consequence of PtdIns(4,5)P2 seques-
tration, the concentration of PtdIns(4,5)P2 is increased resulting in increased PLC
activity if the PLC catalytic site is less than 1 Debye length (≈ 1 nm in physio-
logical conditions) [174]. However, the electrostatic potential together with other
possible mechanisms could explain fully the behavior of PLCβ 2 stimulation. In this
light, lipid-PLC interaction was be decoupled into two major components: the elec-
trostatic and the hydrophobic component. The changes in the ionic strength altered
the balance between the the electrostatic effect and the hydrophobic effect, making
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the latter prevailing on the former. It is not possible to exclude additional regulation
upon partial membrane insertion of the protein PLCβ2. These were analysed by
changing the stored curvature elastic stress of the vesicles.
6.3.5 The stored elastic curvature stress
The particular lipid composition of the vesicles adopted in the cell-free assay in-
clude a very high percentage of PtdEtn. PtdEtn is so-called ”non bilayer” lipid
due to its packing parameter S = 0 (see sec. 1.4.2.2). PtdEtn is a type II lipid
and according to the shape-structure concept, it tends to form negative curved lipid
structures (e.g. inverted hexagonal phase), see figure 1.16. However, under certain
circumstances, the formation of non lamellar structure is not energetically favored,
and frustrated bilayers are formed.
The non bilayer lipids affect the properties of the membrane and can regulate the
activity of membrane proteins or peripheral proteins [367]. Several studies showed
non bilayer lipids stimulate the activity of peripheral proteins (phospholipase A2
[368], CTP:phosphocholine cytidylytransferase [217] or kinase C [369]).
There are several hypotheses that explain how non bilayer lipids affect the mem-
brane and the protein membrane interaction. They are the formation of bilayer
packing defects that promote membrane binding [224, 370], the formation of ’hy-
drophobic spots’ by DAG [371], but the more general model is based on the lateral
pressure π. The lateral pressure (see fig. 1.16) is related to the curvature stress by
the torque tension τ :
τ =
∫
π(z)z dz = 2 k Co (6.1)
where: k is the mean curvature modulus, z is the depth in the lipid bilayer and Co
is the spontaneous curvature. While the stored curvature stress (gc) of a frustrated
bilayer is quantified by the following function:
gc = 2 k Co
2 (6.2)
6.3 Discussion 224
where: k is the mean curvature modulus and Co is the spontaneous curvature.
The insertion of a peripheral membrane protein into a lipid bilayer affects the
lateral pressure. As consequence of the insertion event, the lateral pressure at the
head-groups increases, but the lateral pressure at the acyl chain decreases (in a bi-
layer that contains non bilayer lipids) indeed the overall lateral pressure has to re-
main zero. This translates into a partial release of the stored curvature stress and the
binding event is therefore favourable.
PLCβ1 and PLCβ2 have been shown to be unable to bind PtdCho vesicles,
but they are able to bind vesicles of PtdCho:PtdEt:PtdSer (1:1:1 mol/mol) with
kD ≈ 10−5 M [18]. However, deletion mutants of PLCβ1 or PLCβ2 lacking the
C-terminus do not bind the lipid vesicles, suggesting that the C-terminus contains
residues that mediate the membrane binding. Since the PLCβ2 (2-803 AA) con-
structs used in the studies presented here were missing the C-terminus, no binding to
the lipid vesicles used in the cell-free system was expected unless as a consequence
of the Rac2-PLCβ2 binding and consequent PLCβ2 translocation to the membrane
interface as part of the regulatory mechanism.
Here, the stored curvature stress was altered by changing the lipid composition.
The stored curvature stress was decreased by substituting lipids according to their
geometrical parameter (S); PtdEtn (type II) was substituted with DOPC (type 0).
The stored curvature stress was then decreased further by increasing the degree of
unsaturation of the hydrophobic chains substituting DOPC for DMPC (see tab. 6.2).
Table 6.2. Biophysical properties of the lipids used in this study: cross-sectional area per
lipid molecule (A), bending moduli (k) in J.
lipid k reference Co reference A reference
DOPC 3.7 × 10 −20 [372] -1/160 [372] 72.2 at 30 ◦C [373]
DMPC 6.5 × 10 −20 [374] -1/33 [228, 375] 60-70 Å2 [376]
DOPE 4.5 × 10 −20 [372] -1/53 [377, 378] Ap65Å2 [372]
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The stimulation of PLCβ2 activity was affected by the stored elastic curvature
stress suggesting that the PLCβ2-GG-Rac2 interaction has a component of mem-
brane insertion as part of the regulatory mechanism. PLCβ2 stimulation upon
GG-Rac2 interaction decreased from 3-fold (in PE:PIP2:[3H]-PIP2 10:1:0.0005 w/w
vesicles) to disappear (in DMPC:PIP2:[3H]-PIP2 10:1:0.0005 w/w vesicles). How-
ever, the data collected so far do not allow the attribute of the membrane insertion
exclusively to one of the two or to both proteins (PLCβ2 and GG-Rac2) involved.
Furthermore, the membrane insertion might be only one of the components of a
more complex regulatory mechanism. Indeed, the PLC activity measured as a func-
tion of the lipid charge and of the stored elastic curvature stress suggests that elec-
trostatic interactions as well as the insertion might play a role in the regulation of the
PLC activity. These two components, the electrostatic and the insertion, would need
to be studied in more detail to clarify the dynamics of the regulatory mechanism.
For this purpose, circular dichroism (CD) spectroscopy would be useful to study if
there is a conformational rearrangement in the secondary structure of the protein or
part of the protein upon membrane interaction. These type of experiments could
indicate if the disordered X-Y linker folds into an α helix when in contact with a
lipid bilayer.
6.3.6 The function of the X-Y linker in the regulatory mecha-
nism of PLCβ2
The data collected here to study the function of the X-Y linker fit with the hypothe-
sis of an auto-inhibitory function [25]. Indeed, removal of the the X-Y linker results
in an enzyme with higher basal activity. This effect was observed in the in vivo sys-
tem and in the cell-free system. In the in vivo system the deletion mutants PLCβ 2
(2-803 AA) Δ(470-540 AA) and PLCβ2 (2-803 AA) Δ(470-529 AA) showed ≈1.9
and ≈4.8 higher basal activity than PLCβ2 (2-803 AA) w.t. respectively. The same
trend was observed by comparing the activity of purified PLCβ2 (2-803 AA) w.t.
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and purified PLCβ2 (2-803 AA) Δ(470-540 AA) in presence of GDP-Rac2 using
the cell-free system. The increase of the basal activity in the PLCβ2 deletion mu-
tants was in line with that reported in literature [25] and supports the auto-inhibitory
function of the linker. Based on the data collected with the cell-free system (chang-
ing the electrostatic potential or the stored elastic curvature stress) it is difficult to
indicate by which mechanism the auto-inhibition is released. It is certainly possible
that the X-Y linker is repelled by the electrostatic charge of the membrane, and the
conformational rearrangement of the X-Y linker leads to activation of PLCβ2 [25].
However, alternative mechanisms are also compatible with the data such as par-
tial insertion into the membrane and consequent conformational change. Indeed,
the activity measurements done using the cell-free systems indicate that both the
electrostatic potential and the stored elastic curvature stress regulate PLCβ2 stim-
ulation, compatible with partial protein insertion. Previous structural studies on
lipases showed that the catalytic pocket has an amphiphilic loop that occludes the
catalytic site residues [379]. There is strong evidence to think that the loop under-
goes a conformational rearrangement which makes the catalytic pocket accessible
to the substrate when the protein is at the water-lipid interface. [380]. This might
also be the case with PLCβ2, and CD studies could address this possibility.
6.3.7 Further investigation of the role of the X-Y linker in the
mechanism of PLC activation
In future work, the hypothesised conformational change of the X-Y linker could be
investigated via inter-molecular FRET. With this aim in mind a specific construct of
PLCβ2 (2-803 AA) was designed based on the PLCβ2 crystal structures available
[25, 67]. In order to allow detection of displacement of the linker, one fluorophore
was placed on the C-terminus of PLCβ2 and the other on the X-Y linker, see figure
6.20. The following FRET pair was chosen: yellow fluorescent protein (YFP),
which could be expressed recombinantly on the C-terminus of PLCβ2 and resorufin-
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derived red fluorescing biarsenical dye (ReAsH) which could be chemically labeled
to a specific tetra-cysteine motif engineered in the X-Y linker [381].
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Figure 6.20. (A) Structure of ReAsH dye and the synthesis of ReAsH-EDT2 from fluores-
cein arsenic state followed by reaction with 1,2-ethanedithiol (EDT). Fluorescent complex
formation of ReAsH with the binding modif within the α-helix of the X-Y linker of PLCβ2,
and the distance between the FRET pair sites measured on the basis the structure of PLCβ2
(ID = 2ZKM) by PyMOL applet. The fixed distance between the two arsenics in ReAsH
increases the specificity for the tetracystine binding motif due to their spatial conformation,
each arsenic will bind two thiol groups. The protein labelling has been reported having
a yield ≥ 80% [149]. (B) Excitation and emission spectra of YFP and ReAsH complex.
ReAsH complex excitation maximum is at 593 nm and the emission maximum is at 608
nm.
The decision to use ReAsH arose from the fact that ReAsH, being a small
molecule, is unlikely to alter the protein structure [106, 382], and the binding mo-
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tif could be easily created by side direct mutagenesis. Furthermore, this approach
allows reversible binding of the tetra-cysteine preserving the single cysteines in the
protein, and unbound dye is not fluorescent therefore the background noise remains
low. The ReAsH binding motif: CCGPCC [149] was created aiming to alter the X-
Y linker properties in terms of stability or electrostatic potential as little as possible.
The optimal binding motif, CCGPCC [149], was created in the structured region of
the linker (α-helix conformation) to ensure that the relocation of the linker will as
well result in ReAsH fluorophore relocation, and consequent ReAsH-YFP distance
variation.
Chapter 7
Structural studies on PLC by
electron crystallography, analysis of
conditions for two-dimensional
crystals and future plans
7.1 Introduction
Electron crystallography is a powerful method with the potential to solve protein
structures to high resolution (8 Å or better) [272]. This method is based on im-
age analysis of electron micrographs of two-dimensional (2D) crystals of purified
soluble or membrane proteins, see section 1.5.1. Electron crystallography applied
to PLC would be particularly valuable because this method allows us to retrieve
structural information of PLC in its functional state. Indeed, this approach pro-
vides a close to native environment for an associated membrane protein such as
PLC because two-dimensional crystals can be prepared on a lipid monolayer (see
1.5.1.1), in which case the lipid monolayer would resemble the inner leaflet of the
plasma membrane (see fig. 7.1).
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Figure 7.1. Schematic representation of two-dimensional crystals formation.
Structural determination of PLC would greatly enhance the understanding of
the PLC mechanism of function and regulation. Even structural data at an inter-
mediate resolution (12 Å - 8 Å) could be highly useful. Indeed, at an intermediate
resolution, the electron density could be analysed and interpreted using the exist-
ing structural data for PLC, RA1 and RA2 [36], or the conserved domains of the
other PLC isoforms, PLCδ [21] and PLCβ [25, 67]. If the known structures could
be docked into the electron density, each domain could be identified. This would
lead to the determination of the domain organisation (spatial organisation of each
domain with respect to the others and with respect to the lipid monolayer) and the
identification of which domains (or possibly parts of the domains) might play a
role in the PLC-membrane binding or in the interaction with the transducer. This
information could be compared with current understanding of the mechanism of
regulation based on the functional and biochemical data available [25, 36]. This
comparison would allow us to determine whether a conformational change is re-
quired for interaction with the PtdIns(4,5)P2 substrate or the known effectors. High
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resolution structural data of the full length of PLC would indicate the nature of the
interactions at an atomic level and at this stage hypotheses could be inferred about
the interactions that are not yet well characterised at the biochemical level (Ral-N-
terminal region of PLC, or CDC25-Rap). These hypotheses could then be inves-
tigated further and characterised by performing specifically designed biochemical
experiments.
With these aims in mind, the conditions for the growth of planar two-dimensional
crystals of PLC on a lipid monolayer were investigated. According to the lipid
monolayer approach, this system should more closely resemble the inner leaflet of
a plasma membrane than other types of two-dimensional crystals.
To establish the techniques needed for two-dimensional crystallisation of PLC
the crystal growth, harvesting, staining and imaging were practiced on a model pro-
tein. Streptavidin was chosen as the model protein because two-dimensional crys-
tallisation on a lipid monolayer which contains biotinylated lipids is established
and well documented in literature [383]. Planar two-dimensional crystals of strep-
tavidin were successfully grown, harvested, negatively stained and imaged by EM
as reported in literature [383].
After this initial success in mastering the techniques involved, the focus was
placed on two-dimensional crystallisation of PLC. Various approaches can be used
to bind soluble proteins to a lipid monolayer as mentioned in section 1.5.1 and, sim-
ilarly to streptavidin, a specific protein-lipid interaction was exploited to promote
PLC two-dimensional crystallisation on a lipid monolayer. In fact, two specific
interactions were explored to immobilise PLC at the lipid interface.
Initially, the interaction between an accessible sequence of consecutive his-
tidines (His6-tag) fused on the N-terminus of PLC (1258-2225 AA) and the nickel
nitrilotriacetic acid NTA(Ni2+) head group of commercially available synthetic lipids,
DOGS-NTA(Ni2+), was used (see fig. 7.2). This interaction represents a general
tool that has previously been successfully exploited to drive two-dimensional crys-
tallisation of soluble His-tagged proteins on a lipid monolayer [287, 292, 302, 388].
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Figure 7.2. Structure of water coordinated DOGS-NTA(Ni2+) lipids or in complex with a
His-tagged protein. The tetradentate NTA ligand binds nickel with higher affinity than sim-
ilar tridentate ligands, reducing the possibility of metal leaching. The hexahedral nickel,
having two free coordination sites, can bind two histidine residues in close proximity. Six
consecutive histidines and the metal-chelating head group form a complex that has a disso-
ciation constant in the picomolar range (Kd = 10−13 M at pH 8) [384]. The affinity of this
lipid-protein binding increases with the number of consecutive histidines available on the
protein (from His2 to His10). This high affinity interaction, was initially exploited for the
purification of His-tagged proteins [385], and then successfully used for two-dimensional
crystallisation [386–388]. This proved that DOGS-NTA(Ni2+) meets the requirements of
functionalised lipids suitable for two dimensional crystallisation, such as high affinity bind-
ing to the target protein, miscibility with other bulk lipids and steric accessibility of the
lipid head group at the water-lipid interface. The two unsaturated hydrophobic chains of
DOGS-NTA(Ni2+) maintain the fluidity of the lipid layers.
Furthermore, the His-tag on the protein can also be used for purification of the pro-
tein, thereby serving a double purpose and due to its small size, it does not compro-
mise the folding or the functionality of the protein. The lipid monolayer contained
synthetic lipids, DOGS-NTA(Ni2+), diluted into a so-called bulk lipid to guarantee
sufficient diffusion within the lipid monolayer.
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Subsequently, an alternative type of specific interaction was exploited to immo-
bilise PLC at the lipid monolayer interface. In this case, inactive mutants of PLC
(H1433L or H1388A or H1433L H1388A) capable of binding to the PtdIns(4,5)P2
substrate, were generated based on the structure of the catalytic domain of PLCδ1.
The ability of the PLC mutants (H1433L or H1388A) to hydrolyse PtdIns(4,5)P2
was tested and the inactive mutants were then purified.
After deciding which protein-lipid interactions were to be used to drive two-
dimensional crystallisation, the specificity of PLC binding to the lipidic system
in the two approaches, His6tagged PLC to DOGS-NTA(Ni2+) or inactive PLC
to PtdIns(4,5)P2, were investigated using a comparable lipid system such as giant
unilamellar lipid vesicles, GUVs. In both cases, PLC tagged at the C-terminus
with eGFP and the GUVs were prepared with the same lipid composition as the
lipid monolayer used for crystallisation. Sucrose loaded GUVs were prepared and
incubated with PLC-eGFP, the protein-lipid binding was imaged by fluorescent
microscopy, and it was semi-quantitatively detected using sedimentation followed
by Western blotting.
In the following stage, attention was focused on the level of purity that could
be achieved for the PLC constructs. The protein purification was optimised be-
cause use of highly pure protein increases the chance of obtaining two-dimensional
crystals. Indeed, if impurities or alternative degradation products (rather than mis-
folding products) are present, they can prevent growth of the ordered lattice (see
sec. 1.5.1). The His-tagged constructs of truncated PLC (1258-2225 AA) (His6-
MBP-PLC or His6-PLC-eGFP), which could be expressed as soluble protein and
purification optimisation of which was described in section 3, were used for two-
dimensional crystallisation trials.
In the last stage, a wide range of two-dimensional crystallisation conditions on
a lipid monolayer (protein concentration, lipid concentration, lipid mixture compo-
sition, temperature or incubation time) and their combinations were tested because
the crystallisation is a process dependent on multi-variables. The samples were
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harvested and screened for two-dimensional crystal formation by EM.
7.2 Results
7.2.1 Two-dimensional crystals of streptavidin
Streptavidin has been used as a model protein to study the mechanism of two-
dimensional (2D) crystallisation on a lipid monolayer and the sample preparation
for EM. The structure of streptavidin has been solved independently using X-ray
crystallography [389, 390] making streptavidin an ideal model protein. Here, strep-
tavidin was used to get familiar with the preparation of 2D crystallisation trials of
a soluble protein, but also with the harvesting, staining and imaging of the sample
by EM. Streptavidin is a tetrameric soluble protein with four biotin-binding sites.
It was crystallised on a lipid monolayer containing biotinylated lipids as previously
described in the literature [278, 383]. The protein-lipid binding in such a system
relies on a specific and strong interaction with a dissociation constant of Kd = 4
× 10−14 [391]. Indeed, the avidin-biotin interaction is the strongest non covalent
biological interaction known.
Two-dimensional crystals of streptavidin (see fig. 7.3) were observed in the
samples harvested after three hours of incubation. However, larger patches of two-
dimensional crystals of streptavidin were observed in crystallisation trials incubated
for longer (24 hours). Two methods were used to harvest the sample and transfer
it to an EM grid (see sec. 1.5.1.1). Two-dimensional crystallisation samples of
streptavidin were harvested by a wire-loop and then transfered onto a glow dis-
charged EM grid with the hydrophilic side of the monolayer in contact with the
carbon of the EM grid [308] (see 1.22, A). Alternatively, identical samples were
harvested by direct contact with a hydrophobic EM grid. This was achieved by
placing the hydrophobic EM grid (with the carbon film in direct contact with the
sample) on the top of the sample, by doing so the hydrophobic carbon film was
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Figure 7.3. (A) Coomassie stained SDS-PAGE loaded with streptavidin used for two-
dimensional crystallisation trials. (B) Negatively stained two-dimensional crystals of strep-
tavidin on a lipid monolayer. The sample was prepared using 15 μl of streptavidin (0.1
mg/ml in 20 mM TrisCl pH 7.5, 150 mM NaCl) and 1 μl of DOPC:biotinylated lipid 1:4
mol/mol mixture in hexane:chloroform 1:1 v/v, and (C) the power spectrum.
in contact with the hydrophobic chains of the lipid monolayer (see 1.22, B). The
hydrophobic-hydrophobic interactions retained the sample on the grid when the
grid was lifted away and stained. The samples harvested by direct contact showed
large two-dimensional crystals of steptavidin and only a limited number of features
that suggested monolayer rupture, while the samples harvested with the wire-loop
showed fewer two-dimensional crystals and of smaller in size. The direct method of
harvesting preserved the sample and it seemed to be more gentle compared with the
wire-loop [308, 392]. For these reasons, the direct contact harvesting was preferred
and adopted for PLC.
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7.2.2 Specific protein-lipid interaction using nickel chelating lipids
and histidine tagged PLC
The specific protein-lipid interaction between commercially available nickel chelat-
ing lipids DOGS-NTA(Ni2+) and the histidine tag on the PLC was exploited to
achieve protein-lipid binding and to drive the two-dimensional crystallisation pro-
cess. This interaction represents a general tool to bind histidine tagged soluble
protein and it has been successfully used for two-dimensional crystallisation on a
lipid monolayer [386–388]. The use of NTA(Ni2+) lipids for two-dimensional crys-
tallisation represents a versatile approach that can be used for various His-tagged
proteins which have previously been successfully exploited for two-dimensional
crystallisation studies on a lipid monolayer [393].
A preliminary study on this interaction [394] showed that GUVs prepared by
the swelling method (see sec. 2.7.1) with various lipid composition and fluorescent
lipids (either Rh-PE or NBD-PC) were mainly unilamellar and did not show domain
or lipid segregation, but rather an even distribution of the fluorescent lipids [395].
Specific binding between DOGS-NTA(Ni2+) (within the GUV bilayer) and a His6-
tagged model protein (His6-eGFP) was detected using two independent approaches:
sedimentation of GUVs followed by Western blotting, and imaging with a fluores-
cence microscope. The results obtained with the model protein showed proportion-
ality of binding. For this reason this method allows screening of the effects of dif-
ferent conditions in crystallisation trials, in order to optimise the binding. Here, the
specificity of binding was investigated using the same approaches, but this time us-
ing the construct of His6-PLC (1258-2225 AA) fused with eGFP at the C-terminus
which was purified from bacteria (see sec. 4.2.1). The His6-PLC-eGFP (1258-
2225 AA) was incubated with GUVs which contained DOGS-NTA(Ni2+) chelating
lipid, and the binding was detected by fluorescent microscopy (see fig. 7.4, A-D).
Furthermore, binding was detected by sedimentation of the protein-GUV system
followed by Western blotting (see fig. 7.4, E and F). The specificity of binding be-
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Figure 7.4. Protein distribution in GUV solutions. Binding detection between His6-eGFP
(A, C, E) or wild-type His6-PLC-eGFP (E, D, F) and GUVs prepared with the follow-
ing lipid compositions: DOPC (A, B) or DOPC-DOGS-NTA(Ni2+) 1:1 w/w (C, D). The
GUVs and the proteins were incubated together (His6-protein:DOGS-NTA(Ni2+) 1:1700
mol/mol). For each pair of images, the samples were imaged by fluorescent microscopy,
left, or in bright field, right, to ensure there were GUVs in the field of view. In the presence
of DOPC GUVs, the fluorescent signal of His6-eGFP (or wild-type His6-PLC-eGFP) re-
mained dispersed in the mixture (A). In the presence of DOPC-DOGS-NTA(Ni2+) 1:1 w/w
GUVs, the fluorescent signal of His6-eGFP (or wild-type His6-PLC-eGFP) concentrated
at the bilayer of the GUVs (B). The binding was also detected upon sedimentation of the
GUVs and immuno-detection (using the α His5 antibody, see sec. 2.8) of the total protein
in the pellet and in the supernatant fractions (E, F).
7.2 Results 238
tween the His-tagged protein and the DOGS-NTA(Ni2+) chelating lipid was also
investigated. No binding was detected in absence of the His-tag on the protein, or
in presence of EDTA. Since the specificity of the interaction has been confirmed
(see fig. 7.4), this interaction could therefore be exploited to drive two-dimensional
crystallisation of His6-MBP-PLC (1258-2225 AA) on a lipid monolayer contain-
ing DOGS-NTA(Ni2+) lipids.
7.2.3 Two-dimensional crystallisation trials of PLC
Two-dimensional crystallisation of His6-MBP-PLC was attempted on a lipid mono-
layer. The lipid mixture used for the lipid monolayer formation contained the chelat-
ing lipid, DOGS-NTA(Ni2+), and the diluting lipids. Several lipid mixtures and
conditions have been investigated to find a suitable lipid monolayer as a substrate
for two-dimensional crystallisation. The crystallisation process on a lipid layer is
affected by the properties of the lipid substrate in terms of lipid head group, lipid
mobility, and lipid distribution (see sec. 1.5.1.1). All these factors were taken into
consideration when choosing the lipid composition and the crystallisation condi-
tions. The influence of different parameters on the monolayer, such as the bulk
lipid (DOPC, DMPC, or SOPC), the relative concentration of NTA-DOGS(Ni2+)
lipid, the amount of lipid mixture spread on the water/air interface, were tested in
a preliminary study [394] and the monolayers obtained imaged by EM one by one.
The following NTA-DOGS(Ni2+)-bulk lipid compositions were tested 1:1, 1:5 and
1:10 w/w for each type of bulk lipid considered. SOPC and DMPC formed mainly
vesicles or dense, non-planar aggregates (data not shown). The grids prepared with
DOPC as the bulk lipid (in the absence of any protein) gave the best results, show-
ing large areas of flat lipid monolayer and only occasionally more complex lipid
formations, such as multilayer or non-planar aggregates (data not shown). Increas-
ing the concentration of NTA-DOGS(Ni2+) in DOPC, from 1:10 to 10:1 w/w did
not affect the monolayer morphology (see tab. 7.1). DOPC was used also because
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it has long unsaturated alkyl chains (C18), in fact both the chain length and the de-
gree of unsaturation are directly related to the fluidity of the monolayer [280]. This
guaranteed sufficient diffusion of the lipid molecules within the monolayer which
should favor the crystallisation process. Diffusion ensures that protein-lipid com-
plexes come into contact with each other, this is necessary (but not sufficient) for the
formation of protein-protein contacts which can lead to nucleation and then to crys-
tal formation. Such small nucleation points in the appropriate conditions (of protein
concentration, temperature, time or pH) will then grow with time. The crystalli-
sation trials were incubated at temperatures above the phase transition temperature
otherwise diffusion would be drastically reduced and with it the probability of ob-
taining two-dimensional crystals. A range of temperatures between 4 and 18 ◦C
was tested (see tab. 7.1). The temperature controls the kinetics of the crystallisa-
tion process by affecting the diffusion of the lipids within the lipid monolayer and
Brownian motion within the solution [280].
According to the strategy used to drive the crystallisation of PLC, the strong
interaction between the His6-tag on PLC and the head group of DOGS-NTA(Ni2+)
within the monolayer should recruit PLC to the water-lipid interface. Binding of a
histidine tag protein occurs on a short time scale and, most importantly, the histidine
tag must face the monolayer. This latter feature ensures that all protein-lipid com-
plexes are similarly constrained to have a single orientation from the membrane,
thereby allowing the proteins to interact with each other in the same geometry, and
so to obtain ordered crystals. This orientational control is a necessary condition (but
not sufficient) for good crystal formation. The pH was controlled to make sure that
the histidine residues were not protonated (pKa = 6.0), and pH 8.0 was preferred as
it is the optimum pH for His-tag to associate with NTA(Ni2+). Samples for two-
dimensional crystallisation were also prepared in presence of a ligand [Ins(1,4,5)P3]
or co-factor (Ca2+) in order to stabilise the protein conformation and again favour
protein-lipid contacts.
The construct of His6-MBP-PLC was purified almost to homogeneity (see sec.
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3), and therefore it was suitable for structural studies.
Protein and lipid concentrations are reported to have an affect on the kinetics
of the protein-lipid binding and crystal formation [280, 309], therefore a range of
protein and lipid concentrations were tested, see table 7.1.
Table 7.1. Summary of conditions adopted for two-dimensional crystallisation trials
of His6-MBP-PLC on a lipid monolayer which contained a mixture of DOPC and
DOGS-NTA(Ni2+).
His6-MBP-PLC (μg) 1 3 5 10
DOPC:DOGS-NTA(Ni2+) w/w 10:1 5:1 1:1 1:4 1:10
total lipids (μg) 1 1.5 2
incubation temperature 4 ◦C 18 ◦C RT
ligand/co-factor - 0.2 μM IP3 50 μM CaCl2
incubation time (h) 3 19 24 48
The two-dimensional crystallisation trials were harvested by direct contact with
an EM grid that had been pre-baked at 80 ◦C for 1 hour. To better preserve the
sample, a gentle staining procedure was used as described in section 2.9.2. Al-
though this harvesting procedure allowed a successful transfer of streptavidin two-
dimensional crystals onto EM grids, no planar crystals were observed in the sample
of His6-MBP-PLC. A different type of EM grid was also used, holey carbon film,
which has been shown to increase the efficiency of the transfer due to its more hy-
drophobic character [280]. However, no difference in the sample appearance was
observed. The two-dimensional crystallisation samples of His6-MBP-PLC showed
the formation of more complex structures. Often, and under varied lipid or protein
concentrations, round structures were observed. On the edges of these round struc-
tures, which were identified as lipid vesicles, protein molecules could be distin-
guished bound to the surface (see fig. 7.5, A). In other cases the appearance of the
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lipid vesicles (characterised by straight edges) suggested that protein-lipid binding
was taking place (see fig. 7.5, B).
Other complex structures associated with the protein were observed in the two-
dimensional crystallisation trials. Flat and geometric areas (see fig. 7.6, A) or
thicker tubules of similar diameter (see fig. 7.6, B) were observed. In particular, in
the flat areas it appeared that an initial ordering was taking place (see fig. 7.6, A).
Since a wide range of two-dimensional crystallisation conditions were explored
(see table 7.1) and the same harvesting procedure that was successfully applied to
streptavidin trials, the lack of His6-MBP-PLC crystals was principally attributed
to the crystallisation process itself. In this regard, the specificity of the protein-lipid
binding was tested with an alternative method from the GUVs. Two-dimensional
crystallisation trials on a lipid monolayer were prepared using His6-MBP-PLC and
with a lipid monolayer containing DOPC-DOGS-NTA(Ni2+), only DOPC or in the
absence of any lipid monolayer. Twelve identical samples of each kind were pre-
pared and harvested by direct contact onto an EM grid. Each EM grid was blotted to
avoid interference from the protein in the buffer that wet the grid and then washed
in 4 × SDS-PAGE sample buffer to release the protein bound to the EM grid via the
lipid layer (to test the affinity of the protein for the interface or for the hydropho-
bic EM grid). The same approach was repeated with streptavidin and using a lipid
monolayer containing DOPC-biotinylated lipid, only DOPC or in the absence of
any lipid monolayer. The content of the His6-MBP-PLC and streptavidin samples
obtained were analysed by SDS-PAGE. Clear differences were observed by com-
paring the amounts of protein (His6-MBP-PLC or streptavidin) harvested (on the
EM grid) as a function of the interface (see fig. 7.7). No streptavidin was detected
bound to the EM grid in absence of a lipid monolayer. A very small amount of
streptavidin was detected in the presence of a DOPC lipid monolayer, while a large
amount of streptavidin was detected in the presence of a lipid monolayer containing
DOPC and biotinylated lipids. These data bring evidence for the high specificity of
the streptavidin-biotinylated lipid binding.
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Figure 7.5. EM images of two-dimensional crystal trials of wild-type His6-MBP-PLC
1258-2225 AA (15 μl at 0.1 μg/μl) on a lipid monolayer (1 μl, DOPC-DOGS-NTA(Ni2+)
1:1 v/v). The two-dimensional crystal trials were incubated for 34 hours at RT, the samples
harvested by direct contact with an EM grid and negatively staining (with 2% uralnyl ac-
etate). (A) His6-MBP-PLC molecules (indicated by the arrows) could be distinguished at
the edges of the round structures; (B) collapsed lipid vesicles with straight edges (in the red
box), the appearance of which is often an indication of protein-lipid binding taking place.
The bar in the figure is 80 nm.
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Figure 7.6. EM images of two-dimensional crystal trials of wild-type His6-MBP-PLC
1258-2225 AA (25 μl at 0.1 μg/μl ) on a lipid monolayer (1 μl, DOPC:DOGS-NTA(Ni2+)
1:1). The two-dimensional crystal trials were incubated for 12 hours at RT, the samples har-
vested by direct contact with an EM grid and negatively staining (with 2% uralnyl acetate).
(A) An initial ordering of His6-MBP-PLC molecules seems to take place on a flat surface
(in the red box); (B) lipidic tubules probably formed due to protein association, a schematic
representation of a tubular lipid structure (red) covered by the protein which forms an or-
dered pattern (fishtail pattern) superimposed to a tubular structure observed by EM. The
bars represent (A) 70 nm or (B) 100 nm.
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Figure 7.7. Stained SDS-PA gel showing the relative amounts of streptavidin (A) or His6-
MBP-PLC (B) harvested on a EM grid and bound to lipid monolayers of different lipid
composition (DOPC, DOPC-biotinylated lipids 1:1 v/v or DOPC-DOGS-NTA(Ni2+) 1:1
v/v).
On the other hand, almost identical amounts of His6-MBP-PLC were harvested
on the EM grid regardless of the presence or absence of DOGS-NTA(Ni2+) within
the lipid monolayer. This suggested that the binding specificity between His6-
MBP-PLC and DOGS-NTA(Ni2+) was poor and not comparable with the strep-
tavidin - biotinylated lipid system. The indication of a limited binding specificity
of His6-MBP-PLC generated doubts about the approach chosen to drive the two-
dimensional crystallisation. The preliminary data obtained by GUVs imaging and
sedimentation indicated specificity of binding (see fig. 7.4). However, it is possible
that the behaviour of His6-MBP-PLC depends upon the presentation of a posi-
tive lipid curvature (GUVs) rather than a negative lipid curvature (two-dimensional
crystallisation trials). It cannot be excluded that the hydrophobic loops of PLC par-
tially penetrate into the hydrophobic area of the lipid and that these insertions are
lipid curvature dependent. Alternatively, it is possible that the MBP has affinity for
the lipid monolayer and that it is the cause of the non-specific protein-lipid bind-
ing. Furthermore, these hydrophobic interactions with the lipid monolayer could
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take place in addition to the specific interaction between the His6-tag on PLC and
the DOGS-NTA(Ni2+). This would result in heterogeneity of the protein orienta-
tion in respect to the lipid layer which could be sufficient to prevent crystal growth.
Many more conditions for two-dimensional crystallisation trials could be investi-
gated such as addition of imidazole to increase the specificity of the binding, small
variations of pH which results in variation of the protein charge and of the lipid
curvature [396], and a wider range of the parameters tested. However, based on
the hypothesis of a heterogeneous way of interacting between the protein and the
lipid monolayer, the focus of this work was shifted to the design of an alternative
approach to specifically bind PLC to a lipid monolayer in a functional orientation.
7.2.4 PLC-PtdIns(4,5)P2 binding as alternative interaction to
drive two-dimensional crystallisation and design of PLC
inactive mutants
The binding specificity between the inactive PLC mutant and PtdIns(4,5)P2 sub-
strate was thought to be a valid alternative to the His-tag on PLC - NTA-DOGS(Ni2+)
specific binding to drive the two-dimensional crystallisation of PLC on a lipid
monolayer. The substrate interaction is highly specific and certainly meaningful
at the functional level for the study of PLC. To pursue this idea, it was necessary
to design a PLC inactive mutant. In particular, the required PLC mutant needed
to be capable of binding to the PtdIns(4,5)P2 substrate with high specificity and
sufficient affinity, but be unable to hydrolyse the PtdIns(4,5)P2 substrate.
The inactive mutants of PLC were generated based on the mechanism of catal-
ysis (see fig. 1.13) and the structure of the catalytic domain of PLCδ1 (see fig. 1.12).
Two histidine residues (H311 and H356) have been shown to play key roles in the
catalytic mechanism ( [141, 145, 397]). Sequence alignment between PLCδ1 and
PLC, showed that both these histidine residues are conserved. The corresponding
PLC residues (H1388 and H1488) have been mutated based on previous activity
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studies on PLCδ1 [26,145] by site direct mutagenesis (see sec. 2.2.6). Each residue
was mutated individually generating two single mutants, H1388A and H1488L, as
well as both together generating a double mutant.
This binding process has both enthalpic and entropic contributions to the overall
free energy of the process. The enthalpic contribution of protein-water or protein-
ligand binding are usually very similar. However, during the binding process, or-
dered water molecules within the binding cavity are displaced into the bulk phase
with a net positive effect to the entropic contribution to the free-energy of the bind-
ing process. The binding process is therefore entropy driven [398].
7.2.5 Purification of PLC inactive mutants
The constructs of His6-PLC-eGFP (1258-2258 AA) mutants H1388A, H1488L
and H1388A H1488L were expressed in E. coli C42 DE3 as described in section
4.2.1 and 2.3.5. The cell lysate was prepared as in section 2.5.1 and the mutants
were expressed as described in section 2.3.5.
Each mutant was purified close to homogeneity in four purification steps (see
fig. 7.8). The first purification step was an affinity purification which exploited the
His6-tag using a NTA(Ni2+) chelating column (see sec. 2.5.2.1). This purification
step increased greatly the purity of His6-PLC-eGFP (1258-2258 AA) H1388A. The
band that corresponds to the molecular weight of the target protein (≈ 150 KDa)
could hardly be seen in the SDS-PA gel of the mixture loaded onto the column, but
it became one of the two most intense bands (and of comparable intensity to a band
detected at ≈ 70 KDa) identified in the SDS-PA gel of the elution fractions from the
column (see fig. 7.8, A-1). The second purification step was carried out by perform-
ing ion exchange chromatography (see sec. 2.5.2.2); this considerably increased the
purity and the concentration of the target protein. The SDS-PA gel loaded with the
elution fractions of the ion exchange (heparin) column band showed the main band
at ≈ 150 KDa which was identified as the target protein by Western blotting (data
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Figure 7.8. Purification of the inactive PLC constructs: (A) His6-PLCeGFP H1388A
(1258-2258 AA) or (B) His6-PLCeGFP H1433L (1258-2258 AA) (arrow). Coomassie
stained SDS-PA gel loaded with the cell lysate (L.) or the elution fractions of each of the
following purification stages: affinity chromatography (1), ion exchange chromatography
(2) and size exclusion (3). Characterisation of the protein preparation by Coomassie stained
native gel at the end of the purification process.
not shown), and absence of the band at ≈ 70 KDa (see fig. 7.8, A-2). The His6-tag
of the target protein was removed upon incubation with thrombin (O/N at 4 ◦C) and
selection on the NTA(Ni2+) chelating column. The flow-through which contained
the PLC-eGFP (1258-2258 AA) H1388A was collected and further purified. The
fourth purification step was gel filtration chromatography using a Superdex 200
16/60 column which resolves proteins in the size range of the target protein (≈ 150
KDa) (see sec. 2.5.2.3). The elution fractions characterised by the retention time of
the target protein were analysed by SDS-PAGE (see fig. 7.8, A-3). The major band
detected on the SDS-PA gel had the molecular weight of the monomeric target pro-
tein. These data, the UV trace (data not shown) and SDS-PA gel, ensured the target
protein was in a monomeric state under native conditions. Only two minor bands
corresponding to proteins with a molecular weight between 150 KDa and 100 KDa
were detected. The comparison between the band intensity of the target protein and
the intensity of the other two bands indicated the high level of purity of the target
protein. The native gel loaded with the protein at the end of the purification process
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showed only one band indicating homogeneity of the target protein in respect to
the surface charge (see fig. 7.8, A). Similar results were obtained with His6-PLC-
eGFP (1258-2258 AA) mutant H1488L (see fig. 7.8, B) and H1388A H1488L (data
not shown).
The activity of each purified protein was measured with the mixed micelle assay
(see sec. 2.6.2.1) and it was compared with the activity of the wild-type His6-PLC-
eGFP (1258-2258 AA). The inactive mutants His6-PLC-eGFP (1258-2258 AA)
H1388A, H1488L or H1488L and H1388A showed negligible PLC activity and was
comparable to the negative control (blank) which did not contain PLC (see fig. 7.9).
The positive control prepared with wild-type His6-PLC-eGFP PLC showed PLC
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Figure 7.9. Specific activity of the purified His6-PLCeGFP (1258-2258 AA) H1388A,
H1433L or the wild-type. Data are presented as the mean ± standard deviation of three
independent measurements.
activity and this provided evidence that the assay was performing correctly. There
was no difference in terms of activity between the single and the double mutants.
Therefore, further work to characterise the specificity of the PtdIns(4,5)P2 substrate
binding was carried out with the single PLC mutants (H1388A or H1488L) because
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the substrate binding properties of the single mutants should be less altered than in
the double mutant.
7.2.6 Inactive PLCmutants-PtdIns(4,5)P2 substrate binding us-
ing giant unilamellar vesicles as a model
The specificity of the interaction between the inactive PLC mutant and PtdIns(4,5)P2
was characterised before exploiting this interaction to immobilise PLC on a lipid
monolayer containing PtdIns(4,5)P2 to drive the two-dimensional crystallisation.
The GUV approach used above to detect His6-tagged protein-DOGS-NTA(Ni2+)
binding (see sec. 7.2.2) was adapted to test the binding between inactive PLC
mutant (H1433L or H1388A) and PtdIns(4,5)P2. In this case, the GUVs were
prepared with DOPC (or with DOPC:PtdIns(4,5)P2 1:0.1 w/w) by the swelling
method (as described in sec. 2.7.1). The inactive PLC-eGFP mutants (H1433L
or H1388A) were incubated with the GUVs with the aim of visualising the binding
by imaging and sedimentation. However, the incorporation of an acidic lipid such
as PtdIns(4,5)P2 onto the GUVs bilayer could be challenging. In order to detect
PtdIns(4,5)P2 incorporation into the GUV’s bilayer (or in the outer lipid leaflet), a
fluorescent PtdIns(4,5)P2 probe was designed consisting of the PH domain (1-175
AA) of PLCδ1 fused to eGFP on the N-terminus (see fig. 7.10, A). The PH domain
of PLCδ1 has been reported to bind to PtdIns(4,5)P2 with high affinity (Kd = ≈ 2
μM) [5, 399]. Furthermore, similar chimeric constructs of the PH domain and GFP
have previously been reported to localise PtdIns(4,5)P2 in vivo by fluorescent imag-
ing [9, 400–402] where these probes translocate at the plasma membrane and have
successfully been used to detect depletion and synthesis of PtdIns(4,5)P2 [403].
In this study, the PtdIns(4,5)P2 was required to be detected in vitro and the
fluorescent PtdIns(4,5)P2 probe needed to be expressed (in E.coli) and purified.
Therefore, a single mutation was introduced in the PH domain of PLCδ1 (1-174
AA) R60K in order to express the construct in E.coli and prevent protein cleavage
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Figure 7.10. (A) Vector map of His10-eGFP-PHPLCδ1-strep II (1-175 AA), (B) structure
of PHPLCδ1 in complex with InsP3 (ID = 1MAI) [24]. The binding of the PH domain of
PLCδ1 PtdIns(4,5)P2 is highly specific, it involved 12 hydrogen bonds [24], Coomassie
stained SDS-PA gel loaded with eGFP-PHPLCδ1 (1-175 AA) preparation obtained at the
end of the purification process.
by proteases. The construct was designed with cleaveable purification tags, (strep II
and His10-tag) at the N and C-terminus respectively. The fluorescent PtdIns(4,5)P2
probe was purified in four steps. Firstly, the probe was purified by affinity chro-
matography using a nickel chelating HisTrap column which greatly increased the
purity (see sec. 2.5.2.1). Indeed, the target protein (≈ 70 KDa) could not be dis-
tinguished in the cell lysate, but became one of the major bands after the first step
of purification by SDS-PAGE (data not shown). The StrepTactin column did not
increase the protein purity (indeed, the truncated products were discarded and the
full-length selected in the previous stage since the His10-tag was placed at the C-
terminus of the construct). The two purifications tags were removed simultane-
ously upon incubation with thrombin and prescissor enzymes. The cleaved protein,
eGFP-PHPLCδ1 (1-175 AA, R60K), was selected on the nickel chelating HisTrap
and then on the StrepTactin columns. The flow-through of the StrepTactin column
was loaded on a gel filtration column (Superdex 200). The elution fractions charac-
terised by the retention time of a ≈ 60 KDa protein were analysed by SDS-PAGE
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(7.10, C) and Western blotting (data not shown). The eGFP-PHPLCδ1 (1-175 AA,
R60K) band was identified by Western blotting using the GFP (B2) antibody (see
table 2.8). The eGFP-PHPLCδ1 (1-175 AA, R60K) band was the major band, but
other bands of comparable intensity were visible on the SDS-PA gel. However, this
level of purity of eGFP-PHPLCδ1 (1-175 AA, R60K) was sufficient to be used as
a PtdIns(4,5)P2 probe. Indeed, only the fluorescent protein could be detected by
imaging the GUV system by fluorescent microscopy.
When the eGFP-PHPLCδ1 (1-175 AA, R60K) probe was incubated with GUVs
of DOPC-PtdIns(4,5)P2 (1:0.1 w/w), it concentrated on the surface of the GUVs,
and only a little fluorescence was detected in the solution (see fig. 7.11, A). The
distribution over the GUV surface was quite homogeneous, thereby showing no
significant evidence of lipid segregation or PtdIns(4,5)P2 raft formation. In addition,
by recording the images of the GUV samples in fluorescence or in bright field mode,
it was observed that all the GUVs showed protein concentration on the surface,
although differences in fluorescent intensity were observed. This seems to indicate
that the GUVs have similar lipid composition.
On the other hand, when the eGFP-PHPLCδ1 (1-175 AA, R60K) probe was in-
cubated with GUVs of DOPC it remained dispersed in the bulk phase (see fig. 7.11,
B). The different behaviour of eGFP-PHPLCδ1 (1-175 AA, R60K), depending on
the presence of PtdIns(4,5)P2, confirms that eGFP-PHPLCδ1 (1-175 AA, R60K) was
specifically binding to PtdIns(4,5)P2. Hence, the PtdIns(4,5)P2 probe concentration
on the GUVs (external) surface provided evidence for the effective PtdIns(4,5)P2
incorporation into the GUV bilayer.
Having verified that the GUVs had PtdIns(4,5)P2 in the lipid bilayer, they were
incubated with the catalytically inactive PLC-eGFP (H1433L or H1388A) mutants
in order to characterise their binding to PtdIns(4,5)P2. For both these PLC mutants
the fluorescent signal remained diluted in the mixture. The inactive PLC-eGFP
(H1433L or H1388A) constructs did not concentrate on the surface of the GUVs as
previously observed with eGFP-PHPLCδ1 (1-175 AA, R60K), see figure 7.12.
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Figure 7.11. Images of eGFP-PHPLCδ1 (1-175 AA, R60K) incubated with GUVs of differ-
ent lipid composition. GUVs prepared with (A) DOPC or (B) DOPC-PtdIns(4,5)P2 (1:0.1
w/w). Each sample was imaged by fluorescent microscopy (left) and in bright-field (right).
The fluorescent signal of the eGFP-PHPLCδ1 (1-175 AA, R60K) remained dispersed when
incubated with DOPC GUVs (A). The fluorescent signal of the eGFP-PHPLCδ1 (1-175 AA,
R60K) concentrated on the GUV’s lipid bilayer when incubated with DOPC-PtdIns(4,5)P2
1% w/w GUVs (B). The scale bar is 10 μm.
The lack of concentration of the inactive PLC-eGFP (H1433L or H1388A)
proteins on the GUV’s surface was observed with GUVs of either DOPC or DOPC-
PtdIns(4,5)P2 (1:0.1 v/v). This indicated that inactive PLC-eGFP (H1433L or
H1388A) constructs did not have detectable intrinsic affinity for the GUV lipid bi-
layer and that the binding to PtdIns(4,5)P2 was weak. This weak binding probably
would not be sufficient to drive two-dimensional crystallisation on its own. How-
ever, the PLC-eGFP mutant system could be adapted by expressing a chimeric
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Figure 7.12. Binding detection between His6-PLC-eGFP (wild-type or H1433L) and the
lipid bilayer of GUVs containing (DOPC or DOPC-PtdIns(4,5)P2 1:0.1 w/w) by fluores-
cence microscopy (A, B) or sedimentation followed by immuno-detection Western blotting
(E, F). The fluorescent signal of the PLC-eGFP constructs remained dispersed in the bulk
phase when no PtdIns(4,5)P2 was present, but when the GUV bilayer contained DOPC-
PtdIns(4,5)P2 1% w/w migrated to the interface (A, B). Only a minimal concentration on
the GUV’s bilayer was observed for the inactive mutant PLC-eGFP (H1433L), (B). The
correspondent images of A and B in bright-field are in C and D, and shows that GUVs were
present in the filed of view. The total protein present in the pellet and supernatant upon
GUVs sedimentation was detected by Western blotting. The wild-type His6-PLC-eGFP
or the H1433L were detected almost exclusively in the supernatant when incubated with
DOPC GUVs. Only very little protein of wild-type His6-PLC-eGFP or of H1433L was de-
tected in the pellets when incubated with DOPC-PtdIns(4,5)P2 1:0.1 w/w GUVs and with
comparable amounts.
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construct of the inactive PLC (either H1433L or H1388A) fused to the PHPLCδ1
(1-175 AA, R60K) domain. The PHPLCδ1 (1-175 AA, R60K) domain binds specif-
ically and with high affinity to PtdIns(4,5)P2. Therefore this interaction could be
used for two-dimensional crystallisation of PHPLCδ1-PLC on a lipid monolayer
containing DOPC and PtdIns(4,5)P2.
7.3 Discussion
Electron crystallography is a useful method for structural determination of soluble
and membrane proteins. This technique should be particularly valuable in this study
because it has the potential to determine the structure of PLC in a functional state
representative of the natural one. However, the number of protein structures solved
by electron crystallography is still limited [about 140 structures of membrane (85)
and soluble (43) proteins have been studied by electron crystallography], especially
if compared with X-ray crystallography (represented by 60·000 entries in the pro-
tein data bank) or NMR (more than 10·000 entries in the protein data bank). This
is partly because electron crystallography is still a niche, although an emerging
technique, and partly because electron crystallography requires the growth of two-
dimensional crystals of the target protein, a technique still in its infancy compared
to the growth of three-dimensional crystals.
Two-dimensional crystallisation is a multi-variable process therefore, for any
given protein, it is necessary to screen the effect on the crystallisation of many
parameters. In order to identify the set of conditions that leads to protein crystalli-
sation, two-dimensional crystallisation trials have to be prepared in several sets of
conditions and then screened. The screening involves sample harvesting, vitrifica-
tion (or staining) and imaging by EM. Currently, the degree of automation available
for crystal trial preparation or for the screening process, is limited and in many cases
it is represented by prototypes rather than machines on a general distribution.
The screening process represents the bottle-neck of electron crystallography,
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without mentioning that the harvesting is a critical and delicate step, which could
compromise or destroy any two-dimensional crystal already present in the sample.
For this reason, it was important to master the techniques involved with the har-
vesting and screening of the samples by using a model protein. Two-dimensional
crystals of streptavidin were successfully grown on a lipid monolayer, harvested
and imaged by EM. This assured effective handling of the technique, which was
subsequently applied to PLC.
7.3.1 The interaction between PLC and DOGS-NTA(Ni2+)
The construct wild-type His6-MBP-PLC (1258-2225 AA) was recombinantly ex-
pressed and purified from E.coli C41 DE3 pRARE cells (see sec. 3), and it was
used for two-dimensional crystallisation trials. To drive PLC two-dimensional
crystallisation on a lipid monolayer the interaction between the His6-tag on the N-
terminus of the PLC construct and the head group of nickel chelating lipid [DOGS-
NTA(Ni2+)] was exploited. The use of Ni2+-NTA lipids for two-dimensional crys-
tallisation represents a versatile approach that can be used for various His-tagged
proteins. Protein-lipid binding was analysed on a model system using GUVs. This
system showed specific binding of His6-PLC-eGFP (1258-2225 AA) to DOGS-
NTA(Ni2+) by fluorescence microscopy. Indeed, binding was achieved only when
the GUVs contained DOGS-NTA(Ni2+) in the lipid bilayer and the PLC had the
His6-tag.
However, the binding specificity of His6-MBP-PLC (1258-2225 AA) to DOGS-
NTA(Ni2+) decreased when tested using a lipid monolayer. As expected, the puri-
fied His6-MBP-PLC protein was detected bound to the lipid monolayer when the
lipid monolayer contained Ni2+-NTA lipids, but also when the monolayer did not
include any Ni2+-NTA lipids. It is possible that this non-specific interaction must
be curvature sensitive because it was not observed in GUVs (either by imaging or
by sedimentation). In GUVs, the membrane bilayer has a positive mean curvature
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(H > 0) with respect to the protein, while in the lipid monolayer it has a negative
mean curvature (H < 0) with respect to the protein due to the concave surface of the
buffer.
Based on this result, it was decided to test an alternative specific interaction
to bind PLC to the lipid monolayer and to drive the two-dimensional crystallisa-
tion. According to the new approach, inactive PLC mutants would be designed
and PtdIns(4,5)P2 would be included within the lipid monolayer. However, other
approaches could be tested based on the interaction between the His6-tag and the
DOGS-NTA(Ni2+). For example, imidazole could be added to the trials for a more
selective interaction, or a new construct could be designed with the His-tag po-
sitioned in a different part of the protein (on the C-terminus, or in parts that are
predicted to be exposed on the PLC surface based on the PLCδ1 structure). In
fact, the position of the His-tag (with respect to the protein) determines the orien-
tation that the protein assumes when it is immobilised on the lipid monolayer. A
different orientation of the protein might favour protein-protein contacts and crystal
formation [388].
As an alternative to the monolayer, GUVs could be considered for growing
vesicular two-dimensional crystals. Indeed, the His6-tag and the DOGS-NTA(Ni2+)
interaction showed high specificity on GUVs, if not on monolayers. GUVs, as well
as the lipid monolayer, were successfully imaged by EM. Furthermore, a GUVs
surface is sufficiently large to accommodate a two-dimensional crystal and the use
of GUVs for two-dimensional crystallisation has previously been reported [404].
These characteristics make GUVs a suitable substrate for growing and visualising
two-dimensional crystals. This method gives three further advantages compared
to the monolayer. First, since GUVs are more robust than monolayers, they are
expected to give a higher yield in terms of lipid harvesting. Second, a successful
crystallisation would provide an entire solution containing two-dimensional crys-
tals on the GUVs’ surface, rather than only at the air water interface, which means
that more than one grid can be prepared with the same sample. Third, GUV solu-
7.3 Discussion 257
tions incubated with proteins would provide the notable advantage of being able to
correlate the EM images to the sedimentation results.
7.3.2 PtdIns(4,5)P2 probe
The binding properties of the PH domain of PLCδ1 to PtdIns(4,5)P2 and Ins(1,4,5)P3
have been studied [9]. The binding constant between PHPLCδ1 domain and PtdIns(4,5)P2
in membrane has been reported to be ≈ 2 μM [5, 9]. The high binding specificity
and affinity of this interaction makes the PHPLCδ1 domain particularly appealing
to design probes to localise PtdIns(4,5)P2. The PHPLCδ1 domain has been fused
to GFP and used to localise PtdIns(4,5)P2 in vivo. Using this probe would allow
specific localisation of PtdIns(4,5)P2 (due to the characteristics of the interaction
between the PHPLCδ1 domain and PtdIns(4,5)P2) to be observed by simple fluores-
cent imaging [9, 400]. In this particular part of the work, the same properties of
binding specificity and fluorescence were used to design a similar probe capable
of localizing PtdIns(4,5)P2 in vitro. To pursue this goal, a construct needed to be
prepared in order to recombinantly express and purify the protein. A point mutation
(R60K) needed to be introduced to avoid proteolysis during bacterial expression.
The PtdIns(4,5)P2 probe was purified from E.coli C41 DE3 and its capability to
specifically bind to PtdIns(4,5)P2 and localised PtdIns(4,5)P2 in vitro was verified.
7.3.3 The interaction between inactive PLC and PtdIns(4,5)P2
In order to exploit the interaction between inactive PLC and PtdIns(4,5)P2 to drive
two-dimensional crystallisation, three inactive PLC mutants (H1388A, H1488L
and H1388A H1488L) were designed based on the sequence alignment with PLCδ1.
These mutants were expressed as part of the construct His6-PLC-eGFP (1258-
2225AA). They were recombinantly expressed in E.coli C41 DE3 pRARE and
purified from these cells. In vitro activity measurements confirmed that these
mutants were inactive. The ability of these mutants to bind to PtdIns(4,5)P2 was
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investigated using GUVs and by fluorescence microscopy imaging. None of the
inactive PLC showed binding to PtdIns(4,5)P2 substrate, therefore none of these
constructs were suitable for use in two-dimensional crystallisation according to the
initial plan. This finding fits with the auto-inhibitory mechanism of PLCs, which
was proposed recently [25]. According to this mechanism, charge repulsion would
occur between the negatively charged lipid bilayer (the plasma membrane) and the
auto-inhibitory loop that links the X and the Y halves of the catalytic domain (see
fig. 6.3). In vivo, where the PLC is held at the membrane interface by GTPase
binding, charge repulsion takes place and it results in a conformational rearrange-
ment of the auto-inhibitory loop. The conformational rearrangement is proposed to
make the catalytic pocket accessible to the PtdIns(4,5)P2 substrate, thereby permit-
ting substrate turn-over. However, in the crystallisation system described above, the
GTPase is absent, therefore the same charge repulsion would take place, thereby
preventing PLC-lipid bilayer binding.
Even if the interaction between inactive PLC and PtdIns(4,5)P2 within a lipid
monolayer was not suitable for two-dimensional crystallisation, adaptations could
be made and two alternative systems could be designed. The PHPLCδ1 domain has
been shown to drive the relocation of the protein they are part of [399]. Based on
this, the PHPLCδ1 domain could be fused on the N-terminus of a inactive PLC ep-
silon construct, and this chimeric construct could be used for two-dimensional crys-
tallisation on a lipid monolayer which contains PtdIns(4,5)P2. This system would
rely on the PHPLCδ1 domain-PtdIns(4,5)P2 interaction, which has been shown to be
specific and sufficiently strong to immobilise the protein at the water-lipid interface
and possibly drive the crystallisation.
Alternatively, a more complex system could be considered, which would more
closely mimic the in vivo conditions. The samples for two-dimensional crystallisa-
tion could be prepared in presence of GTPγS geranylgeranyl-RhoA and an inactive
PLC in the buffer solution. The prenylated GTPγS RhoA would be expected to
localise at the lipid interface, upon insertion of the geranylgeranyl chain within the
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lipid monolayer and to bind PLC mutants which should result in PLC concentra-
tion at the lipid monolayer interface, thereby driving the crystallisation.
Chapter 8
General discussion
This work addressed the functional aspects and regulatory mechanisms of the PLC
family by using a multidisciplinary approach. This type of approach elucidated
details of the function, combining data obtained using more than one technique,
or by studying each hypothesis and its implications from different perspectives.
The data obtained were then combined to extend the general understanding of the
mechanism of PLC regulation. This work focused mainly on PLC and PLCβ,
which were taken as examples of PLCs regulated by small GTPases.
The experimental settings adopted in this work often required the use of purified
PLCs. For this purpose, PLCs were recombinantly expressed fused with purifica-
tion tags. For PLC two different expression systems, insect cells and E.coli cells,
and various PLC constructs corresponding to different truncations were screened
to identify which system and which construct gave the highest yield of soluble pro-
tein. The greatest yield of soluble protein of ≈ 0.5 mg/liter was obtained by ex-
pression in E.coli cells of a truncated construct of PLC 1258-22258 AA (from
the EF-hands to the RA2 domain), fused with a N-terminal MBP to enhance the
protein solubility, and a His6-tag to serve the double purpose of protein purification
and specific protein-lipid binding. This protein, His6-MBP-PLC 1258-22258 AA,
was expressed in a functional state with a specific activity of 26.7 ± 0.3 mmol of
PtdIns(4,5)P2 hydrolysed/mg of PLC/min, and with the His6-tag accessible for lipid
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binding.
The systematic optimisation of the purification process lead to a purity of the
His6-MBP-PLC (1258-22258 AA) preparation close to homogeneity, see section
3. The high purity level of this protein preparation made His6-MBP-PLC (1258-
22258 AA) suitable for structural studies. His6-MBP-PLC (1258-22258 AA) was
used for two-dimensional crystallisation on a lipid monolayer, aiming to obtain
structural information in a state that closely mimics the natural environment and
therefore functionally relevant. Several crystallisation conditions were screened and
the conditions that led to protein-lipid binding were identified. Although ultimately
unsuccessful, this screening process delineated alternative approaches to achieving
protein-lipid binding which could drive two-dimensional protein crystallisation on
a lipid monolayer.
The binding interaction of PLC with transducers of the Ras GTPase family
was studied in vitro, combining biochemical assays (pull-down) with intermolec-
ular and intramolecular FRET measurements, see section 4. In the first instance,
His6-PLC-eGFP (1258-2258 AA) and mCherry-K-Ras, labeled with a fluorescent
pair suitable for monitoring intermolecular FRET, were recombinantly expressed in
E.coli cells and purified. Intermolecular FRET between His6-PLC-eGFP (1258-
2258 AA) and mCherry-K-Ras was successfully detected, thereby reinforcing the
evidence of the GTP-dependent binding, (also detected by pull-down), and charac-
terising in a quantitative manner the binding by estimating the dissociation constant,
Kd ≈ 3.8 ± 1.0 μM. More importantly, the same proteins and settings as were used
to monitor intermolecular FRET could be adopted to test binding inhibitors in a
quantitative and cost-effective manner. After validation of intermolecular FRET as
a successful approach to monitor the binding between PLC and Ras in vitro, in-
tramolecular FRET was used to study the implication of the binding at a structural
and functional level. Indeed, it has been hypothesised that Ras binding might induce
a conformational change that is responsible for PLC activation. In this case, PLC
fused with two fluorophores, His6mRFP-PLC-eGFP (1258-2258 AA), was used to
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screen for long range conformational changes within PLC. However, no changes
in intramolecular FRET were observed, thus failing to corroborate, although not to
disprove, the concept of a conformational change that might result in a significant
change in the distance or orientation between the N- and C-terminal fluorophores of
PLC. However, a short range conformational change, limited to a specific region,
cannot be excluded and it could be key for the activation of PLC upon GTPase
binding. This possibility can be investigated by monitoring intramolecular FRET,
but using a PLC molecule with the two fluorophores placed in strategic sites of
PLC, having one fluorophore placed internally and the other placed at the N- or
C-Terminus.
A versatile cell-free system was optimised to measure basal PLC activity and
PLC activation upon GTPase interaction. The reliability of the cell-free system was
demonstrated by comparison of the degree of PLC activity obtained with an es-
tablished in vivo assay which uses Cos7 cells and with the cell-free system. The
cell-free system used lipid vesicles of controllable lipid composition, purified PLC
and purified GTPases which were prenylated in vitro. This assay proved the direct
binding between PLC and GG-RhoA (see sec. 5) and between PLCβ and GG-Rac2
(see sec. 6), and it allowed the detection and quantification of the PLC activation
in a GDP/GTP dependent manner. More importantly, and for the first time, the
cell-free system facilitated the quantitative study of PLC activity dependency upon
the lipid substrate presentation (see sec. 6). For this study, PLCβ2 and Rac2 were
used as a model. The PLCβ2 activity and activation upon GTP-GG-Ras2 direct in-
teraction was unaffected by changes of the membrane curvature. Variations of the
net charge of the membrane did not significantly affect PLCβ2 activity, but did alter
PLCβ2 activation. Positively charged vesicles reduced PLCβ2 activation and a sim-
ilar trend was observed for lipid membranes with a negative charges above a certain
threshold. The activation trends of PLCβ2 in response to GG-Rac2 as a function of
the net membrane charge could only partially be explained by the auto-inhibitory
mechanisms recently proposed by Hicks and co-workers [25]. The investigation of
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other regulatory mechanisms that could fully explain PLCβ2 behaviour led to the
identification of another important factor, the stored elastic curvature stress. The
stored elastic curvature stress within the lipid membrane notably affects the PLC ac-
tivity, the lower the stored elastic curvature stress the lower the activity. This global
analysis of the data obtained by using the cell-free system indicates that the mech-
anism of PLC activation is complex and under the control of many factors. Indeed,
PLCs are activated by direct binding to the GTPases and in a GDP/GTP dependent
manner. However, this protein-protein interaction is not sufficient on its own to fine
tune PLC activation and the PLC-lipid interaction seems to play a key role in the ac-
tivation mechanisms. Both the membrane net charge and the stored elastic curvature
stress have been shown to regulate PLC activation. A role for the membrane charge
in the PLC regulation was suggested in a previous study [25], and the data collected
in this study are in agreement with it, while the role of the stored elastic curvature
stress in PLC regulation was identified in this study for the first time. At this stage,
the identification of the components that play a role in PLC regulation is important
to understand the complexity of the regulatory mechanism, and valuable to the de-
sign of further experiments which aim to study how these factors might affect PLC
activity. Two mechanisms of activation have been proposed: according to the first,
PLC translocates from the cytosol to the membrane surface as consequence of GT-
Pase binding, and this is necessary and sufficient to fully activate PLC. According
to the second mechanism a conformational change, in addition to the translocation,
is necessary to fully activate PLC. The results obtained with the cell-free system
indicated that there are additional factors to the translocation that regulate PLC ac-
tivation. These additional factors are linked to protein-lipid interaction, but at this
stage a conformational change has not been detected. A conformational change and
its role in the activation process might be identified by combining intramolecular
FRET measurements (using a construct specifically designed as described above),
and activity data obtained by using the cell-free system.
The complementary use of biochemistry and biophysical approaches lead to a
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better understanding and characterisation of the regulatory mechanism of the PLCs.
In particular, from this study, which is in line with the recent works on the regula-
tory mechanism of PLCs [25, 36], emerged that the membrane properties modulate
the PLC activity. This study brought strong evidence that the membrane plays an
important role in the PLC regulation. The PLC regulation by the membrane should
not be considered less important than the PLC regulation by the GTPases. Despite
the fact that, so far, the PLC regulation by GTPases was object of more intense
studies, the regulatory role of the membrane on PLCs is gaining more and more
attention. This trend well fits into the general growing interest for the lipid mem-
brane and their role in biology. An equilibrated view of the membrane-protein and
protein-protein contributions to whole and complex mechanism of PLC regulation
should be the starting point for further investigations. Future studies, especially if
they are curried in a multi disciplinary fashion, are expected to extend the current
understanding and to characterise in detail the complementary PLCs regulation by
membranes and proteins.
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